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ABSTRACT 
 
 
Although platinum drugs cisplatin, carboplatin and oxaliplatin are routinely used in 
the clinic to treat various cancers including testicular, ovarian, head and neck, and 
colorectal cancers, problems of drug resistance and side effects would limit their use. 
Thus thousands of cisplatin analogues have been prepared by changing nature of the 
leaving groups and carrier ligands with the aim of reducing the side effects and 
widening the spectrum of activity. It has been possible to reduce side effects by 
changing the nature of the leaving groups e.g. carboplatin that has bicarboxylate 
leaving group as against chloride in cisplatin is less toxic than cisplatin. Changing the 
carrier ligands has impacted activity to the compounds and types of cancer that is 
successfully targeted. For example, oxaliplatin which has DACH (1R, 2R)-(-)-1, 2-
diaminecyclohexane) carrier ligand as against ammonia in cisplatin, is active against 
colorectal cancer while cisplatin and carboplatin are not. Substantial resemblance 
between chemistry of palladium (II) and platinum (II) has prompted studies of Pd(II) 
complexes as potential anticancer drugs.  
Combining drugs with different modes of action can synergize their effects, where a 
combination therapy comprised of different mechanisms often provide distinct 
advantages over monotherapy. Much research is currently done on the combination of 
targeted therapy with phytochemicals. In this study, six novel palladium compounds 
(NH1, NH2, NH3, NH4, NH5 and NH6) have been synthesized using bulky 
planaramine ligands: quinoline, benzimidazole, 8-hydroxyquinoline and imidazo(1,2-
α)pyridine. Moreover five tumour active phytochemicals: curcumin, EGCG, emetine, 
patulin and 6-shogaol have been combined with commonly used Pt based drugs as 
 XVI 
well as designed palladium compounds with the aim of providing a means of 
overcoming cisplatin resistance in ovarian and colorectal cancers.  
All of the designed palladiums have been characterized by elemental microanalysis, 
IR spectroscopy, 1H-NMR spectroscopy, Mass spectroscopy. Moreover, three of the 
compounds (NH3, NH4 and NH6) have been characterized by single x-ray 
crystallography. Anticancer activity of the compounds were tested against eight 
different human cancer cell lines (ovarian cancer: A2780, A2780cisR and 
A2780ZDO473R; colorectal cancer: HT-29 and CACO-2; breast cancer: MCF-7; cervical 
cancer: Hela) by MTT reduction assay. NH3 has shown 10 to 96 times greater activity 
than cisplatin against all tested cell lines while NH1 has shown comparable activity. 
In binary combination with curcumin and EGCG, NH3 has shown sequence and 
concentration dependent synergism against ovarian and colorectal cancer models. 6-
shogaol and curcumin in combination with NH1 have also shown synergism in many 
instances. Cisplatin in combination with emetine and patulin shows strong synergistic 
effect in A2780 and A2780cisR cell lines. Similarly oxaliplatin in combination with 
patulin has produced synergism in HT-29 cell line. DNA damage, cellular 
accumulation and metalDNA binding study have provided mechanistic insight on 
the antitumour activity of palladiums/platinums administered alone and in 
combination with selected phytochemicals.  
Finally, proteomic study was conducted to identify the proteins that underwent 
changes in expression due to drug treatments in A2780, A2780cisR, HT-29 and CACO-
2 cell lines. 47 such proteins were identified. In conclusion it can be said that designed 
palladiums NH3 and NH1 have the potential to be novel anticancer drug candidates if 
found to be active and safe during in vivo animal model study and clinical trial. 
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CHAPTER ONE 
1  INTRODUCTION 
1.1 What is cancer? 
 
Cancer may be defined as uncontrolled and widespread proliferation of cells characterized by 
invasiveness and metastasis (travelling to the other organs of body through blood circulation 
or lymph vessels). The origin of the term ‘cancer’ credited to Greek physician Hippocrates 
who first used the words ‘carcinos’-means non-ulcer forming tumours and ‘carcinoma’-
means ulcer forming tumours. The world’s oldest record of cancer was discovered in Egypt 
in 1500 BC and it was mentioned that there was no treatment of it except palliative care 
(Sudhakar 2009).  
1.2 Global perspective of cancer 
 
Cancer has appeared as the most dreaded disease of our time by causing early death sentence 
in many minds. International Agency for Research on Cancer, WHO compiled cancer 
prevalence and death estimates for 2012 in 184 countries throughout the world. It has been 
reported  that 14,100,000 new diagnosis, 8,200,000 cancer deaths occurred and 32,600,000 
people were living with cancer in 2012 worldwide and the figures are projected to rise by at 
least 70% by 2030 (Ferlay, Soerjomataram et al. 2015). The ongoing worldwide demographic 
and epidemiologic changes indicate a rising cancer affliction over the next years, particularly 
in less developed countries, with over 20,000,000 new cancer diagnosis projected per annum 
by 2025 (Bray 2014). Overall, the prevalence of cancer is higher in men than in women by 
almost 25% while the mortality rates are higher in more developed nations than in less 
developed ones (by about 15% in men and 8% in women). In 2012, the three most frequently 
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diagnosed cancers were lung (18,200,000), breast (16,700,000) and colorectal (13,600,000) 
while the most common causes of cancer mortalilty applied to cancers of lung (1,600,000 
deaths), liver (745,000 deaths) and stomach (723,000 deaths) (Ferlay, Soerjomataram et al. 
2015).  
1.3 Cell survival and cell death 
 
All living entity, from bacterium to mammal, is outcome of recurrent process of cell growth 
and division. A cell reproduces through orderly successive events in which contents are 
duplicated and two cells are produced. The entire process is known as the cell cycle. The 
number of cells in organisms is firmly synchronized by regulation of cell division and control 
of cell death.  
1.3.1 Cell cycle 
 
Cell cycle can be separated into two major phases: interphase and the mitotic (M) phase in 
eukaryotic cells. During interphase cell grows and a copy of DNA is made, while in mitotic 
(M) phase DNA and cytoplasm are split into two sets thus forming two identical cells. 
Preparation for division during interphase happens in three steps: S, G1 and G2 phases. The S 
or synthesis phase is when DNA replication occurs, while G1 and G2 so-called gap phases are 
less dramatic but equally important. During G1 phase the cell conducts a series of checks and 
when necessary signals are received, it will synthesize RNA and proteins needed to promote 
cell growth. The interval of G1 phase can fluctuate significantly depending on external 
conditions and extracellular signals from other cells. If extracellular conditions are 
unfavourable, cells may stay longer time through G1 and may even proceed to a resting state 
known as G0, in which they may persist for days, weeks, or even years before resuming 
proliferation (Alberts, Johnson et al. 1997). During G2 phase the cells similarly check its 
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readiness and continue to grow for M phase. Mitosis is again divided into several stages- 
prophase, prometaphase, metaphase, anaphase, and telophase. Figure 1.1 shows the different 
phases of cell cycle. 
 
Figure 1.1: Different phases of cell cycle 
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1.3.2 Cell Death 
 
More than thirteen different types of cell death have been proposed (Galluzzi, Vitale et al. 
2012). Morphologically cell death can be classified as apoptotic, necrotic or autophagic 
(Kroemer, Galluzzi et al. 2009). Apoptotic cells are distinguished by cell shrinkage, 
protrusion of plasma membrane, condensation of chromatin, breakdown of nuclear materials 
and formation of apoptotic bodies. Autophagy is distinguished by the amassing of 
autophagosomes and autophagolysosomes for cytoplasm, organelle, and protein degradation. 
On the other hand, necrosis is marked by the bulging of the cell and its organelles along with 
early membrane damage (Tan, Lu et al. 2014).  
Proposed mechanisms of cell death pathways mediated through apoptosis are portrayed in 
Figure 1.2, autophagy in Figure 1.3 and necrosis in Figure 1.4.  
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Figure 1.2: Apoptotic cell death mechanism  
 
Figure 1.3: Autophagic cell death mechanism  
 
Figure 1.4: Necrotic cell death mechanism  
37 
 
1.4 Genes involved in cancer 
 
All cancers begin with mutation of one or more genes in a cell which produces abnormal 
proteins or no protein at all. An abnormal protein delivers altered information than a normal 
protein, which can induce cell proliferation excessively and cause cancer. There are two 
fundamental types of genetic mutations such as: acquired and germline mutations. Acquired 
mutations are the most common cause of cancer that occur from damage to genes during a 
person’s life due to smoking, exposure of ultraviolet radiation, viruses, and age. In contrast, 
germline mutations are hereditary, passed from generation to generation and found in every 
cell. Oncogenes, tumour suppressor genes and DNA repair genes are the three main classes of 
genes that are linked with the prevalence and development of cancer. 
1.4.1 Oncogenes 
 
Mutations in proto-oncogenes are usually prevailing in nature, and the altered form of a 
proto-oncogene is known as oncogene. The class of genes that cause normal cells to become 
malignant through their mutation are called proto-oncogenes (Chial 2008). Several proto-
oncogenes code for cell surface receptors which traverse the cell membrane, receive signals 
from the external environment and pass the information inside the cell. For instance: EGFR, 
the receptor of the epidermal growth factor (EGF) and KDR, the receptor of the vascular 
endothelial growth factor (VEGF). EGFR stimulation is responsible for increased cell 
proliferation whereas VEGF activation cause angiogenesis. Proto-oncogenes can also code 
for intracellular proteins including Src, HRAS and KRAS which normally function 
downstream of membrane bound receptor pathways to stimulate cell proliferation. Few of the 
proto-oncogenes, namely cyclin D1 (CCND1) and cyclin E1 (CCNE1), usually function to 
drive cells through different phases of the cell cycle when the cells get proper directions 
(Chial 2008). Moreover, some transcription factors like Myc also act as proto-oncogenes. 
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1.4.2 Tumour suppressor genes 
 
Tumour suppressor genes slow down cell division or induce cell death through apoptosis. 
They are like brakes on a car that would normally keep the cell from dividing too quickly. 
During any unfavorable conditions with the gene, for example a mutation, cell division can 
get out of control. The most important tumour suppressor is p53 tumour-suppressor protein 
encoded by the TP53 gene. TP53 mutations were reported to occur in almost every type of 
cancer at rates varying from 10% to more than 95% (Rivlin, Brosh et al. 2011). APC, pVHL, 
CD95, YPEL3, ST5, ST7, and ST14 genes also belong to the family of tumour suppressor 
genes. 
1.4.3 DNA repair genes 
 
DNA repair genes code for proteins which correct for mistakes in copying. Mutations in 
DNA repair genes can cause a failure in repair, which subsequently allows further mutations 
to accumulate and leads to cancer. Examples are BRCA1 and BRCA2 genes. 
1.5 Mechanism of carcinogenesis 
 
Carcinogenesis usually develops in three stages: initiation, promotion and progression (Liu, 
Yin et al. 2015). The likely cellular and molecular mechanisms involve interactions or 
covalent binding of carcinogens with intracellular DNA, RNA and proteins, occasioning in 
gene-mutational alterations (Taningher, Saccomanno et al. 1990). The first step in primary 
cancer development is initiation. Different chemicals act as initiators that are often not 
reactive with DNA, but changed after metabolism in the body and are then able to cause 
mutation through covalent binding (Richmond and Su 2008). Initiation causes irreversible 
genetic damage. This means that daughter cells originated from division of the mutated cell 
will also transmit the mutation.  
39 
 
During promotion step, promoters bind to cell membrane receptors and interact in intra-
cellular signaling pathways that increase cell proliferation. Promoters exhibit threshold values 
and do not essentially cause cancer on their own, but increase the clonal expansion of 
initiated cells, and eventually leads to cancer (Klaunig, Kamendulis et al. 2000). 
The last step of carcinogenesis is progression. It refers to the serial transformations from a 
benign tumour to a neoplasm and to malignancy. Progression is irreversible step associated 
with karyotypic modifications which is associated with an augmented cellular proliferation, 
invasiveness, metastasis and changes in biochemistry and morphology due to the persistent 
mutations or genetic instability (Oliveira, Colaço et al. 2007).  Mechanism of carcinogenesis 
has been depicted in figure 1.5. 
 
Figure 1.5: Stages of carcinogenesis [Adapted from Liu, Yin et al. 2015] 
1.6 Types of cancer 
 
The common public is more conversant with cancer names based on their primary sites but 
clinicians and other health professionals normally refer to cancers based on their histological 
type. Cancer can also be classified by grades and stages. 
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1.6.1 Classification based on primary sites 
 
Based on the primary site of origin, cancers may be termed as lung cancer, pancreatic cancer, 
prostate cancer, colorectal cancer, liver cancer, kidney cancer, mouth cancer, brain cancer, 
breast cancer, ovarian cancer, uterine cancer, testicular cancer etc.  
1.6.2 Classification based on histology 
 
Six major groups of cancer based on tissue types are carcinoma, sarcoma, myeloma, 
leukemia, lymphoma and mixed types (Weinberg 2007). 
Carcinoma: It develops from epithelial cells which constitutes the lining of internal organs or 
external parts of the body. Most of the cancers fall into this category (80 – 90%) which can 
be further classified into two types: adenocarcinoma (cancer in organ or gland) and squamous 
cell carcinoma.  
Sarcoma: It is the malignancy of connective tissues e.g. bones, cartilage, muscle, fat, vein, 
artery or cappilaries. In appearance, sarcoma would look like the tissue in which it grows (R 
Dundas and I Murray 2012). 
Leukaemia (liquid cancers): This type of cancer initiates from the bone marrow and leades to 
the production of abnormal blood cells (mainly white blood cells). 
Lymphoma (solid cancers): These are also recognized as the cancers of the lymphatic system 
and which usually affect lymph nodes at internal organs of the body. Lymphomas are of two 
kinds – Hodgkin’s lymphoma (Reed-Sternberg cells present) and Non-Hodgkin’s 
lymphomas.  
Myeloma: This cancer originates in the plasma cells of bone marrow that are responsible for 
the production of antibodies in reply to infectious conditions.  
Mixed type: These have two or more components of the cancer such as mixed mesodermal 
cancer, adenosquamous carcinoma and teratocarcinoma.  
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1.6.3 Classification based on grade 
 
Abnormality of cells compared to surrounding normal tissues defines grade of cancer. 
Greater the abnormality, the greater will be the grade (from I–IV). 
Grade I – cells are well differentiated and looks little abnormal than normal cells 
Grade II –moderately differentiated cells with slightly more abnormal appearance 
Grade III –poorly differentiated cells with very abnormality in appearance 
Grade IV – cells are completely undifferentiated, immature and very primitive  
 
1.6.4 Classification based on stage 
 
There are several types of staging methods among which TNM staging is most common. T 
stands for tumour size, N stands for the degree of regional spread or node involvement and M 
stands for distant metastasis. For instance, T0 indicates no evidence of tumour, T 1 to 4 
indicates increasing tumour size.  
In other ways, Stage 0 refers to the tumour being in situ or limited to surface cells only while 
stage I refers to the malignancy being restricted to the tissue of origin. Stage II refers to the 
cancer with limited local spread; Stage III refers to the cancer with extensive local and 
regional spread; while stage IV is advanced cancer with distant spread and metastasis. 
1.7 Treatment methods of cancer 
 
Surgery, radiotherapy and chemotherapy constitute the primary management options for 
cancer. Currently physicians also prescribes hormonal therapy, immunotherapy and other 
targeted therapies e.g. growth signal inhibitors, angioinhibitors in certain cases (Sudhakar 
2009). Clinicians select the treatment strategy depending upon some important parameters : 
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type, location and grade of tumour as well as the patient's condition and demands (Souhami 
and Tobias 2005).  
Surgery and radiotherapy is considered as loco-regional treatment which applies for treating 
localised cancers. Whereas, chemotherapy considered as systemic treatment which is used for 
advanced stages of cancers that show metastasis. Previously, chemotherapy was applied only 
when surgery and radiotherapy were proven to be ineffective. But recently chemotherapy has 
become the first-line treatment for a number of cancers often in combination with surgery or 
radiotherapy. Since the present study is focused on the synthesis of novel palladium based 
chemotherapeutic drugs, activity of the designed complexes alone and in combination with 
phytochemicals, brief discussion about chemotherapy and metal based chemotherapeutic 
drugs is given under following subsections. 
1.8 History of Chemotherapy 
 
In the early 1900s, the famous German chemist Paul Ehrlich coined the term “chemotherapy” 
and defined it as the employment of chemicals to treat disease. As applied to cancer, the word 
chemotherapy is used to mean management of cancer using specific chemical agents or drugs 
that would selectively destroy tumour cells and tissues. The use of chemotherapy to treat 
cancer began at the start of the 20th century but the exercise of modern cancer chemotherapy 
truly began in late 1947, after successful therapy of nitrogen mustard against lymphomas. 
The success of combination chemotherapy against childhood leukaemia (in the 1960s) and 
advanced Hodgkin's disease (in the early 1970s) overcame the prevailing nihilism about the 
capability of drugs in the treatment of advanced cancers (DeVita and Chu 2008). Recently 
chemotherapy represents the major treatment options received by over 70 percent of stage III 
and IV patients of various cancer  in USA (DeSantis, Lin et al. 2014). 
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1.9 Types of chemotherapeutic drugs 
 
The word chemotherapy is meant to include a number of families based on chemical structure 
and mechanism of action. Examples are alkylating agents, antibiotics, antimetabolites, 
topoisomerase inhibitors and mitotic inhibitors (Espinosa, Zamora et al. 2003). 
Alkylating agents: These are prototype chemotherapeutics and add alkyl groups to the DNA 
of cells. Alkylating agents kill the cells by forming strong covalent bonds with electron-rich 
atoms in biomolecules like sulfur in proteins and nitrogen in DNA. N7 position of guanine in 
DNA is predominantly susceptible to alkylation (Colvin 2003). Examples of drugs in this 
group include nitrogen mustards, cyclophosphamide and platinum complexes. 
Antitumor antibiotic: These drugs interfere with the DNA inside cells and slow or stops 
cancer cells from growing and prevent them from multiplying. Bleomycin, anthracycline and 
mitomycin are the examples of antitumour antibiotics. 
Antimetabolites: This is a group of agents that imitate the structure of naturally occurring 
molecules essential for normal metabolic process inside the cell and thus interfere with DNA 
or RNA synthesis e.g. folic acid, pyrimidine or purine analogues. The mechanism involves: 
(1) cell deception towards incorporating the agents in metabolic pathways needed for RNA or 
DNA synthesis so that a false genetic message is conveyed; (2) inhibition of the enzymes 
required for the synthesis of biomolecules. Prominent antimetabolites are 5-flouro uracil, 
methotrexate and gemcitabine. 
Topoisomerase inhibitors: These agents inhibit topoisomerase enzymes (topoisomerase I 
and II) which are responsible for controlling the supercoiling of DNA. Irinotecan, topotecan 
and camptothecin are examples of topoisomerase I inhibitors whereas etoposide and 
doxorubicin are topoisomerase II inhibitors. 
Mitotic inhibitors: The drugs belonging to this group exert their cytotoxic effects by binding 
with tubulin and inhibiting formation of microtubules thus causing metaphase arrest. They 
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are obtained from plants and other natural products e.g. vincristine, vinblastine, paclitaxel and 
docetaxel.  
1.10 Noble Metal based chemotherapy 
 
The metal which resists oxidation and corrosion in natural environment and hardly attacked 
by acids is termed as noble metal. Ruthenium, rhodium, palladium, silver, osmium, iridium, 
platinum and gold have been grouped together in the list of noble metals. Generally the term 
‘noble metals’ directs our focus towards wealth and power e.g. jewellery, coins and other 
expensive art-works. Recently these metals have been used for a variety of purposes ranging 
from aerospace, electrical appliances and catalysts to health (Medici, Peana et al. 2015). 
Medical applications of noble metals have been traced back from very ancient periods. For 
instance, use of silver against wounds and ulcers by Hippocrates, use of gold by the Chinese 
since 2500 B.C. Lately gold compounds have been used in treatment of arthritis, silver 
compounds as antibacterial agents in clinic. But the new era of employing noble metals in 
discovery of new therapeutic agents started especially after serendipitous discovery of 
cisplatin as an anticancer agent. A number of studies have been conducted which have led to 
the production of significant number noble metal derivatives with potential antineoplastic 
activity. Some of these compounds will be highlighted in the following subsections. 
1.10.1 Platinum based compounds 
 
 As stated earlier, cisplatin or cis-diammine-dichloroplatinum(II) is the compound that 
pioneered the horizon of combating cancer using platinum and other noble metals. Nowadays 
it would be hard to find any cancer hospital around the globe which is not using cisplatin, the 
‘penicillin’ of cancer. But the use of cisplatin is restricted to limited spectrum of cancers and 
suffers from drug resistance as well as toxicity. Thus thousands of new platinum complexes 
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have been synthesized to improve the performance of cisplatin. Until today two other 
platinum complexes (carboplatin, oxaliplatin) have been approved by FDA and used globally 
among cancer patients. Three other platinum complexes namely nedaplatin, lobaplatin and 
heptaplatin are being used as anticancer therapy in Asian countries. Many of the platinum 
complexes including picoplatin, satraplatin, ormaplatin and phenanthriplatin are in preclinical 
studies, clinical trials or have been waiting in queue for FDA review. Figure 1.6 represents 
structures of platinum drugs used in the clinic and a few other optimistic anticancer drug 
candidates.  
Globally Used Platinum Drugs 
 
      Cisplatin (1978)         Carboplatin (1989)  Oxaliplatin (2002) 
 
Locally Used Platinum Drugs 
 
Nedaplatin (1996, Japan)        Lobaplatin (2004, China)       Heptaplatin (2005, Korea) 
 
Other Optimistic Platinum Drugs 
 
Satraplatin            Picoplatin   Ormaplatin  
Figure 1.6: Prominent Platinum compounds against cancer 
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1.10.2 Palladium based compounds 
 
Due to structural similarity and considerable overlap in coordination chemistry between 
platinum and palladium metal, palladium complexes were given significant interest in search 
of novel anticancer agents immediately after FDA approval for cisplatin. But none of them 
found to be promising in early studies due to 105 times faster hydrolysis profile of palladium 
complexes than platinums. The idea of incorporating bulky ligands into palladium complexes 
reduced dissociation rate and thus solve the problem of reaching reactive species into 
pharmacological targets (Kapdi and Fairlamb 2014). The host laboratory also adapted this 
hypothesis and synthesized a number of novel palladium complexes with promising 
antitumour activity (Daghriri, Huq et al. 2004, Huq, Daghriri et al. 2004, Cheng, Huq et al. 
2006, Huq, Tayyem et al. 2007, Mazumder, Beale et al. 2012). Since the present study is 
focused on the synthesis of palladium based anticancer drugs in search of suitable alternative 
of existing platinum based drug, a thorough literature review has been accomplished and a 
comprehensive review on tumour active palladium complexes has already been published 
(Alam and Huq 2016). In that review, the genealogy of 847 palladium compounds has been 
presented and their structure activity relationships summarized from 264 research articles.  
None of the complexes entered into clinical trial but many of them showed very promising 
results in preclinical studies and a few have been patented. Figure 1.7 represents potential 
anticancer palladium drug candidates for clinical trial in near future (Alam and Huq 2016). 
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Figure 1.7: Prominent Palladium compounds against cancer 
1.10.3 Other noble metal based compounds 
 
In 1980 [RuCl3(NH3)3] started the race of ruthenium based anticancer agents as cisplatin 
contenders but its reduced solubility led to the search of other suitable candidates. NAMI-A 
(imidazolium trans-[tetrachloro(DMSO)(imidazole)ruthenate (III)], KP-1019 (Indazolium 
trans-[tetrachlorobis(1H-indazole)ruthenate(III)] and NKP-1339 (Sodium salt of KP-1019) 
among ruthenium complexes have been entered into clinical trial and gave encouraging 
results in Phase –I study (Trondl, Heffeter et al. 2014). 
Since d8 electronic configuration of Au (III) and Pt (II) is similar and Au (III) forms square 
planar tetracoordinated complexes, Au (III) compounds could be a good source for a 
substitute of cisplatin which should interact with DNA in a similar manner. Although none 
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from hundreds of gold complexes developed has entered into clinical trial, many of them 
have promising results to be entered into Phase –I study (Nardon, Boscutti et al. 2014).  A 
few rhodium, osmium, iridium and rhenium complexes have been also found to exhibit 
antineoplastic activities in different cancer models but none of them are expected to be 
entered into clinical trial (Medici, Peana et al. 2015).  
1.11 Chemotherapy resistance 
 
Survival rate and quality of life of cancer patients have been improved due to headway of 
chemotherapy, but in majority of instances patients suffer advanced disease in the long run 
due to intrinsic or acquired drug resistance (Liu 2009). Intrinsic or primary drug resistance 
exists prior to any given treatment e.g. melanoma and hepatoma. Intrinsic drug resistance had 
been encountered in about half of all cancer patients in the 1990s (Pinedo and Giaccone 
1998). On the other hand acquired resistance develops gradually after initially responding 
towards chemotherapy e.g. ovarian cancer. All too often, it has been observed that cancer 
cells show resistance not only to a single chemotherapeutic drug but also to different varieties 
of structures and groups which is called multiple drug resistance (Gottesman 2002).  
1.11.1 Mechanism of resistance 
 
Failure in chemotherapy can develop due to host factors or specific genetic and epigenetic 
alteration of cancer cells. Host factors include mainly poor absorption, improper distribution, 
quick metabolism and rapid excretion of chemotherapeutic drugs; improper drug 
administration, changes in the tumour microenvironment, unusual features of the tumour 
blood supply (Green, Frankel et al. 1999, Pluen, Boucher et al. 2001).  
Biological mechanisms of chemo-resistance can be categorized as decreased drug uptake, 
increased drug efflux, inhibition of cell death, increased detoxification of drugs, DNA 
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damage repair, alternation of drug targets, stem cells, and epithelial to mesenchymal 
transition (EMT) (Housman, Byler et al. 2014, Wu, Yang et al. 2014). In the following 
subsections specific resistance mechanisms of platinum drugs will be discussed only because 
it best suits with the objective of the present study.   
1.11.1.1 Reduced drug accumulation 
 
Accumulation of drug into the cells can be hampered by either decreased uptake into the cells 
or increased efflux from the cells. However, it can also occur by both of the mechanisms. 
Reduced cisplatin accumulation might account for 70-90% of total resistance in some cancer 
cells (Kelland 1993) but cisplatin resistance is not directly proportional to reduced 
accumulation (Johnson, Laub et al. 1997). Decreased cisplatin uptake can be demonstrated by 
the higher concentration of cisplatin in extracellular fluid which can be ensued due to 
variation in passive diffusion of uptake (Yoshida, Khokhar et al. 1994, Kelland 2000) or 
active transport system involving Na+-K+-ATPase or gated ion channel (Andrews, Velury et 
al. 1988, Gately and Howell 1993).  Moreover, the copper transporter 1(CTR1), a 
transmembrane protein which is involved in the uptake of cisplatin has been found to be 
greatly involved in cisplatin resistance. Research has shown that CTR1 is down-regulated in 
cisplatin resistant cancer cell lines (Ishida, Lee et al. 2002, Katano, Kondo et al. 2002, 
Holzer, Manorek et al. 2006), depletion of CTR1 increases cisplatin resistance and copper 
chelators enhance the uptake and efficacy of cisplatin (Ishida, McCormick et al. 2010). Of 
note, clinical concentrations of cisplatin prompts degradation of CTR1 with reduced influx of 
cisplatin, and thus causes acquired resistance (Holzer and Howell 2006). In recent times, 
CTR2  is found to regulate endocytosis and control tumour growth and sensitivity to cisplatin 
and carboplatin in vivo (Blair, Larson et al. 2009, Blair, Larson et al. 2011). 
A number of cell membrane transporter proteins have been associated with resistance against 
chemotherapeutics by increasing drug efflux. The ATP-binding cassette (ABC) transporter 
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family is the most prominent one having 49 members and only 3 of them investigated 
extensively in relation to multiple drug resistance (Holohan, Van Schaeybroeck et al. 2013). 
Borst et.al suggested that multidrug resistance proteins including MRP1, MRP2, MRP3 and 
MRP5 mediate some extent of cisplatin resistance by triggering efflux of cisplatin (Borst, 
Evers et al. 2000). Other concurrent and later studies reinforced that MRP2 (cMOAT) is the 
major protein responsible for more export of cisplatin from cells and drug resistance (Koike, 
Kawabe et al. 1997, Cui, König et al. 1999, Liedert, Materna et al. 2003, Korita, Wakai et al. 
2010, Yamasaki, Makino et al. 2011). However, MRP2 is not universally associated with 
cisplatin resistance and converse demonstration of increasing sensitivity also observed 
(Siddik 2003). Overexpression and mutation of MRP1 and MRP4 in an oxaliplatin-selected 
ovarian tumour cell line is found to be associated with resistance to oxaliplatin and cisplatin 
(Beretta, Benedetti et al. 2010). Copper transporting P type adenosine triphosphate (ATP7A 
and ATP7B) which has a role in cisplatin efflux, are also found to be up-regulated in cisplatin 
resistant tumour cells (Komatsu, Sumizawa et al. 2000, Katano, Kondo et al. 2002, Aida, 
Takebayashi et al. 2005). Involvement of either the multidrug resistance (MDR) P-
glycoprotein pump or the major vault/lung resistance-related protein (MVP/LRP) transporter 
in cisplatin efflux has been largely inconclusive (Siddik 2003, Shen, Pouliot et al. 2012). 
1.11.1.2 Reduced bioavailability of drug 
 
It is well established fact that cisplatin molecules have to undergo aquation reaction to 
generate reactive species to interact with DNA which is facilitated by the lower chloride 
concentration (~ 4 mM) in cytoplasm. However, these activated cisplatin molecules could be 
deactivated through binding with various cytoplasmic nucleophilic species including 
glutathione and cysteine rich metallothionein. Glutathione binds with the reactive species of 
cisplatin impulsively or in presence of glutathione S-transferase (GST) enzyme and the 
subsequent conjugates are readily evacuated by the ATP-dependent S-conjugate export 
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pump. Concentrations of glutathione (0.5-10 mM) increase following chronic cisplatin 
exposure, and induce resistance by reducing activated cisplatin molecules available for 
interaction with the target DNA (Figure 1.8).  
 
 
Figure 1.8: Schematic representation of the pathways involved in inactivation of cisplatin  
 
Glutathiones cause drug resistance through direct detoxification or by hindering the mitogen-
activated protein kinase (MAPK) pathways (Townsend and Tew 2003).  Levels of GSH, 
GST𝜋 are in positive correlation with cancer stage and chemo-resistance in patients with 
different cancers (Green, Robertson et al. 1993, Joncourt, Buser et al. 1998, Jardim, 
Moschetta et al. 2013, Yu, Du et al. 2014). Moreover, GST gene polymorphisms have been 
found to be associated with the response of patients against chemotherapy (Kap, Richter et al. 
2014). Elevated GSH levels have also be reported to cause increased DNA repair (Kelland 
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1993), increase in inhibitory effect on apoptosis by buffering drug-induced oxidative stress 
(Slater, Kimland et al. 1995).  
Besides, metallothionein which is a small protein of 62 amino acids including 20 cysteine 
residues has been found to be increased its concentration in cisplatin resistant phenotype 
compared to its parent (Kelley, Basu et al. 1988, Kasahara, Fujiwara et al. 1991). 
Metallothionein readily binds with cisplatin due to its high affinity towards heavy metals e.g. 
cadmium, lead. However, conclusive clinical data on cisplatin resistance and metallothionein 
correlation are missing (Galluzzi, Vitale et al. 2012). 
1.11.1.3 Enhanced DNA repair capability 
 
To kill the cells, cisplatin binds to DNA and forms adducts primarily in the form of N7-
d(GpG) and N7-d(ApG)intrastrand. Formed DNA-platinum adducts subsequently result in 
significant kinking of the DNA required for cell death. The formation of cisplatinDNA 
adducts and the persistence of cisplatin is indispensable for cell death. Hence, increased rate 
of adduct repair diminish the apoptotic process and confer resistance. However, the 
contribution of increased DNA repair in mediating cisplatin resistance is low (only 1.5–2.0-
fold). The most important pathways for DNA repair mechanisms are (i) nucleotide excision 
repair (NER) pathway, (ii) mismatch repair (MMR) pathway and (iii) DNA-dependent 
protein kinase (DNA-PK) pathway. 
Nucleotide excision repair (NER) pathway is the most significant pathway that requires more 
than 30 proteins. The pathway has been described pictorially in Figure 1.9. Briefly, the 
kinking of DNA is first recognized by XPE and XPC-DDB1/2 and DNA damage is verified 
by transcription factor II H (TFIIH) complex which further assembles the pre-incision 
complex: RPA, XPA, and XPG. Then XPB and XPD helicases simultaneously unwind the 
DNA. Several bases have been excised upstream and downstream from the adduct through 
endonucleases ERCC1-XPFand XPG. Subsequently, the oligonucleotide containing the 
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adduct is released. The gap is filled in by the DNA repair synthesis complex containing RPA, 
RFC, PCNA, and Pol δ/ε. DNA repair pathway completes through ligation of DNA by DNA 
ligase I (Amable 2016). The equilibrium between DNA damage and DNA repair determines 
either cell death or survival followed by cisplatin administration. 
  
Figure 1.9: Schematic representation of NER pathway 
Mismatch repair (MMR) pathway usually handles erroneous insertions, deletions and mis-
incorporations of bases that occur during DNA transcription (Kunkel and Erie 2005). MMR 
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pathway includes at least five proteins (MLH1, MSH2,MSH3, MSH6 and PMS2) and acts 
with expenditure of energy derived from breakdown of ATP (Fishel 2001). MMR proteins 
usually attempt to repair cisplatin induced DNA lesions,  but failing to do so convey a 
proapoptotic signal (Vaisman, Varchenko et al. 1998). According to this model, in case of 
cisplatin resistance, MSH2 and MLH1 proteins are often mutated or under expressed (Aebi, 
Kurdi-Haidar et al. 1996, Fink, Aebi et al. 1998, Kamal, Soria et al. 2010). Of note, at least in 
ovarian and colorectal cancers, MMR contributes little compared to NER in the context of 
cisplatin resistance. 
DNA dependent protein kinase pathway (DNA-PK) is primarily responsible for repairing 
DNA double-strand breaks induced by ionizing radiation. However, the presence of cisplatin-
DNA adducts blocks Ku subunits of DNA-PK to translocate on a duplex DNA substrate. 
Consequently, kinase activity is inhibited and thus phosphorylation of DNA-PK proteins 
itself and other transcription factors are inhibited (Turchi and Henkels 1996). 
1.11.1.4 Abnormalities of apoptosis 
 
Molecular factors triggering acquired cisplatin resistance do so by eventually inhibiting 
apoptosis via down-regulating pro-apoptotic proteins/tumour suppressor genes or up-
regulating anti-apoptotic proteins/oncogenes. Mutation of p53 genes plays predominant role 
in loss of apoptotic function which is demonstrated in 50% of all cancers. Cisplatin resistance 
has been found to be increased with mutation of wild type p53 gene in various cancers 
compared to the presence of wild type counterpart (Sarkis, Bajorin et al. 1995, Houldsworth, 
Xiao et al. 1998, Cabelguenne, Blons et al. 2000, Reles, Wen et al. 2001) . Mutation is 
commonly observed in exons 4–9 of p53 that disrupts the ability of the tumor suppressor to 
bind to DNA or transactivate p53-dependent genes e.g. Bax. It is evident from several such 
studies that inhibition of apoptosis in tumour cells expressing mutant p53 is a key mechanism 
in context of cisplatin resistance (Siddik 2003). 
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Anti-apoptotic proteins, such as survivin and XIAP, aggravate resistance when over-
expressed that directly or indirectly inhibit caspases (Ikeguchi, Liu et al. 2002). The 
inhibition of the activation of caspases 3 and 8 in resistant cells is due to down-regulation of 
the apoptotic signal through absence of Fas expression after chronic cisplatin treatment (Qin 
and Ng 2002). The link between cisplatin resistance and inhibition of MAPK activation has 
been recognized recently. Cisplatin-mediated activation of SAPK/JNK (stress activated 
protein kinase/ c-Jun N-terminal kinase) is significantly reduced in cisplatin resistant cervical 
cancer cell lines and consequently attenuates apoptosis through inhibition of JNK, p38 
kinase, or ERK (Wang, Martindale et al. 2000, Brozovic, Fritz et al. 2004, Basu and Tu 
2005). Likewise, blockade of MEK–ERK pathway via MEK inhibitor PD98059 induces 
cisplatin resistance (Yeh, Chuang et al. 2002). 
Numerous in vitro and in vivo studies have confirmed that activation of NF-κB inhibits 
apoptosis in different types of cancer (Venkatraman, Anto et al. 2005, Zheng, Lv et al. 2014). 
Other study suggests that combination of cisplatin and NF-κB inhibitors may have 
therapeutic potential to overcome drug resistance (Nessa, Beale et al. 2012, Zhu, Luo et al. 
2016).  
1.11.1.5 Other mechanisms 
 
Activation of EMT pathway has been reported to be associated with cisplatin resistance in 
some studies through overexpression of TWIST1, SNAIL1 and E-cadherin proteins(Shen, 
Pouliot et al. 2012, Zhu, Chen et al. 2012, Liu, Wang et al. 2014). Micro RNAs, cancer stem 
cells, DNA methylation, stress response chaperons were also found to contribute in cisplatin 
resistance mechanism in different studies (Castagna, Antonioli et al. 2004, Bai, Tanaka et al. 
2006, Drayton 2012, Xu, Yu et al. 2012, Pouliot, Shen et al. 2013, Wang, Liu et al. 2013, 
Wang, Guo et al. 2014). 
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To conclude, it can be said that cisplatin resistance mechanism is multifactorial in nature. A 
glimpse of diverse mechanisms involved in cisplatin-resistant cancer cells has been portrayed 
in Figure 1.10. 
 
Figure 1.10: Overall cisplatin resistance mechanism 
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1.11.2 Strategies to combat drug resistance 
 
To overcome drug resistance and consequently reduce mortality or at least increase survival 
rate of cancer patients, scientists are conducting research by targeting the resistance 
mechanisms of respective chemotherapy. Cisplatin resistance is currently being handled by 
different strategies e.g. synthesis of analogues of cisplatin using different metals (as discussed 
earlier), synthesis of rule breaker platinums which bind with DNA differently than cisplatin 
(Arzuman, Beale et al. 2014), combination of cisplatin with other chemotherapeutic drugs 
(Helm 2009), combination of cisplatin with phytochemicals (McGuire, Hoskins et al. 1996), 
increasing drug uptake (Jandial, Farshchi-Heydari et al. 2009), targeted activation (Godwin, 
Baird et al. 2013) and nano formulation of cisplatin(Yang, Du et al. 2014). Since the host 
laboratory is aiming to overcome drug resistance through combination of phytochemicals 
with platinums and their new analogues, in the following section this strategy will be 
highlighted only.  
1.12 Phytochemicals in drug combination 
 
Epidemiological data proved the beneficial effects of the consumption of  fruits and 
vegetables in cancer (Chan and Fong 2009). Initially, use of phytochemicals was advocated 
only as cancer chemo-preventives but now this is extended to the proposal that the same may 
be true for cancer chemotherapy. Quite a few potential lead compounds derived from plants 
such as vincristine, vinblastine, paclitaxel, camptothecin, podophyllotoxin and 
combretastatins have been currently successfully employed in clinic against various cancers 
(Vinod, Maliekal et al. 2013). The antitumour activities of phytochemicals can be credited to 
their strong antioxidant properties and through the regulation of various cell signalling 
pathways (Fernando and Rupasinghe 2013) as shown in Figure 1.11. In many instances, 
phytochemicals inhibit activation of transcription factors such as NF-κB which stimulate the 
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production of pro-inflammatory cytokines and chemokines, as well as tumour cell survival 
and metastasis (Surh 2003).  
 
Figure 1.11: Cellular signalling mechanism relating to anticancer attributes of 
phytochemicals 
Reported data indicate that many cancer patients undergoing chemotherapy use 
phytochemicals improve treatment outcome (Richardson, Sanders et al. 2000). For instance- 
in a gynaecologic clinic of USA, 51% of the 113 consecutive ovarian cancer patients were 
identified to consume herbs occasionally since they were diagnosed with ovarian cancer 
(Powell, Dibble et al. 2002).Therefore, it is a small step to proceed further to employ 
phytochemicals in sensitizing resistant cancer patients toward chemotherapy (Garg, Buchholz 
et al. 2005). Several studies demonstrated that phytochemicals can act synergistically with 
cancer chemotherapy (HemaIswarya and Doble 2006, Wang, Yang et al. 2015). Table 1.1 
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highlights few phytochemicals that reported to increase the efficacy of chemotherapeutic 
drug when combined together. 
Table 1.1: Synergism from drugs and phytochemicals in combination 
 
Phytochemical Chemo drug Increased drug sensitivity 
(x fold) 
4´-Methylether-
scutellarein 
Etoposide 5.0 
Apigenin 5-fluorouracil 5.8 
Artemisinin Doxorubicin 3.6 
Artesunate Doxorubicin 4.2 
Baicalin Doxorubicin 6.3-7.8 
Berbamine Doxorubicin 28.3 
Curcumin 5-fluorouracil 10.1 
Dauricine Doxorubicin 5.0 
Didydroartemisinin Cisplatin 12.3 
Ginosenoside Rh2 Doxorubicin 31.1 
Ligustrazine Doxorubicin 6.0-178 
Matrine Doxorubicin 2.2 
Schizandrol A Daunorubicin 8.0 
Tanshinone II A Doxorubicin 2.5 
 
A number of phytochemicals have been investigated in combination with cisplatin, 
oxaliplatin as well as newly designed platinum and palladium compounds against ovarian 
cancer model to overcome drug resistance (Mazumder, Beale et al. 2012, Yunos, Mutalip et 
al. 2013, Huq, Yu et al. 2014, Arzuman, Beale et al. 2015, Arzuman, Beale et al. 2016). In 
this project two phytochemicals (emetine and patulin) were selected for combination with 
cisplatin and oxaliplatin against ovarian and colorectal cancer models. Three other 
phytochemicals curcumin, EGCG and 6-shogaol have also been investigated for combination 
study with newly designed palladium complexes.  
1.12.1 Emetine (Eme) 
 
Emetine is a naturally occurring alkaloid, found mainly in Alangiaceae, Icacinaceae, and 
Rubiaceae plant families. Major source of emetine is Psychotria ipecacuanha Stokes 
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(Rubiaceae) or Cephaelis ipecacuanha A. Rich. The earliest uses of emetine in traditional 
medicine reported as anti-amoebic, emetic and expectorant (Lambert 1918, Grollman 1966). 
Recently emetine has been demonstrated many biological properties including antiviral, 
anticancer, antiparasitic and contraceptive activities (S Akinboye and Bakare 2011). 
Anticancer potential of emetine was first came into focus in early 1900s (Lewisohn 1918) and 
entered up to Phase II clinical trial (Mastrangelo, Grage et al. 1973, Siddiqui, Firat et al. 
1973). But it was later withdrawn due to mix outcome with dose limiting effects e.g. muscle 
weakness and cardiotoxicity. Since then, emetine was considered to induce apoptosis in 
various human cancer cells (Möller, Weiss et al. 2006, Möller and Wink 2007). The cellular 
signalling mechanism for antineoplastic effects of emetine has been related to down 
regulation of anti-apoptotic bcl-xL mRNA and up regulation of pro-apoptotic bcl-xS mRNA 
(Boon-Unge, Yu et al. 2007, Sun, Yogosawa et al. 2015). Recently, focus has been given to 
employ emetine in combination with other chemotherapeutics to overcome drug resistance 
(Larsson, Hassan et al. 2009, Foreman, Jesse et al. 2014, Sun, Yogosawa et al. 2015).    
 
Figure 1.12: Structure of emetine and its source 
1.12.2 Patulin (Pat) 
 
Patulin is a polyketide lactone, biosynthesized as a metabolic product by a variety of fungal 
species of Penicillium, Aspergillus, and Byssochlamys (Saladino, Manyes et al. 2016). It is 
usually observed as food contaminants in mouldy fruits, vegetables and cereals with most 
61 
 
abundantly in apples and apple products (Zaied, Abid et al. 2013). Although there is evidence 
of carcinogenicity of patulin in experimental animal (Ciegler, Beckwith et al. 1976), 
International Agency for Research on Cancer classified it in group 3 or as ‘not carcinogenic 
to humans’.  
However, patulin has been reported to induce apoptosis in various cancer models (Alam, Pal 
et al. 2014, Boussabbeh, Salem et al. 2015). The mechanism of cytotoxicity has been 
attributed with covalent adducts formation with sulfhydryl groups, amino terminals (Lee and 
Röschenthaler 1986) of proteins and glutathione (Schumacher, Müller et al. 2006). A recent 
study revealed the antitumour potential of patulin against melanoma. The mechanism of 
action involved activation of ER stress, increase in p53 and Bax expressions, down-regulation 
of Bcl-2, and increase in caspase-3 activity (Boussabbeh, Salem et al. 2016). 
 
Figure 1.13: Structure of patulin and its source (rotten apple containing Penicillium sp.) 
1.12.3 Curcumin (Cur) 
 
Curcumin (diferuloylmethane) is a polyphenol obtained from the rhizomes and leaves of 
Curcuma longa (Zingiberaceae). It has been categorized among the most comprehensively 
studied nature derived compounds, due to its nontoxic and wide range bioactvities, e.g. 
anticancer, antioxidant, antimicrobial, anti-inflammatory, antiplatelet and hepatoprotective 
properties (Perrone, Ardito et al. 2015). Several in vitro, in vivo and even clinical trial studies 
on curcumin have been conducted; indicating that it may be a potential anticancer therapy for 
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various cancers (Bar-Sela, Epelbaum et al. 2010, Perrone, Ardito et al. 2015, Uzzan and 
Benamouzig 2016).  
 
Figure 1.14: Tautomeric structures of curcumin and its source 
Several studies proved that curcumin shows antineoplastic action by inhibiting two primary 
processes: angiogenesis and tumour growth (Maheshwari, Singh et al. 2006). Curcumin 
affects angiogenesis via multiple interdependent pathways: i) attenuation of transcription of 
NF-κB and AP-1, which inhibits the expression of IL-8 and ultimately prevents the induction 
of VEGF synthesis; ii) direct inhibition of NO, iNOS, COX-2 and 5-LOX; iii) direct 
inhibition of VEGF and iv) down-regulation of MMP-2 and MMP-9, and up-regulation of 
MMP-1 (Yance Jr and Sagar 2006).  
Curcumin induces cell death either intrinsic or extrinsic apoptotic pathways. Low doses of 
curcumin lead to oxidative stress and apoptotic cell death, while at higher doses ROS and 
ATP is reduced, leading towards necrotic cell death (Helson 2013). The nutshell of the 
molecular targets of curcumin has been depicted in Figure 1.15 (Anand, Sundaram et al. 
2008). 
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Figure 1.15: Molecular targets of curcumin [Adapted from Anand et. al 2008] 
1.12.4 Epigallocathechin-3- gallate (EGCG) 
 
EGCG is a typical flavone-3-ol phenolic compound with eight free hydroxyl groups belongs 
to catechin group, which is the main component of green tea. Diverse pharmacological 
actions including antioxidant, anti-inflammatory, antidiabetes, antiobesity, antitumour, 
neuroprotective and hepatoprotective activity of EGCG have been reported (Min and Kwon 
2014). Moreover, it reduce blood lipids and sugar, regulate gene expression and molecular 
signalling pathways (Masuda, Suzui et al. 2001, Bose, Lambert et al. 2008).  
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Figure 1.16: Structure of EGCG and its sources 
Antineoplastic effects of EGCG has been investigated extensively in last decades, probably 
due to highest anticancer effects of EGCG among 10 polyphenols present in green tea. The 
anticancer activity of EGCG has been correlated with following: i) Inhibition of carcinogenic 
activity and tumorigenesis; ii) Inhibition of tumour proliferation and angiogenesis; iii) 
Inhibition of tumour migration and invasion; iv) Induction of cell death. Proposed molecular 
mechanism for antitumour action of EGCG has been represented in Figure 1.17. Recently 
combination strategy of EGCG with chemo drugs has taken much attention of scientists and 
reported to enhance the chemotherapeutic effects of bleomycin, capecitabine, cisplatin, 
docetaxel, doxorubicin, Leptomycin B and paclitaxel in combination (Luo, Wang et al. 2010, 
Wu, Xin et al. 2012, Wu, Xin et al. 2012, Hagen, Chedea et al. 2013, Wang, Chen et al. 2014, 
Cromie and Gao 2015, Mayr, Wagner et al. 2015). 
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Figure 1.17: Antitumour mechanism of EGCG 
1.12.5 6-Shogaol (6-SG) 
 
 6-shogaol [1-(4-hydroxy-3-methoxyphenyl)-4-decen-3-one] is the dehydrated form of 6-
gingerol, found in small quantities in fresh ginger (Zingiber officinale) but abundant in dried 
or cooked ginger (Qi, Zhang et al. 2015). 6-shogaol is responsible for the pungent taste of 
ginger and possesses beneficial effects in oxidative stress, neuroinflammation and cognitive 
deficits (Li, Nitteranon et al. 2012, Moon, Kim et al. 2014). Currently, it has been established 
that 6-Shogaol is effective in attenuating ovarian, lung, colon, prostate, breast and skin cancer 
cell growth; and better than 6-gingerol as an anticancer agent (Rhode, Fogoros et al. 2007, 
Kim, Lee et al. 2008, Sang, Hong et al. 2009, Saha, Blando et al. 2014, Ray, Vasudevan et al. 
2015).  
Mechanistic studies for antitumour activity of 6-shogaol revealed variety of interconnected 
signal transduction pathways. It includes apoptosis through the production of reactive oxygen 
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species and activation of caspases (Pan, Hsieh et al. 2008); impairing tubulin polymerization 
(Ishiguro, Ando et al. 2007); inhibition of metastasis through suppression of NFκB activity 
(Ling, Yang et al. 2010); modulation of notch signalling pathway and induction of autophagic 
cell death (Ray, Vasudevan et al. 2015); G2/M cell cycle arrest by p53/p21-cdc2/cdc25A 
crosstalk (Qi, Zhang et al. 2015); activation of peroxisomal proliferator activated receptor γ 
(Tan, Kang et al. 2013); modulation of STAT3 and MAPKs signalling pathways (Kim, Kim 
et al. 2015) and TRAIL-mediated apoptosis through ROS-induced release of Cyt-c and 
reduced expression of c-FLIP(L) (Han, Woo et al. 2015). 
 
Figure 1.18: Structure of 6-shogaol and its sources 
1.13 Rationale of the present study 
 
Platinum based anticancer drugs (cisplatin, oxaliplatin and carboplatin) are still in the 
mainstay of treatment in ovarian, testicular and colorectal cancer; with more than $2 billion 
sales every year. But narrow spectrum of activity, drug resistance and dose limiting side 
effects limit their use. In order to overcome the problems, continuous efforts are being 
applied in designing new platinums as well as other metal based drugs. Indeed, metal 
complexes can be tumour active if they possess the appropriate proportion of kinetic lability 
and thermodynamic stability to bind with the cellular targets. In recent years, palladium based 
complexes have been considered as a major source of getting novel shotgun chemotherapy 
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(Alam and Huq 2016). The present study is a succeeding work of designing tumour active 
palladium complexes carried out in the host laboratory.  
This project continues to synthesize and characterize six palladium compounds namely NH1, 
NH2, NH3, NH4, NH5 and NH6 followed by the determination of antitumour activity of the 
compounds in various cancer models. To gather mechanistic insight into the cytotoxicity of 
the designed compounds, nature of their in vitro interaction with DNA; intracellular 
accumulation; and extent of palladium-DNA binding is also carried out. 
Another goal of this study is to overcome drug resistance through combination of selected 
phytochemicals (emetine and patulin) with cisplatin and oxaliplatin in both ovarian and 
colorectal cancer models. Moreover, this study also attempts to investigate synergism from 
binary combinations of designed palladiums with selected phytochemicals (curcumin, EGCG 
and 6-shogaol) in human ovarian and colorectal cancer cell lines. Since molecular 
mechanisms of action of the designed palladiums and selected phytochemicals are generally 
different, it has been hypothesized that such combinations of novel palladiums with 
phytochemicals may also provide synergistic effect. The outcome of this study will justify the 
use of herbal therapy consumed by cancer patients in addition to targeted therapy; the 
outcome of such combined treatments has not been evaluated. Previous studies from the host 
laboratory revealed either sequence or concentration dependent synergism from combination 
of platinums or palladiums with phytochemicals (Mazumder, Beale et al. 2012, Nessa, Beale 
et al. 2012, Arzuman, Beale et al. 2015, Anwar, Yu et al. 2016).  
Finally we aimed to identify the key proteins that are associated with drug resistance through 
proteomic study. Proteins that expressed differently in sensitive and resistant ovarian cancer 
cells are likely associated in conferring drug resistance and are logical candidates for 
treatment response biomarkers and therapeutic targets (Stewart, White et al. 2006). 
Moreover, proteomic tactics coupled with other biochemical approaches can afford detailed 
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mechanistic insight of metal-based anticancer drugs-induced cell death, correlation of protein 
alterations to drug targets, and prediction of drug resistance and toxicity (Ying and Jen-Fu 
2008). 
The specific objectives of this project are given below- 
 Synthesis of palladium complexes (NH1, NH2, NH3, NH4, NH5 and NH6) using 
bulky planaramine ligands (quinolone, benzimidazole, 8-hydroxyquinoline and 
imidazo[1, 2-α]pyridine) and characterization  
 Determination of the antitumour activity of the complexes and selected 
phytochemicals (Eme, Pat, Cur, EGCG and 6-SG) against selected human ovarian 
(A2780, A2780cisR and A2780ZDO473R), colorectal (HT-29 and CACO-2), breast 
(MCF-7) and cervical (HeLa) carcinoma 
 Binary sequenced combination study with platinums or designed palladiums with 
selected phytochemicals in ovarian and colorectal tumour models   
 Determination of the nature of interaction of the designed palladium compounds with 
DNA  
 Investigation on the relationship between combined drug action with cellular Pt/Pd 
accumulation from administered drugs as well as Pt/PdDNA binding 
 Identification of key proteins responsible for cytotoxicity of drugs alone and in 
combinations 
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Chapter Two 
2  Materials and Methods 
Preamble 
 
This study is a continuation of the project from the Cancer Research Group in the Discipline 
of Biomedical Science, The University of Sydney steered by Associate Professor Fazlul Huq. 
A number of cisplatin analogues, rule breaker platinums, other platinum compounds with 
multiple metal centres and few palladium complexes have been synthesized earlier. 
Synergism from combination of various phytochemicals with cisplatin, carboplatin, 
oxaliplatin and designed novel drugs against ovarian cancer from host laboratory has also 
been investigated. In the present study synthesis of another six novel palladium complexes 
has been attempted using planaramine ligands along with their characterization through X-ray 
crystallography (for 3 compounds), elemental microanalysis, Mass spectroscopy, 1H-NMR 
spectroscopy and IR spectroscopy. Anticancer activity of the designed complexes has been 
investigated against ovarian, colorectal, breast and cervical cancer cell lines. Using agar gel 
electrophoresis, interaction of the complexes with DNA has been carried out. Atomic 
absorption spectroscopy has been used for determination of intracellular accumulation of 
platinum and palladium and levels of platinumDNA and palladiumDNA binding. Studies 
on combination from selected phytochemicals with cisplatin (Cis), oxaliplatin (Ox) and 
designed palladium compounds have also been carried out. To identify the mechanism of 
combined drug action; cellular accumulations of platinum and palladium, levels of 
platinumDNA and palladiumDNA binding have been determined as applied to selected 
drug combinations. Finally, proteomic studies using 2D- gel electrophoresis and mass 
spectroscopy have been carried out to distinguish the significant proteins responsible for 
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cytotoxity of designed palladiums and chemoresistance. Figure 2.1 gives a pictorial view of 
experimental section at a glimpse. The list of the reagents and equipments used in this study 
is given in appendix –I. 
 
 
Figure 2.1: Outline of methodology used in the present study 
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2.1 Synthesis of compounds 
 
2.1.1 Synthesis of NH1 
[Bis(quinoline)palladium(II)chloride] 
 
0.5 millimoles of potassium tetrachloropalladate (0.163 g) were dissolved in 7.5 mL of mQ 
water to which 0.25 mL of concentrated HCl was added. Five millimoles of quinoline (0.60 
mL) was added drop wise over 1 h to the solution of potassium tetrachloropalladate at 50°C. 
The reaction mixture was stirred at room temperature for 2 weeks. 4 mL of 0.25 M 
hydrochloric acid was then added to the mixture and stirring was continued for another 2 
weeks at room temperature. The mixture was centrifuged at 5500 rpm for 10 min to collect 
precipitate of NH1. The crude product was purified by dissolving in 0.05 M HCl, followed by 
filtration and collected after washing successively with ice-cold water and ethanol. The 
purified product was air dried and weighed. 
2.1.2 Synthesis of NH2 
[Tris(benzimidazole)monochloro 
palladium(II)chloride] 
 
0.5 millimoles of potassium tetrachloropalladate (0.163 g) were dissolved in 7.5 mL of mQ 
water to which 0.25 mL of concentrated HCl was added. Five millimoles of benzimidazole 
(0.6 g) dissolved in a mixture of 2 mL of DMF and 2 mL of mQ water, was added drop wise 
over 2 h to the solution of potassium tetrachloropalladate at 45°C. The reaction mixture was 
stirred at room temperature for 2 weeks. 4 mL of 0.25 M hydrochloric acid was added to the 
mixture and stirring was continued for 1 week at room temperature. The mixture was 
centrifuged at 5500 rpm for 10 min to collect precipitate of NH2. The crude product was 
purified by dissolving in 0.05 M HCl, followed by filtration and collected after washing 
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successively with ice-cold water and ethanol. The purified product was air dried and 
weighed. 
2.1.3 Synthesis of NH3 [Bis(1,8 
quinolato)palladium(II)] 
 
0.5 millimoles of potassium tetrachloropalladate (0.163 g) were dissolved in 7.5 mL of mQ 
water to which 0.25 mL of concentrated HCl was added. Five millimoles of 8-
hydroxyquinoline (0.726 g) dissolved in 7.5 mL of ethanol, was added drop wise over 1 h to 
the solution of potassium tetrachloropalladate at 40°C. The reaction mixture was stirred at 
room temperature for 2 weeks. 4 mL of 0.25 M hydrochloric acid was added to the mixture 
and stirring was continued for 1 week at room temperature. The mixture was centrifuged at 
5500 rpm for 10 min to collect precipitate of NH3. The crude product was purified by 
dissolving in 0.05 M HCl, followed by filtration and collected after washing successively 
with ice-cold water and ethanol. The purified product was air dried and weighed. Vapour 
diffusion technique was used during production of suitable crystals of NH3 for 
crystallography using methanol and diethyl ether as solvents. 
2.1.4 Synthesis of NH4 [{Tetrakis- imidazo (1, 2-
)pyridine} Pd(II).2Cl] 
 
0.5 millimoles of K2PdCl4 (0.163 g) were dissolved in 5 mL mQ water and treated with 
concentrated hydrochloric acid (0.25 mL). Six millimoles of imidazo (1, 2-)pyridine (0.608 
mL, 0.708 g) were added drop wise over 1 h to the solution of potassium tetrachloropalladate 
at 50°C. The reaction mixture was stirred at room temperature for 1 week. 2.5 mL of 0.25 M 
hydrochloric acid was added to the mixture and stirred at 40 o C for 24 h and continued 
stirring for another 6 days at room temperature. The mixture was centrifuged at 5500 rpm for 
10 min and the precipitate was separated followed by washing with 0.05 M HCl and ice-cold 
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ethanol plus mQ water. The filtrate was collected and left for crystallization through slow 
evaporation. Crystals of NH4 was observed after one week and then dried via vacuum 
desiccator and collected. 
2.1.5 Synthesis of NH5 [{Bis- imidazo (1, 2-
)pyridine}palladium(II)chloride] 
 
0.5 millimoles of K2PdCl4 (0.163 g) were dissolved in 5 mL mQ water and then hydrolysed 
using concentrated hydrochloric acid (0.25 mL). Four millimoles of imidazo (1, 2-)pyridine 
(0.406 mL, 0.472 g) was added drop wise over 1 h to the solution of potassium 
tetrachloropalladate at 50 o C. After stirring the mixture at room temperature for 1 week, 4 mL 
of 0.25 M hydrochloric acid was added and stirred at room temperature for 1 week and then 
centrifuged at 5500 rpm for 10 min to collect precipitate of NH5. The crude product was 
purified by dissolving in 0.05 M HCl, followed by filtration and collected after washing 
successively with ice-cold water and ethanol. The purified product was air dried and 
weighed. 
2.1.6 Synthesis of NH6 [{Tetrakis- imidazo (1, 2-
)pyridine}Pd(II).2Cl.4H2O. imidazo (1, 2-
)pyridine] 
 
0.5 millimoles of K2PdCl4 (0.163 g) were dissolved in 5 mL mQ water and treated with 
concentrated hydrochloric acid (0.25 mL). 8 millimoles of imidazo (1, 2-)pyridine (0.811 
mL, 0.945 g) were added drop wise over 1 h to the solution of potassium tetrachloropalladate 
at 50°C. The reaction mixture was stirred at room temperature for 1 week. 2.5 mL of 0.25 M 
hydrochloric acid was added to the mixture and stirred for 1 week at room temperature. 
Crystals of NH6 was observed after evaporation of the filtrate but nothing was detected on 
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filter paper during vacuum filtration and washing with 0.05 M HCl, ice-cold ethanol and mQ 
water. 
2.2 Characterization of compounds 
 
Among the synthesized compounds, NH3, NH4 and NH6 produced suitable single crystals 
and characterized by X-ray crystallography along with elemental microanalysis and spectral 
techniques e.g. IR, Mass and HNMR. But for other compounds (NH1, NH2 and NH5) no 
suitable single crystal was observed and characterization was done only through 
microanalysis and spectroscopy.  
2.2.1 X-ray Crystallography 
 
Facility available in School of Chemistry, The University of Sydney, Australia, was used for 
characterization of the compounds (NH3, NH4 and NH6) by X-ray diffractometry. A single 
crystal of each sample was attached with Exxon Paratone N to a nylon loop and quenched in 
a cold nitrogen gas stream from an Oxford Cryosystems Cryostream. Data were collected 
from a SuperNova dual diffractometer  and processed by CrysAlisPro software, included the 
application of a Gaussian and a multi-scan absorption correction (Rigaku 2015). Subsequent 
computations were carried out with the assistance of the WinGX and ShelXle 
interfaces(Hübschle, Sheldrick et al. 2011, Farrugia 2012). 
2.2.2 Elemental microanalysis 
 
Microanalysis was carried out to determine elemental composition of the complexes, using 
Elemental Analyser, Model PE2400 (PerkinElmer, Shelton, CT, USA) available at School of 
Chemistry, Macquarie University, Australia.  
Platinum and palladium contents were determined by graphite furnace atomic absorption 
spectroscopy (AAS).  Varian SpectrAA240 plus Atomic Absorption Spectrophotometer was 
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used for determination of platinum content in cisplatin and palladium in NH1, NH2, NH3, 
NH4, NH5 and NH6. All the glassware used in AAS analysis, were washed with detergent 
first, then soaked in 20% (v/v) HCl for 48 h, followed by 20% (v/v) HNO3 for another 48 h 
and finally rinsed with mQ water. Calibration curves (Figure 2.2 and Figure 2.3) were 
produced based on absorbance values of standard platinum and palladium solutions. The 
furnace parameters were same as those given in the Varian manual (Knowles 1988).  
Platinum standard solution was prepared by diluting 0.001 mL of [970 µg/mL Pt in 5% (v/v) 
HCl] Pt standard solution (purchased from Sigma) with 0.1 M HCl up to 10 mL to get the 
concentration100 ppb. On the other hand, palladium standard solution was prepared by 
diluting 0.049 mL of [1020 μg/mL Pd in 4.8 % (w/v) HCl] Pd standard solution (purchased 
from Mallinckrodt Specialty Chemicals Company) with 0.1 M HCl up to100 mL to get the 
concentration 500 ppb. 
 
Figure 2.2: AAS calibration curve for platinum 
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Figure 2.3: AAS calibration curve for palladium 
2.2.3 Mass spectroscopy 
 
Mass spectra aids in characterization of a compound by determining the molecular ion mass 
and masses of the molecular fragments. Generally during mass spectroscopy, a high energy 
electron beam from an ionizing source is bombarded on the sample and breaks it into 
molecular ion and other fragments of the molecule. The fragmented ions are separated on the 
basis of their mass to charge ratio (m/z).  
Mass spectral characterization of NH1, NH2, NH3, NH4, NH5 and NH6 was conducted in 
the School of Chemistry, The University of Sydney. Solutions of the compounds were made 
by dissolving each sample in 10% DMF and 90% methanol and then 2 µL was transferred 
into a drawn glass capillary pre sputter coated with silver and inserted into a nanospray 
holder attached to a Thermo Orbitrap mass spectrometer with flow rate set at 0.2 mL/min 
consisting of methanol/water mixture (50% v/v) and ions being observed in positive ion 
mode.  
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2.2.4 1H-NMR spectroscopy 
 
In this study 1HNMR spectrum was used to identify the functional groups present in the 
synthesized compounds. During obtaining 1H-NMR spectra of the compounds using a Bruker 
AVANCE DPX400 spectrometer, NH1and NH3 were dissolved in deuterated DMSO; NH2, 
NH4 and NH6 were dissolved in D2O; NH5 was dissolved in deuterated DMF. All spectra for 
respective compounds were referenced to internal solvent residues and recorded at 300 K (±1 
K).    
2.2.5 IR spectroscopy 
 
Since infrared spectrum of a molecule is considered as the fingerprint of the molecule, 
infrared (IR) spectroscopy is commonly used for structural characterization and compound 
identification. In the present study, IR spectroscopy was used to detect functional groups 
towards structural elucidation of the compounds. IR spectra of NH2 and NH3 were recorded 
using a Varian FT-IR spectrometer. But IR characterization of NH1, NH4, NH5 and NH6 
was conducted using PerkinElmer FT-IR spectrometer.  
2.3 Antitumour activity of single drug and 
combination study 
 
2.3.1 Cell lines  
 
Three ovarian cancer cell lines (A2780, A2780CisR and A2780ZDO473R), two colorectal cancer 
cell lines (HT-29 and CACO-2), one breast cancer cell line (MCF-7) and one cervical cancer 
cell line (HeLa) were used for determination of anticancer activity of the synthesized 
complexes. But for combination study two ovarian cancer (A2780, A2780CisR) and two 
colorectal cancer (HT-29 and CACO-2) cell lines were used. Among all of the cell lines, 
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ovarian cancer cell lines were obtained from Dr Philip Beale (NSW Cancer Centre, Royal 
Prince Alfred Hospital, Sydney, Australia) as a gift. HeLa, HT-29 and CACO-2 cells were 
obtained as a gift from Dr. Mu Yao (Department of Endocrinology, The University of 
Sydney, Australia); MCF-7 cells were also obtained as a gift from Dr. Aviva Levina 
(Department of Chemistry, The University of Sydney, Australia).   
2.3.2 Recovery of cells  
 
The vials containing the desired cells were taken out from the cryogenic liquid nitrogen 
container and thawed at 37ºC until fifty percent of the liquid melted. The cells from 
respective vials were shifted into pre-labelled tubes bearing 9 mL of culture medium. The 
sterile tubes were then spun at 2500 rpm for 2 min and the medium was discarded from tubes. 
Fresh cell suspensions were made by the addition of 2 mL of new medium to the cells in each 
tube. The cell suspensions were then transferred into pre-labelled flasks each having 8 mL of 
new medium and incubated in 5% (v/v) CO2 incubator at 37 ºC. 
2.3.3 Maintenance of cell lines 
 
Monolayer cell culture technique was used for maintenance of cells where respective cell 
lines were grown in tissue culture flasks using CO2 incubator in appropriate conditions 
(37°C, 95% air v/v and 5% CO2). Media of the cell culture flasks were first withdrawn and 
discarded. The flasks were then rinsed with 1 mL of PBS to remove traces of serum that 
would inhibit the action of the trypsin. 1 mL of 0.05% (w/v) trypsin was added to each flask 
which was rotated to cover the entire cell layer by trypsin. After incubation of the flasks for 3 
min in the incubator at 37°C, cell detachment was checked by tilting the flasks. 9 mL of 10% 
(w/v) fetal bovine serum (FBS) was then added to the each flask to inhibit the action of 
trypsin. The cells in the medium were counted and appropriate dilution of cells was set up. 
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During subculture, 9 mL of this cell suspension was withdrawn from the flask; reconstituted 
by adding 9 mL of fresh 10% (w/v) FBS to each flask and returned to the incubator.  
2.3.4 Storage of cell lines 
 
The late log phase growth cells were collected, centrifuged and then resuspended in 10% 
(w/v) FBS/RPMI 1640 media at a concentration of 1.95 x 105 cells/mL. 20% (v/v) of DMSO 
(equal in volume to that of the cell suspension) was slowly added to the cells to give a final 
DMSO concentration of 10% (v/v). 1 mL of this mixture of cells and cryoprotectant (DMSO) 
was then transferred to pre-labelled vials and stored into cryogenic liquid nitrogen container. 
2.3.5 Preparation of media, phosphate buffer saline 
and 0.05% tripsin 
 
Medium used in the study was prepared by mixing 450 mL of RPMI 1640, 50 mL of fetal 
bovine serum, and saturated 0.25 mL NaOH. Phosphate buffer saline (PBS) solution was 
prepared by adding 900 mL of mQ water to 9.6 g PBS powder in a one litre volumetric flask 
while the mixture was gently stirred.  After dissolving PBS powder, the pH of the solution 
was adjusted to 7.5 using 1 M NaOH. Final volume of the solution was made up to 1 L by 
adding mQ water and then it was immediately sterilised using membrane filter (0.22 μm). 
For 0.05 % tripsin solution, 10 ml of 0.5% (w/v) Trypsin-EDTA solution 10X and 80 ml of 
PBS were mixed together and pH was adjusted to 7.5 using 1 M HCl. Final volume was made 
up to 100 mL with PBS, immediately sterilised using membrane filter (0.22 μm). 
 
2.3.6 Cell counting and seeding 
 
After growing the cells in tissue flaks (incubated at humidified atmosphere of 37°C, 95% air 
v/v and 5% CO2) the cells were counted by Bio-Rad TC10 automated cell counter and seeded 
into the plates. After counting, respective cell lines were seeded in separate 96 well plates. 
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4000-6000 cells/well in 10% FBS/RPMI 1640 culture medium were seeded into corning flat-
bottomed 96-well culture plates. 100 μL of cell mixture (cells in the medium) were added to 
each well. The plates were then incubated for 24 h in 5% CO2 incubator. 
2.3.7 Preparation of drug solutions 
 
Depending on the solubility of drugs, different solvents e.g. mQ water, DMF, ethanol and 
DMSO were used. When DMF and water together were used as solvent, drugs were first 
dissolved in a 1 mL of DMF, then diluted by adding mQ water and finally filtered to sterilize. 
Stock solutions of each drug were sterilized using 0.22 μM membrane filter and aliquoted 
into several 5 mL tubes and stored at 4°C. Each of the stock solutions was serially diluted 
using RMPI 1640 medium as the vehicle to give final concentrations. Final volume of 
solutions at each concentration was 2 mL. The following Table 2.1 shows details of 
calculation for preparing drug samples.  
Table 2.1: Preparation of stock solution of drugs 
Drug Formula 
weight 
Concentration 
(g/5 mL) 
Solvent (Ratio) 
Cisplatin (Cis) 300 1 mM (0.001) DMF + mQ H2O (1:4) 
Oxaliplatin (Ox) 397.29 2.5 mM (0.003) DMF + mQ H2O (1:4) 
NH1 435.65 0.5 mM (0.001) DMSO 
NH2 531.71 5 mM (0.013) Ethanol + mQ H2O (1:1) 
NH3 394.70 0.5 mM (0.0009) DMSO 
NH4 649.85 1 mM (0.0032) mQ H2O 
NH5 413.60 1 mM (0.002) Ethanol 
NH6 840.05 1 mM (0.004) mQ H2O 
Emetine (Eme) 553.6 10 mM (0.027) mQ H2O 
Patulin (Pat) 154.12 5 mM (0.0038) Ethanol 
Curcumin (Cur) 368.38 10 mM (0.018) Ethanol 
EGCG 458.37 10 mM (0.022) mQ H2O 
6-Shogaol (6-SG) 276.37 10 mM (0.013) Ethanol 
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2.3.8 Addition of drugs into cells 
 
Each cell line was plated at a density of 3500 to 5500 cells/ well in 96 well plate and left 
overnight in CO2 incubator at 37°C. Later on, different concentrations of drugs (as described 
in the previous section) were added to the cells contained in 96 well plates. Each treatment 
was done in triplicate in the same plate while the control wells did not receive any drug 
treatment (contained cells and medium only). The plates were then incubated again for 72 h 
in CO2 incubator. Generally, each plate was designed for three different types of drug 
treatments at four different concentrations. 
2.3.9 MTT [3-(4, 5-dimethythiazol- 2-yl)-2,5-diphenyl 
tetrazolium bromide] assay 
 
Inhibition of cell growth was determined by MTT assay on the basis of formation of 
formazan crystals observed in living cells due to reduction of MTT through mitochondrial 
succinate dehydrogenase. MTT solution was prepared by dissolving 1 mg/mL of MTT 
powder into serum free-RPMI-1640 medium and then filtered using membrane filter (0.45 
μM). After 72 h of incubation of the cells in 96 well plates, the medium was drained from the 
plates. 50 μL of the MTT solution was added to each well, and placed in the incubator for 
four hours. Following this, the MTT solution was drained and 150 μL of DMSO solution was 
added to each well. The living cells if still present remained attached at the bottom of the well 
in plate which can be distinguished by purple colour. The optical density (OD) values of the 
living cells were read at 550 nm using iMarkTM Bio-Rad Microplate Reader Version 
1.04.02E.  
2.3.10 Calculation of IC50 value and RF 
 
The required drug concentration for killing 50% of cell population is termed its IC50 or half 
maximal inhibitory concentration which was determined from the plot of percentage of alive 
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cells against concentration (dose-response curves). For each drug concentration in a particular 
cell line, at least three independent experiments were conducted. The resistance factor (RF) is 
known as the concentration of the drug required for 50% cell kill in the resistant cell line over 
the same in the parent cell line. 
2.3.11 Combination study 
 
During combination studies, cells were treated at three different concentrations of compounds 
and their combinations applying to three sequences of administration: 0/0 h, 0/4 h and 4/0 h. 
Bolus or 0/0 h indicates both platinum or palladium drug and phytochemicals added 
simultaneously. 0/4 h indicates platinum or palladium drug added first followed by 
phytochemicals four hours later while 4/0 is converse.  
Cells were treated at three different concentrations of compounds and their combinations, 
generally at constant ratios of their IC50 values in human ovarian cancer (A2780 and 
A2780cisR); human colorectal cancer (HT-29 and CACO-2) cell lines as shown in Table.2.2.  
Table 2.2: Summary of ratio of platinum/palladium drugs and phytochemicals used in 
combination study 
Combinations Molar Ratio 
Ovarian cancer cell lines Colorectal cancer cell lines 
A2780 A2780cisR HT-29 CACO-2 
Cisplatin + Emetine 1: 0.046 1: 0.003 Not done Not done 
Cisplatin + Patulin 1: 1.52 1: 0.222 Not done Not done 
Oxaliplatin + Emetine Not done Not done 1: 0.046 1: 0.066 
Oxaliplatin + Patulin Not done Not done 1: 1.79 1: 4.02 
NH1 + Curcumin 1: 1.24 1: 1.26 Not done Not done 
NH1 + 6-Shogaol 1: 1.73 1: 0.097 Not done Not done 
NH3 + Curcumin 1: 63.55 1: 76.07 1: 199.97 1: 61.43 
NH3 + EGCG 1: 64.20 1: 52.31 1: 278.26 1: 177.16 
 
Dose response curves and IC50 values of compounds were used as a guideline to design the 
concentration ratios in combination studies. The established methodology in the host 
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laboratory has been used for drug addition in combination study. In short, 100 μL of cells 
were seeded in each well of the 96-well plate before treatment with compounds while 
untreated cells served as the control. The plates containing treated cells were incubated in 
CO2 incubator for 72 h. MTT reduction assay was then performed to determine inhibition of 
cell growth applying to combined and single drug treatments. Combination index (CI) values 
were calculated using the Chou-Talalay method (Chou 2010) to provide a quantitaive 
measure of synergism, additiveness or antagonism. At least triplicate measurements were 
done for each experiment.  
2.3.12 Combination indices (CI) analysis 
 
Combination index is the quantitative measurement of combined drug action which can be 
defined as sum of the quotients of drug concentrations used in the study. According to Chou 
and Talalay median-effect equation, CI value for two drugs is calculated as follows (Chou 
2010):  
 
In the above equation, D1 = dose of first drug during combination for x% inhibition; D2 = 
dose of second drug during combination for x% inhibition; D1x = dose of first drug for x% 
inhibition when acting alone; D2x = dose of second drug for x% inhibition when acting alone. 
In the present study Calcusyn software (V2) (Biosoft, UK) was used for calculation of CI 
values and described as synergistic when CI < 1, additive when CI =1 and antagonistic when 
CI > 1. For the cell culture study the linear correlation coefficient (r), greater than 0.95 was 
considered as good. 
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2.4 DNA damage study 
 
This study was conducted to obtain the preliminary idea that whether the drug kill the cancer 
cells though interaction with DNA. NH3, NH4, NH5 and NH6 were chosen for DNA damage 
study in A2780, A2780CisR and HT-29 Cell lines. Drugs selected for DNA damage study were 
added to exponentially growing cells and collected as cell pellets for further extraction of 
DNA. Established cell collection methodology in the host laboratory is given in Figure 2.4. 
 
Figure 2.4: Cell collection methodology 
 
EZ-10 spin column genomic DNA minipreps KIT was used for genomic DNA extraction. 
The protocol described for cultured animal cell in the KIT was exactly followed to obtain 
pure genomic DNA. Briefly, the pellet was resuspended with ACL solution buffer and mixed 
with protenase K and then incubated at 55°C for 10 min. RNase A was added and vortexed; 
incubated at room temperature for 5 minutes and then centrifuged for 5 minutes at 12,000 
rpm for 5 minutes. Supernatant was taken and mixed with AB solution for 2 minutes. After 
discarding flow through, wash solution was added and spun at 10,000 rpm for 1 minute. The 
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columns were put into Eppendorf tubes and elution buffer was added and incubated at 50° C 
for 2 minutes. The tubes were centrifuged 10,000 rpm for 2 minutes to elute the DNA and 
then quantified UV absorption spectrophotometer at 260 nm. 
Before starting electrophoresis TAE buffer (100 mL 50 X TAE buffer 24.22 g of 2M Tris 
base, 5.71 mL of 2M glacial acetic acid and 1.861 g of 50 mM EDTA were mixed together in 
94.3 mL of mQ water) and 1% agarose gel was prepared. To achieve the concentration of 
working 1 X TAE buffer solution, 40 mL of 50X TAE buffer solutions was then diluted with 
mQ water to give 2000 mL. Agarose gel was prepared by mixing 2 g of agarose gel power 
with 200 mL of ready prepare 1 X TAE buffer. The mixture was boiled for 2 minutes in 
microwave, mixed through swirling and continued to boil for five minutes more. After 
cooling at room temperature for a while 125 mL of ethidium bromide was added into the gel 
and swirled. The gel was gently transferred into the tray with comb placed in position and 
then solidified at room temperature. In the beginning of electrophoresis, 250 µL of ethidium 
bromide was poured into both sides of electrophoresis chamber and the gel was immersed 
into the electrophoresis chamber filled with TAE buffer. The samples selected for DNA 
damage study including the blank were defrosted and mixed with 2 μL of marker dye [0.25% 
v/v bromophenol blue and 40% (w/v) of sucrose]. Each sample was then loaded onto agarose 
gel and then electrophoresis was conducted at 120 V for 2 hours. DNA bands were observed 
under UV light and gel pictures were taken by a Kodak Gel Logic 100 imaging system. The 
images were then analyzed using Kodak molecular imaging software (Kodak MI software). 
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2.5 Cellular accumulation metalDNA 
binding assay 
 
The objective of this study was to identify the mechanism of drug action (alone and in 
combination). Specifically to identify the relationship between combined drug action with 
their cellular uptake level and DNA binding level. Table 2.4 details the selected drugs and 
their sequence of administration in respective cell lines for the study. 
2.5.1 Cellular accumulation study protocol 
 
Since cytotoxicity assay proved NH3 to be the most active drug, mechanistic studies were 
concentrated mainly on NH3 as a single drug and in combination with selected 
phytochemicals. That is why, uptake of NH3 as a single drug was determined in A2780, 
A2780cisR, HT-29 and CACO-2 cell lines. Cellular uptake of cisplatin and oxaliplatin were 
used as reference in ovarian and colorectal cancer models respectively. NH1 was also chosen 
as a single drug to determine their uptake in A2780 cell line. 
From all combination sets NH3 + Cur (0/4) and NH3 + EGCG (0/0) in A2780 cell line; NH3 
+ Cur (0/4) and NH3 + EGCG (0/4) in A2780cisR cell line; NH3 + Cur (4/0) in HT-29 cell 
line and NH3 + EGCG (0/4) in CACO-2 cell line were selected for cellular accumulation 
study. Table 2.3 gives the final concentration of the selected drugs used in cellular uptake, 
metal-DNA binding and proteomics study. 
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Table 2.3: Final concentration of drugs used for mechanistic study 
Drug Concentration of drugs (µM) 
Cisplatin 1000 
Oxalipaltin 84 
NH3 33 
NH1 500 
Curcumin 2250 
EGCG 4989 
Emetine 9.5 
6-Shogaol 1890 
Patulin 472 
 
For determining the uptake as a single drug, 0.125 µl of the drug and 0.125 µl of milliQ water 
were added into the culture disks seeded with the desired concentration of respective cells. 
Whereas in case of combination sets, 0.125 µl of both drugs were added into the culture disks 
after 24 hours of seeding of the cells in desired concentration. Cell pellet was collected as 
pictorially described earlier in Figure 2.4.  
For determination of platinum content, each of the cell pellets was suspended in 0.5 mL 1% 
triton-X, held on ice while being sonicated for 30 minutes to lyse the cells. (Farrell, Kelland 
et al. 1992). The lysed cells were then centrifuged for 2 minutes at 14,000 rpm and 
supernatant was collected for total intercellular platinum assay by graphite furnace AAS as 
described in section 2.2.2.  
2.5.2 Metal-DNA binding study protocol 
 
The same set of drugs (as mentioned for cellular accumulation study) was selected for metal-
DNA binding study to get further mechanistic view. In case of cisplatin and oxaliplatin, 
levels of platinum-DNA binding were investigated while for designed palladium complexes 
levels of palladium-DNA binding were determined. Pure genomic DNA was extracted 
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following the method described in section 2.4 and metal contents bound with DNA were 
measured using the same strategy mentioned in section 2.2.2.  
2.6 Proteomic study 
 
Proteomics is a latest discipline which comprehends the study and characterization of 
proteome (protein products of genome). Other than the analysis of protein cellular activities 
and functions, proteomics study give information regarding the protein networks organized in 
discrete signal transduction pathways (Wang, He et al. 2006). To identify the key proteins 
responsible for anticancer action of selected drugs administered alone and in combination, 1-
D and 2-D gel electrophoresis were conducted in this study. 
The objectives of this study were (1) To identify the proteins which are responsible for 
anticancer effect of the novel palladium NH3 in ovarian cancer cells (2) To find the proteins 
that are responsible for cisplatin resistance in ovarian cancer cells (3) To search for the 
proteins that are responsible for the synergistic action of the combined drug treatment (4) To 
identify the proteins that contribute to antitumour activity of NH3 and NH1 in colorectal 
cancer cells. 
2D-gel protein profiles of non-treated cells were compared and analysed. The 2D-gel profiles 
were then compared with those from single drug treatment and with combined drug 
treatments. The analysis of the protein spots was performed using the updated Melanie 7.0 
software. Table 2.4 lists the compounds alone or in combination selected for proteomic study 
and Figure 2.5 visualizes the experimental outline of proteomic study. Further details are 
provided in Appendix-II. 
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Table 2.4: Drugs of choice for proteomic study 
Selected drug 
(alone/combination) 
Sequence 
of addition 
Cell line Amount added to culture dish 
(µL) 
NH3 alone ---- A2780, A2780CisR 
and HT-29  
0.375 (NH3) + 0.375 (media) 
NH1 alone ---- HT-29 0.375 (NH1) + 0.375 (media) 
Cisplatin, Emetine 0/4 
4/0 
A2780 
A2780CisR 
0.375 (Cis) + 0.375 (Eme) 
Cisplatin, Patulin 4/0 A2780CisR 0.375 (Cis) + 0.375 (Pat) 
NH3, Curcumin 0/4 
0/4 
4/0  
A2780 
A2780CisR 
HT-29 
0.375 (NH3) + 0.375 (Cur) 
NH3, EGCG 0/0 
0/4 
0/4 
A2780 
A2780CisR 
CACO-2 
0.375 (NH3) + 0.375 (EGCG) 
Oxaliplatin, Patulin 0/0 
0/0  
HT-29 
CACO-2 
0.375 (Ox) + 0.375 (Pat) 
NH1, 6-Shogaol 0/4 A2780 
 
0.375 (NH1) + 0.375 (6-SG) 
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Figure 2.5: Flow diagram for proteomic study 
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CHAPTER THREE 
3  RESULTS 
 
3.1 Structures  
 
Among six designed complexes (NH1, NH2, NH3, NH4, NH5 and NH6) structures of 
three (NH3, NH4 and NH6) were characterized by X-ray crystallography. Table 3.1 
gives the information relating to their physical appearance and percent yield and 
Figure 3.1 portrays the structure of all synthesized palladium compounds.   
Table 3.1: Molecular weight, physical state and yield of designed complexes 
Compound (MW) Physical appearance Percent Yield (%) 
NH1 (435.65) White powder 94.47 
NH2 (531.74) White powder 89.84 
NH3 (394.73) Orange powder, Orange crystal 82.32 
NH4 (649.85) Colourless crystal 59.69 
NH5 (413.6) Cream colour powder 77.18 
NH6 (840.05) Colourless crystal 79.15 
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Figure 3.1: Structure of designed complexes 
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3.2 Elemental composition 
 
The result of elemental microanalysis is being presented in Table 3.2 in terms of the 
percentage of carbon (C), hydrogen (H), nitrogen (N) and palladium (Pd) for compounds 
NH1, NH2, NH3, NH4, NH5 and NH6. 
Table 3.2: Elemental composition of synthesized palladium complexes 
Element NH1 (MW=435.65) NH2 (MW=531.74) 
Calculated (%) Observed (%) Calculated 
(%) 
Observed (%) 
C 49.63  50.41 ± 0.4 47.43  48.87 ± 0.4 
H 3.24  3.24 ± 0.4 3.41  3.31 ± 0.4 
N 6.43  6.45 ± 0.4 15.80  16.14 ± 0.4 
Pd 24.43  24.71 ± 1.0 20.01  19.87 ± 1.0 
Element NH3 (MW=394.73) NH4 (MW=649.85) 
Calculated (%) Observed (%) Calculated 
(%) 
Observed (%) 
C 54.77  55.15 ± 0.4 51.75  51.48 ± 0.4 
H 3.06  3.67 ± 0.4 3.72  3.50 ± 0.4 
N 7.10  6.94 ± 0.4 17.24  17.06 ± 0.4 
Pd 26.96  26.64 ± 1.0 16.38  16.65 ± 1.0 
Element NH5 (MW=413.6) NH6 (MW=840.05) 
Calculated (%) Observed (%) Calculated 
(%) 
Observed (%) 
C 40.66  41.19 ± 0.4 50.06  49.28 ± 0.4 
H 2.92  2.56 ± 0.4 4.56 4.50 ± 0.4 
N 13.55 13.31± 0.4 16.67 16.76 ± 0.4 
Pd 25.73  25.44 ± 1.0 12.67  12.63 ± 1.0 
 
3.3 Spectral analyses 
 
To aid in the structural characterization of the compounds, spectral studies involving infrared 
(IR), mass (MS) and 1H NMR were carried out. Majority of the peaks are assigned on the 
basis of reported spectra of the ligands and their corresponding metal complexes (Daghriri, 
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Huq et al. 2004, Cheng, Huq et al. 2006, Mazumder, Beale et al. 2012, Arzuman, Beale et al. 
2014, Arzuman, Beale et al. 2016). 
3.3.1 IR Spectra 
 
The IR spectra of NH1, NH2, NH3, NH4, NH5 and NH6 are given in Figure 3.2 to Figure 3.7 
respectively. The major peaks of the designed compounds are mentioned in Table 3.3 where 
‘s’ indicates strong, ‘m’ indicates medium, ‘w’ refers to weak, ‘br’ refers to broad and ‘d’ 
stands for doublet. Detailed discussion of the observed IR bands corresponding to the 
functional groups or chemical bonds are described in chapter four. 
Table 3.3: Selected peaks in IR spectra 
Compounds IR (cm-1) 
NH1 1588 (m, br with a shoulder, C=N stretch), 1461 (s, ring stretch), 
1392 (m, C-H bending), 1316 (s, C-N Stretching), 1210 (m, C-N 
Stretching), 1130 (m, C-C bending), 869 (w, CH aromatic stretching), 
753 (s, CH out of plane bending), 644 (s, aromatic C=C bending) and 
514 (w, Pd-N) 
NH2 3072 (w, CH aromatic),  1504 (s, ring stretch) 1435 (m, ring stretch), 
1263 (m, C-N stretch),  819 (s, aromatic out of plane bending), 744 
(s, CH out of plane bending) and 516 (w, Pd-N) 
NH3 3055 (w, CH stretch),  2360 (s, ring stretch),  2341 (s, ring stretch),  
1572 (m, C=C ring stretch), 1497 (s, d ring stretch), 1461 (s, br with a 
shoulder ring stretch), 1372 (s, OH bending), 1316 (m, C-N 
stretching), 1283 (s, CO stretch), 1214 (m, C-N stretching), 1172 (s, 
CO stretch), 1114 (m, C-C bending), 824 (s, aromatic out of plane 
bending), 738 (s, CH out of plane bending),  657 (s, CH out of plane 
bending) and 529 (w, Pd-N) 
NH4 3369(s, CH stretching),  3152(w, CH aromatic), 3061(w, CH 
aromatic), 1827(w, CH bending aromatic), 1653(w, CH bending 
aromatic), 1635(m, ring stretch),  1510 (s, ring stretch) , 1319 (m, C-
N stretching), 1181(m, C-N), 738 (s, CH), 569(w, Pd-N) and 422 (w, 
Pd-N) 
NH5 3133 (w, CH aromatic), 1637 (m, ring stretch), 1509 (s, ring stretch) , 
1320 (m, ring stretch), 1163 (m, C-N), 1039 (s, CH in plane bending), 
746 (s, CH), 552 (w, Pd-N), and 427 (w, Pd-N) 
NH6 3392 (s, CH stretching), 3101(w, CH aromatic), 1636 (m, ring 
stretch), 1505 (s, ring stretch), 1319 (m, C-N stretching), 1170 (m, C-
N), 758 (s, CH), 594 (w, Pd-N), 449 (w, Pd-N) and 424 (w, Pd-N) 
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Figure 3.2: IR spectrum for NH1 
 
Figure 3.3: IR spectrum for NH2 
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Figure 3.4: IR spectrum for NH3 
 
 
Figure 3.5: IR spectrum for NH4 
97 
 
 
Figure 3.6: IR spectrum for NH5 
 
 
Figure 3.7: IR spectrum for NH6 
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3.3.2 Mass Spectra 
 
Major peaks for the designed palladiums are shown in Table 3.4 and spectra are given in 
figure 3.8 to 3.13. 
Table 3.4: Prominent peaks in MS spectra  
Compounds MS (ESI) m/z  
NH1 [Pd(C9H7N)2Cl2] 
(MW=435.65) 
[{Pd(C9H7N)2Cl2}2 Cl]=834.94 (100%); 
[{Pd(C9H7N)2Cl2}2 Cl + 3H]=803.54 (55%); 
[Pd(C9H7N)2Cl2 + C9H7N Cl ]=485.30 (30%); 
[Pd(C9H7N)2Cl2 Cl]=400.98 (30%); 
[Pd(C9H7N)2Cl2]=457.27 (40%). 
NH2 [Pd(C7H6N2)3Cl2] 
(MW=531.74) 
[Pd(C7H6N2)3Cl2 Cl + H]=479.03 (100%); 
[Pd(C7H6N2)3Cl2 Cl + C7H6N2]=579.10 (35%); 
[Pd(C7H6N2)3Cl2 + C7H6N2 + H2O + 3H]=670.87 (3.5%). 
NH3 [PdC18H12N2O2] 
(MW=394.73) 
[PdC18H12N2O2]=395.00 (100%); 
[PdC18H12N2O2 + PdC18H12N2O2]=789.99 (18%); 
[PdC18H12N2O2 + PdC18H12N2O2 + H2O + 4H]=811.97 (33%); 
[PdC18H12N2O2 + PdC18H12N2O2 + 2H2O + 2H]=827.71 (7%); 
[PdC18H12N2O2 + H2O + 3H]=416.98 (18%); 
[PdC18H12N2O2 + Cl + H2O  3H]=445.35 (13%). 
NH4 [PdC28H24N8.Cl2] 
(MW=649.85) 
[Pd(C7H6N2)4.Cl C7H6N2]=497.03(100%); 
[Pd(C7H6N2)4.Cl C7H6N2 C7H6N2]=378.97(75%) 
[Pd(C7H6N2)4.Cl C7H6N2 C7H6N2 Cl]=342.00(27%) 
NH5 [Pd(C7H6N2)2Cl2] 
(MW=413.6) 
[Pd(C7H6N2)2Cl2 Cl]=378.97 (100%); 
[Pd(C7H6N2)2Cl2 + C7H6N2 Cl)]=497.03 (85%); 
[Pd(C7H6N2)2Cl2 Cl]=342.00 (36%); 
[Pd (C7H6N2)2 Cl2 + H2O + 5H]=436.93 (7%). 
NH6 
[PdC35H38N10Cl2O4] 
(MW=840.05) 
[Pd (C7H6N2)4.4H2O.2Cl.(C7H6N2)(C7H6N2) 4H2O Cl]=378.97 
(100%); 
[Pd (C7H6N2)4.4H2O.2Cl. (C7H6N2)(C7H6N2) 4H2O Cl]=344.00 
(72%); 
[Pd (C7H6N2)4.4H2O.2Cl.(C7H6N2)(C7H6N2) 4H2O Cl]=497.03 
(30%); 
[Pd (C7H6N2)4.4H2O.2Cl.(C7H6N2)(C7H6N2) H2O]=289.05 (32%). 
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Figure 3.8: Mass spectrum of NH1 
 
Figure 3.9: Mass spectrum of NH2 
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Figure 3.10: Mass spectrum of NH3 
 
 
Figure 3.11: Mass spectrum of NH4 
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Figure 3.12: Mass spectrum of NH5 
 
Figure 3.13: Mass spectrum of NH6 
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3.3.3 1H-NMR Spectra 
 
The major peaks observed in 1H-NMR spectra of NH1, NH2, NH3, NH4, NH5 and NH6 are 
listed in Table 3.5. The numbering of atoms for the respective ligands used in designed 
palladium complexes is given in Figure 3.14. The spectra of the designed palladium 
complexes are given in Figures 3.15 to 3.20. The letters s, d, t, q, m and br stand for singlet, 
doublet, triplet, quartet, multiplet and broad respectively.  
 
      
Quinoline ligand in NH1     Benzimidazole ligand in NH2  
      
8-hydroxyquinoline ligand in NH3 Imidazo (1,2-α)pyridine ligand in NH4 to NH6  
Figure 3.14: Numbering of atoms in the ligands 
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Table 3.5: Prominent peaks observed in 1H-NMR spectra  
Compound 1H-NMR peaks 
NH1 
DMSO δ ppm: 8.91(d, due to C2H); 8.69 (t, due to C3H); 8.38 (d, due to 
C4H); 8.14 (d, due to C5H); 8.02 (m, due to C6H); 7.85 (t, due to C7H); 7.79 
(t, due to C8H); 7.57 (m, due to) 2.49 (s, due to DMSO) 
NH2 D2O δ ppm: 8.53 (s, due to C2H; 8.39 (d, due to C4H); 8.23 (s, due to NH); 
7.73 (t, due to C5H); 7.45 (t, due to C6H); 7.24 (t, due to C7H); 7.13 (t, due 
to); 6.89 (s, due to) 
NH3 DMSO δ ppm: 8.58 (d, due to C2H); 8.47 (d, due to C2H); 7.67 (q, due to 
C6H); 7.46 (t, due to C3H); 7.11 (d, due to C4H); 6.93 (d, due to C7H); 3.69 
(s, due to water); 2.49 (s, due to DMSO). 
NH4 D2O δ ppm: 8.70 (d, due to CH), 8.38 (d, due to CH), 8.11 (s, due to CH), 
7.94 (m, due to CH), 7.84 (d, due to CH), 7.53 (d, due to CH), 7.46 (m, due 
to CH), 7.34 (t, due to CH), 7.03 (t, due to CH), 4.80 ppm (s, due to D2O) 
NH5 DMF δ ppm: 8.73 (d, due to CH), 8.55 (d, due to CH), 8.16 (d, due to CH), 
7.50 (d, due to CH), 7.63 (m, due to CH), 7.20 (m, due to CH), 8.02 (s, due 
to DMF), 3.50 (s, due to water), 2.92 (s, due to DMF), 2.75 ppm (s, due to 
DMF) 
NH6 D2O δ ppm: 8.40 (q, due to CH), 7.84 (d, due to CH), 7.59 (d, due to CH), 
7.51 (d, due to CH), 7.41 (q, due to CH), 7.34 (q, due to CH), 7.03 (t, due to 
CH), 6.981 (s, due to CH), 4.80 ppm (s, due to D2O). 
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Figure 3.15: 1H-NMR spectrum of NH1 
 
Figure 3.16: 1H-NMR spectrum of NH2 
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Figure 3.17: 1H-NMR spectrum of NH3 
 
 
Figure 3.18: 1H-NMR spectrum of NH4 
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Figure 3.19: 1H-NMR spectrum of NH5 
 
Figure 3.20: 1H-NMR spectrum of NH6 
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3.4 X-ray crystallographic analysis of NH3, 
NH4 and NH6 
 
X-ray crystallography provides three dimensional molecular structure applying to crystal of a 
compound. Since x-ray crystallography is the technique that provides exact structure of a 
compound, attempts were made to crystallize the synthesized novel compounds. But only for 
NH3, NH4 and NH6, suitable single crystals could be grown succesfully. A suitable crystal is 
bombarded with an x-ray beam at a particular wavelength to obtain the diffraction pattern. 
The resulting diffraction pattern is intially processed to yield information about crystal 
packing and size of the repeating unit forming the crystal. Intensities of diffraction spots are 
used to determine “structure factors” from which a map of the electron density is calculated. 
The resulting structure is then refined to conform with the map more accurately and to adopt 
a thermodynamically favoured conformation (Smyth and Martin 2000). 
3.4.1 Crystal structure of NH3 
 
Formula C18H12N2O2Pd, M 394.70, monoclinic, space group P21/c(#14), a 9.3997(4), b 
10.1091(4), c 14.8435(6) Å, 100.769(4), V 1385.62(10) Å3, Dc 1.892 g cm
-3, Z 4, crystal 
size  0.062 by 0.060 by 0.016 mm, colour orange, habit plate, temperature 150(1) Kelvin, 
(Cu K) 1.5418 Å, (Cu K) 10.906 mm-1, Tmin,max 0.54, 1.00, 2max 152.46, hkl range 
-11 8, -12 12, -18 18, N 14466, Nind 2895(Rmerge 0.0884), Nobs 2155(I > 2(I)), Nvar 209, 
residuals* R1(F) 0.0470, wR2(F2) 0.1135, GoF(all) 1.204, min,max -0.917, 1.786 e
- Å-3.  
 
*R1 = ||Fo| - |Fc||/|Fo| for Fo > 2(Fo); wR2 = (w(Fo
2 - Fc
2)2/(wFc
2)2)1/2 all 
reflections w=1/[2(Fo
2)+(0.04P)2+1.0P] where P=(Fo
2+2Fc
2)/3 
 
Following tables (3.6 to 3.10) give different atom coordinates, thermal parameters (isotropic 
and anisotropic), occupancies, bond angles and bond lengths observed in crystal structure of 
NH3. Figure 3.21 shows the ORTEP representation of NH3.  
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Table 3.6: Non-Hydrogen atom coordinates, isotropic thermal parameters and Occupancies in 
NH3 
Atom X Y Z Ueq( Å2) Occupancy 
Pd(1) 0.35715(4)    
0.37545(4) 
0.45026(2) 0.02500(14) 1 
O(1) 0.2434(4) 0.4383(4) 0.3298(3) 0.0294(8) 1 
O(2) 0.4679(5)  0.3101(4) 0.5705(3) 0.0321(8) 1 
N(1) 0.2411(5)  0.5110(4) 0.5034(3) 0.0262(9) 1 
N(2) 0.4720(5)  0.2394(4) 0.3969(3) 0.0260(9) 1 
C(1) 0.1540(6)  0.5338(5) 0.3426(4) 0.0288(11) 1 
C(2) 0.1487(6)  0.5757(5) 0.4333(4) 0.0268(10) 1 
C(3) 0.2416(6)  0.5405(6) 0.5888(4) 0.0296(11) 1 
C(4) 0.1502(6)  0.6385(6) 0.6143(4) 0.0329(11) 1 
C(5) 0.0570(6)  0.7039(6) 0.5464(5) 0.0347(12) 1 
C(6) 0.0535(6)  0.6758(6) 0.4535(4) 0.0317(11) 1 
C(7) -0.0392(7)  0.7363(6) 0.3782(4) 0.0347(12) 1 
C(8) -0.0334(6)  0.6984(6) 0.2906(4) 0.0339(12) 1 
C(9) 0.0610(6)  0.5973(6) 0.2719(4) 0.0309(11) 1 
C(10) 0.5582(6)  0.2144(6) 0.5576(4) 0.0282(11) 1 
C(11) 0.5619(6)  0.1716(5) 0.4658(4) 0.0254(10) 1 
C(12) 0.4698(6)  0.2087(6) 0.3108(4) 0.0287(10) 1 
C(13) 0.5564(6)  0.1075(6) 0.2855(4) 0.0314(11) 1 
C(14) 0.6467(6)  0.0379(6) 0.3523(4) 0.0311(11) 1 
C(15) 0.6525(6) 0.0697(6) 0.4463(4) 0.0288(11) 1 
C(16) 0.7428(7)  0.0055(6) 0.5205(4) 0.0349(12) 1 
C(17) 0.7402(7)  0.0460(6) 0.6079(4) 0.0360(12) 1 
C(18) 0.6498(6)  0.1489(6) 0.6279(4) 0.0311(11) 1 
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Table 3.7:  Hydrogen atom coordinates, Isotropic thermal parameters and Occupancies in 
NH3 
Atom X Y Z Ueq( Å2) Occupancy 
H(3) 0.3056 0.4946 0.6355 0.035 1 
H(4) 0.1529 0.6589 0.6770 0.039 1 
H(5) -0.0062 0.7693 0.5627 0.042 1 
H(7) -0.1053 0.8031 0.3888 0.042 1 
H(8) -0.0945 0.7412 0.2409 0.041 1 
H(9) 0.0610 0.5725 0.2102 0.037 1 
H(12) 0.4076 0.2564 0.2642 0.034 1 
H(13) 0.5527 0.0873 0.2226 0.038 1 
H(14) 0.7051 -0.0314 0.3358 0.037 1 
H(16) 0.8044 -0.0648 0.5096 0.042 1 
H(17) 0.8018 0.0030 0.6572 0.043 1 
H(18) 0.6515 0.1737 0.6898 0.037 1 
 
Table 3.8:  Anisotropic thermal parameters ( Å2) in NH3 
 Atom   U(1,1)   U(2,2)   U(3,3)   U(1,2)   U(1,3)   U(2,3) 
Pd(1)  0.0268(2)  0.02427(19)  0.02220(19)  0.00228(15)  0.00000(12)  0.00077(14) 
O(1)  0.0335(19)  0.0320(19)  0.0212(17)  0.0058(16)  0.0012(14)  0.0016(15) 
O(2)  0.041(2)  0.033(2)  0.0208(17)  0.0089(17)  0.0007(16)  0.0005(15) 
N(1)  0.026(2)  0.0214(19)  0.030(2)  0.0026(16)  0.0023(17)  -0.0011(17) 
N(2)  0.029(2)  0.0219(19)  0.026(2)  0.0048(17)  0.0014(17)  0.0003(17) 
C(1)  0.026(2)  0.023(2)  0.037(3)  -0.003(2)  0.004(2)  0.001(2) 
C(2)  0.025(2)  0.026(2)  0.027(3)  -0.004(2)  0.0003(19)  0.004(2) 
C(3)  0.026(2)  0.030(3)  0.029(3)  -0.003(2)  -0.004(2)  0.001(2) 
C(4)  0.035(3)  0.034(3)  0.028(2)  0.001(2)  0.004(2)  -0.003(2) 
C(5)  0.031(3)  0.032(3)  0.041(3)  0.005(2)  0.006(2)  -0.002(2) 
C(6)  0.029(3)  0.027(2)  0.036(3)  -0.001(2)  -0.001(2)  0.001(2) 
C(7)  0.032(3)  0.034(3)  0.037(3)  0.004(2)  0.002(2)  0.005(2) 
C(8)  0.031(3)  0.033(3)  0.034(3)  0.002(2)  -0.003(2)  0.006(2) 
C(9)  0.031(3)  0.035(3)  0.025(2)  -0.003(2)  -0.001(2)  0.003(2) 
C(10)  0.025(2)  0.031(3)  0.028(3)  0.001(2)  0.003(2)  -0.004(2) 
C(11)  0.028(2)  0.025(2)  0.023(2)  -0.0027(19)  0.0014(19)  0.0005(19) 
C(12)  0.030(3)  0.030(3)  0.024(2)  -0.002(2)  -0.0007(19)  0.001(2) 
C(13)  0.035(3)  0.035(3)  0.023(2)  -0.002(2)  0.003(2)  0.000(2) 
C(14)  0.033(3)  0.030(3)  0.031(3)  0.001(2)  0.006(2)  -0.003(2) 
C(15)  0.028(3)  0.029(2)  0.028(3)  0.000(2)  0.002(2)  0.004(2) 
C(16)  0.036(3)  0.034(3)  0.032(3)  0.007(2)  -0.001(2)  0.000(2) 
C(17)  0.034(3)  0.038(3)  0.032(3)  0.005(2)  -0.005(2)  0.003(2) 
C(18)  0.032(3)  0.035(3)  0.025(2)  0.000(2)  0.002(2)  -0.001(2) 
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Table 3.9: Non hydrogen bond lengths ( Å) in NH3 
First Atom Second 
atom 
Distance First atom Second 
atom 
Distance 
Pd(1) N(1) 2.003(5) Pd(1) O(2) 2.002(4) 
Pd(1) N(2) 2.001(4) Pd(1) O(1) 2.007(4) 
O(1) C(1) 1.317(7) O(2) C(10) 1.324(7) 
N(1) C(3) 1.301(8) N(1) C(2) 1.388(7) 
N(2) C(12) 1.312(8) N(2) C(11) 1.380(7) 
C(1) C(9) 1.391(8) C(1) C(2) 1.421(8) 
C(2) C(6) 1.419(8) C(3) C(4) 1.408(9) 
C(4) C(5) 1.375(9) C(5) C(6) 1.403(9) 
C(6) C(7) 1.420(8) C(7) C(8) 1.367(9) 
C(8) C(9) 1.415(9) C(10) C(18) 1.389(8) 
C(10) C(11) 1.437(8) C(11) C(15) 1.401(8) 
C(10) C(11) 1.437(8) C(11) C(15) 1.401(8) 
C(12) C(13) 1.401(8) C(13) C(14) 1.373(8) 
C(14) C(15) 1.423(8) C(15) C(16) 1.416(8) 
C(16) C(17) 1.364(9) C(17) C(18) 1.410(9) 
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Table 3.10: Non hydrogen bond angles ( º ) in NH3 
First atom Second atom Third atom Angle 
N(1) Pd(1) O(2) 96.05(18) 
N(1) Pd(1) N(2) 179.6(2) 
O(2) Pd(1) N(2) 84.07(18) 
N(1) Pd(1) O(1) 84.03(19) 
O(2) Pd(1) O(1) 178.92(18) 
N(2) Pd(1) O(1) 95.84(18) 
C(1) O(1) Pd(1) 110.6(4) 
C(10) O(2) Pd(1) 110.7(3) 
C(3) N(1) C(2) 120.6(5) 
C(3) N(1) Pd(1) 129.6(4) 
C(2) N(1) Pd(1) 109.7(4) 
C(12) N(2) C(11) 120.0(5) 
C(12) N(2) Pd(1) 129.6(4) 
C(11) N(2) Pd(1) 110.4(4) 
O(1) C(1) C(9) 123.9(6) 
O(1) C(1) C(2) 119.4(5) 
C(9) C(1) C(2) 116.7(5) 
N(1) C(2) C(6) 120.6(5) 
N(1) C(2) C(1) 116.2(5) 
C(6) C(2) C(1) 123.2(5) 
N(1) C(3) C(4) 122.1(5) 
C(5) C(4) C(3) 118.6(5) 
C(4) C(5) C(6) 121.1(5) 
C(5) C(6) C(2) 116.9(5) 
C(5) C(6) C(7) 125.7(6) 
C(2) C(6) C(7) 117.4(6) 
C(8) C(7) C(6) 120.0(6) 
C(7) C(8) C(9) 121.8(5) 
C(1) C(9) C(8) 121.0(5) 
O(2) C(10) C(18) 124.3(5) 
O(2) C(10) C(11) 119.1(5) 
C(18) C(10) C(11) 116.6(5) 
N(2) C(11) C(15) 121.6(5) 
N(2) C(11) C(10) 115.7(5) 
C(15) C(11) C(10) 122.7(5) 
N(2) C(12) C(13) 122.0(5) 
C(14) C(13) C(12) 119.5(5) 
C(13) C(14) C(15) 119.8(5) 
C(11) C(15) C(16) 118.4(5) 
C(11) C(15) C(14) 117.1(5) 
C(16) C(15) C(14) 124.5(6) 
C(17) C(16) C(15) 119.2(6) 
C(16) C(17) C(18) 122.7(6) 
C(10) C(18) C(17) 120.4(5) 
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Figure 3.21: ORTEP representation of NH3 
3.4.2 Crystal structure of NH4 
 
Formula C28H24Cl2N8Pd, M 649.85, triclinic, space group P1(#2), a 9.1549(5), b 
9.4744(7), c 9.5144(5) Å, 66.459(6), 63.643(6), 67.749(6)º, V 657.24(8) Å3, Dc 1.642 g 
cm-3, Z 1, crystal size  0.165 by 0.119 by 0.051 mm, colour colourless, habit prism, 
temperature 150(1) Kelvin, (MoK) 0.71073 Å, (MoK) 0.945 mm-1, 
T(Gaussian)min,max 0.887, 0.959, 2max  61.05, hkl range -13 13, -13 13, -13 13, N 36377, 
Nind 4012(Rmerge 0.0627), Nobs 3746(I > 2(I)), Nvar 178, residuals
* R1(F) 0.0385, 
wR2(F2) 0.1033, GoF(all) 1.347, min,max -1.313, 2.875 e
- Å-3.  
 
*R1 = ||Fo| - |Fc||/|Fo| for Fo > 2(Fo); wR2 = (w(Fo
2 - Fc
2)2/(wFc
2)2)1/2 all 
reflections w=1/[2(Fo
2)+(0.05P)2+0.30P] where P=(Fo
2+2Fc
2)/3 
 
Tables 3.11 to 3.19 give different atom coordinates, thermal parameters (isotropic and 
anisotropic), occupancies, bond angles, bond lengths, torsion angles and hydrogen bond 
geometry observed in crystal structure of NH4. Figure 3.22 shows the ORTEP representation 
of NH4. 
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Table 3.11: Non-Hydrogen atom coordinates, Isotropic thermal parameters and Occupancies 
in NH4 
Atom X Y Z Ueq( Å2) Occupancy 
Pd(1) 0.0000 0.5000 0.0000 0.01580(8) 1 
Cl(1) 0.25005(7) 0.20716(7) 0.31325(7) 0.02405(13) 1 
N(1) 0.2385(2) 0.5165(2) -0.1367(2) 0.0172(3) 1 
C(1) 0.3775(3) 0.4467(3) -0.0896(3) 0.0204(4) 1 
N(2) 0.4557(2) 0.5999(2) -0.3412(2) 0.0193(4) 1 
C(2) 0.5132(3) 0.4962(3) -0.2145(3) 0.0223(4) 1 
C(3) 0.5399(3) 0.6876(3) -0.4927(3) 0.0265(5) 1 
N(3) 0.0265(2) 0.3512(2) -0.1171(2) 0.0174(3) 1 
C(4) 0.4518(4) 0.7866(3) -0.5936(3) 0.0296(5) 1 
N(4) 0.1203(2) 0.1443(2) -0.2144(2) 0.0195(4) 1 
C(5) 0.2782(3) 0.7982(3) -0.5447(3) 0.0248(5) 1 
C(6) 0.1939(3) 0.7115(3) -0.3949(3) 0.0209(4) 1 
C(7) 0.2865(3) 0.6098(3) -0.2897(3) 0.0170(4) 1 
C(8) -0.0284(3) 0.3920(3) -0.2448(3) 0.0205(4) 1 
C(9) 0.0273(3) 0.2663(3) -0.3063(3) 0.0220(4) 1 
C(10) 0.2089(3) -0.0062(3) -0.2298(3) 0.0269(5) 1 
C(11) 0.2936(3) -0.1035(3) -0.1254(4) 0.0296(5) 1 
C(12) 0.2911(3) -0.0501(3) -0.0040(3) 0.0259(5) 1 
C(13) 0.2044(3) 0.0998(3) 0.0110(3) 0.0215(4) 1 
C(14) 0.1174(3) 0.1999(3) -0.0987(3) 0.0172(4) 1 
 
Table 3.12: Hydrogen atom coordinates, Isotropic thermal parameters and Occupancies in 
NH4 
Atom X Y Z Ueq( Å2) Occupancy 
H(1) 0.3788 0.3750 0.0140 0.024 1 
H(2) 0.6248 0.4656 -0.2146 0.027 1 
H(3) 0.6565 0.6790 -0.5256 0.032 1 
H(4) 0.5072 0.8486 -0.6981 0.036 1 
H(5) 0.2191 0.8677 -0.6173 0.030 1 
H(6) 0.0776 0.7191 -0.3625 0.025 1 
H(8) -0.0953 0.4929 -0.2841 0.025 1 
H(9) 0.0069 0.2627 -0.3942 0.026 1 
H(10) 0.2107 -0.0412 -0.3114 0.032 1 
H(11) 0.3550 -0.2079 -0.1337 0.036 1 
H(12) 0.3507 -0.1198 0.0681 0.031 1 
H(13) 0.2027 0.1352 0.0922 0.026 1 
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Table 3.13:  Anisotropic thermal parameters ( Å2) in NH4 
 Atom   U(1,1)   U(2,2)   U(3,3)   U(1,2)   U(1,3)   U(2,3) 
Pd(1)  0.01446(12)  0.01672(12)  0.01341(11)  -0.00408(8)  0.00043(8)  -0.00725(8) 
Cl(1)  0.0236(3)  0.0248(3)  0.0205(3)  -0.0037(2)  -0.0058(2)  -0.0073(2) 
N(1)  0.0153(8)  0.0190(8)  0.0154(8)  -0.0049(7)  -0.0012(7)  -0.0071(6) 
C(1)  0.0176(10)  0.0221(10)  0.0181(9)  -0.0047(8)  -0.0032(8)  -0.0060(8) 
N(2)  0.0156(8)  0.0236(9)  0.0169(8)  -0.0070(7)  -0.0005(7)  -0.0076(7) 
C(2)  0.0153(10)  0.0273(11)  0.0217(10)  -0.0054(8)  -0.0039(8)  -0.0072(9) 
C(3)  0.0206(11)  0.0335(13)  0.0211(11)  -0.0147(10)  0.0030(9)  -0.0074(9) 
N(3)  0.0164(8)  0.0187(8)  0.0164(8)  -0.0052(7)  -0.0010(7)  -0.0086(6) 
C(4)  0.0303(13)  0.0354(13)  0.0189(10)  -0.0184(11)  -0.0008(10)  -0.0026(10) 
N(4)  0.0191(9)  0.0215(9)  0.0186(8)  -0.0060(7)  -0.0006(7)  -0.0120(7) 
C(5)  0.0288(12)  0.0264(11)  0.0185(10)  -0.0101(10)  -0.0082(9)  -0.0026(9) 
C(6)  0.0205(10)  0.0232(10)  0.0192(10)  -0.0080(8)  -0.0045(8)  -0.0063(8) 
C(7)  0.0157(9)  0.0184(9)  0.0161(9)  -0.0061(7)  0.0002(7)  -0.0086(7) 
C(8)  0.0186(10)  0.0226(10)  0.0189(10)  -0.0050(8)  -0.0039(8)  -0.0075(8) 
C(9)  0.0215(10)  0.0265(11)  0.0210(10)  -0.0067(9)  -0.0057(8)  -0.0108(9) 
C(10)  0.0268(12)  0.0252(11)  0.0315(12)  -0.0046(9)  -0.0041(10)  -0.0190(10) 
C(11)  0.0287(13)  0.0209(11)  0.0366(14)  -0.0017(9)  -0.0056(11)  -0.0160(10) 
C(12)  0.0270(12)  0.0210(11)  0.0258(11)  -0.0033(9)  -0.0082(10)  -0.0064(9) 
C(13)  0.0213(10)  0.0210(10)  0.0189(10)  -0.0040(8)  -0.0028(8)  -0.0082(8) 
C(14)  0.0157(9)  0.0190(9)  0.0152(9)  -0.0055(7)  0.0009(7)  -0.0089(7) 
 
Table 3.14:  Non Hydrogen bond lengths ( Å) in NH4 
First atom   Second 
atom  
 Distance   First 
atom  
 Second 
atom  
  Distance 
Pd(1)  N(3)  2.0108(18)  Pd(1)  N(3)  2_565  2.0108(18) 
Pd(1)  N(1)  2.0141(18)  Pd(1)  N(1)  2_565  2.0141(18) 
N(1)  C(7)  1.339(3)  N(1)  C(1)    1.375(3) 
C(1)  C(2)  1.364(3)  N(2)  C(7)    1.379(3) 
N(2)  C(3)  1.380(3)  N(2)  C(2)    1.386(3) 
C(3)  C(4)  1.359(4)  N(3)  C(14)    1.343(3) 
N(3)  C(8)  1.378(3)  C(4)  C(5)    1.416(4) 
N(4)  C(10)  1.377(3)  N(4)  C(14)    1.384(3) 
N(4)  C(9)  1.391(3)  C(5)  C(6)    1.367(3) 
C(6)  C(7)  1.419(3)  C(8)  C(9)    1.360(3) 
C(10)  C(11)  1.359(4)  C(11)  C(12)    1.423(4) 
C(12)  C(13)  1.369(3)  C(13)  C(14)    1.414(3) 
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Table 3.15: Non Hydrogen bond angles ( º ) in NH4 
First  atom   Second atom Third atom  Angle 
N(3)    Pd(1)  N(3)  2_565  180.0 
N(3)    Pd(1)  N(1)    89.31(7) 
N(3)  2_565  Pd(1)  N(1)    90.69(7) 
N(3)    Pd(1)  N(1)  2_565  90.69(7) 
N(3)  2_565  Pd(1)  N(1)  2_565  89.31(7) 
N(1)    Pd(1)  N(1)  2_565  180.0 
C(7)    N(1)  C(1)    107.52(18) 
C(7)    N(1)  Pd(1)    124.64(16) 
C(1)    N(1)  Pd(1)    127.67(15) 
C(2)    C(1)  N(1)    109.5(2) 
C(7)    N(2)  C(3)    122.2(2) 
C(7)    N(2)  C(2)    107.79(18) 
C(3)    N(2)  C(2)    130.0(2) 
C(1)    C(2)  N(2)    106.2(2) 
C(4)    C(3)  N(2)    118.3(2) 
C(14)    N(3)  C(8)    107.47(18) 
C(14)    N(3)  Pd(1)    126.29(16) 
C(8)    N(3)  Pd(1)    125.81(15) 
C(3)    C(4)  C(5)    120.7(2) 
C(10)    N(4)  C(14)    122.2(2) 
C(10)    N(4)  C(9)    129.8(2) 
C(14)    N(4)  C(9)    107.93(19) 
C(6)    C(5)  C(4)    121.3(2) 
C(5)    C(6)  C(7)    117.6(2) 
N(1)    C(7)  N(2)    108.91(19) 
N(1)    C(7)  C(6)    131.3(2) 
N(2)    C(7)  C(6)    119.81(19) 
C(9)    C(8)  N(3)    109.9(2) 
C(8)    C(9)  N(4)    106.1(2) 
C(11)    C(10)  N(4)    118.4(2) 
C(10)    C(11)  C(12)    120.5(2) 
C(13)    C(12)  C(11)    121.3(2) 
C(12)    C(13)  C(14)    117.6(2) 
N(3)    C(14)  N(4)    108.6(2) 
N(3)    C(14)  C(13)    131.5(2) 
N(4)    C(14)  C(13)    119.9(2) 
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Table 3.16: Torsion angles  ( º ) in NH4 
First  atom  Second  atom  Third atom Fourth atom Angle 
C(7)  N(1)  C(1)  C(2)  -0.3(3) 
Pd(1)  N(1)  C(1)  C(2)  -175.74(16) 
N(1)  C(1)  C(2)  N(2)  0.4(3) 
C(7)  N(2)  C(2)  C(1)  -0.3(3) 
C(3)  N(2)  C(2)  C(1)  177.3(2) 
C(7)  N(2)  C(3)  C(4)  -0.1(4) 
C(2)  N(2)  C(3)  C(4)  -177.4(3) 
N(2)  C(3)  C(4)  C(5)  -0.5(4) 
C(3)  C(4)  C(5)  C(6)  0.4(4) 
C(4)  C(5)  C(6)  C(7)  0.3(4) 
C(1)  N(1)  C(7)  N(2)  0.1(2) 
Pd(1)  N(1)  C(7)  N(2)  175.72(14) 
C(1)  N(1)  C(7)  C(6)  -178.1(2) 
Pd(1)  N(1)  C(7)  C(6)  -2.5(3) 
C(3)  N(2)  C(7)  N(1)  -177.7(2) 
C(2)  N(2)  C(7)  N(1)  0.1(2) 
C(3)  N(2)  C(7)  C(6)  0.8(3) 
C(2)  N(2)  C(7)  C(6)  178.6(2) 
C(5)  C(6)  C(7)  N(1)  177.2(2) 
C(5)  C(6)  C(7)  N(2)  -0.8(3) 
C(14)  N(3)  C(8)  C(9)  0.2(3) 
Pd(1)  N(3)  C(8)  C(9)  173.05(16) 
N(3)  C(8)  C(9)  N(4)  -0.3(3) 
C(10)  N(4)  C(9)  C(8)  -177.4(2) 
C(14)  N(4)  C(9)  C(8)  0.3(2) 
C(14)  N(4)  C(10)  C(11)  1.1(4) 
C(9)  N(4)  C(10)  C(11)  178.5(2) 
N(4)  C(10)  C(11)  C(12)  -0.3(4) 
C(10)  C(11)  C(12)  C(13)  -0.2(4) 
C(11)  C(12)  C(13)  C(14)  -0.1(4) 
C(8)  N(3)  C(14)  N(4)  -0.1(2) 
Pd(1)  N(3)  C(14)  N(4)  -172.84(14) 
C(8)  N(3)  C(14)  C(13)  179.0(2) 
Pd(1)  N(3)  C(14)  C(13)  6.2(3) 
C(10)  N(4)  C(14)  N(3)  177.8(2) 
C(9)  N(4)  C(14)  N(3)  -0.1(2) 
C(10)  N(4)  C(14)  C(13)  -1.4(3) 
C(9)  N(4)  C(14)  C(13)  -179.3(2) 
C(12)  C(13)  C(14)  N(3)  -178.2(2) 
C(12)  C(13)  C(14)  N(4)  0.8(3) 
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Table 3.17: Hydrogen bond geometry in NH4 
Donor Hydrogen Acceptor  D-H( Å) H-A( Å) D-A( Å) DHA Angle( º) 
C(1) H(1) Cl(1)  0.95 2.62 3.505(2) 155.9 
C(6) H(6) Cl(1) 2_565 0.95 2.67 3.609(2) 169.3 
C(8) H(8) Cl(1) 2_565 0.95 2.61 3.511(2) 157.6 
C(9) H(9) Cl(1) 1_554 0.95 2.79 3.432(2) 126.0 
C(13) H(13) Cl(1)  0.95 2.69 3.634(2) 170.7 
Table 3.18: Hydrogen bond lengths ( Å) in NH4 
 First atom   Second 
atom  
 Distance  First atom   Second 
atom  
 Distance 
C(1)  H(1)  0.9500  C(2)  H(2)  0.9500 
C(3)  H(3)  0.9500  C(4)  H(4)  0.9500 
C(5)  H(5)  0.9500  C(6)  H(6)  0.9500 
C(8)  H(8)  0.9500  C(9)  H(9)  0.9500 
C(10)  H(10)  0.9500  C(11)  H(11)  0.9500 
C(12)  H(12)  0.9500  C(13)  H(13)  0.9500 
Table 3.19: Hydrogen bond angles ( º ) in NH4 
First atom   Second atom   Third atom Angle 
C(2)  C(1)  H(1)  125.2 
N(1)  C(1)  H(1)  125.2 
C(1)  C(2)  H(2)  126.9 
N(2)  C(2)  H(2)  126.9 
C(4)  C(3)  H(3)  120.8 
N(2)  C(3)  H(3)  120.8 
C(3)  C(4)  H(4)  119.6 
C(5)  C(4)  H(4)  119.6 
C(6)  C(5)  H(5)  119.4 
C(4)  C(5)  H(5)  119.4 
C(5)  C(6)  H(6)  121.2 
C(7)  C(6)  H(6)  121.2 
C(9)  C(8)  H(8)  125.1 
N(3)  C(8)  H(8)  125.1 
C(8)  C(9)  H(9)  126.9 
N(4)  C(9)  H(9)  126.9 
C(11)  C(10)  H(10)  120.8 
N(4)  C(10)  H(10)  120.8 
C(10)  C(11)  H(11)  119.7 
C(12)  C(11)  H(11)  119.7 
C(13)  C(12)  H(12)  119.3 
C(11)  C(12)  H(12)  119.3 
C(12)  C(13)  H(13)  121.2 
C(14)  C(13)  H(13)  121.2 
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Figure 3.22: ORTEP representation of NH4 
3.4.3 Crystal structure of NH6 
 
Formula C35H38Cl2N10O4Pd, M 840.05, triclinic, space group P1(#1), a 9.6573(2), b 
10.2458(2), c 10.3227(3) Å, 96.938(2), 109.086(2), 93.133(2)º, V 953.34(4) Å3, Dc 
1.463 g cm-3, Z 1, crystal size 0.187 by 0.128 by 0.047 mm, colour colourless, habit prism, 
temperature 150.0(1) Kelvin, (Mo K) 0.71073 Å, (Mo K) 0.678 mm-1, Tmin,max 
0.903, 1.000, 2max 70.56, hkl range -15 15, -16 16, -16 16, N 45699, Nind 15848(Rmerge 
0.0293), Nobs 14831(I > 2(I)), Nvar 458, residuals
* R1(F) 0.0334, wR2(F2) 0.0784, 
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GoF(all) 1.146, min,max -0.688, 0.668 e
- Å-3.  
 
*R1 = ||Fo| - |Fc||/|Fo| for Fo > 2(Fo); wR2 = (w(Fo
2 - Fc
2)2/(wFc
2)2)1/2 all 
reflections w=1/[2(Fo
2)+(0.03P)2+0.2P] where P=(Fo
2+2Fc
2)/3 
 
Tables 3.20 to 3.28 give different atom coordinates, thermal parameters (isotropic and 
anisotropic), occupancies, bond angles, bond lengths, torsion angles and hydrogen bond 
geometry observed in crystal structure of NH6. Figure 3.23 shows the ORTEP representation 
of NH6. 
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Table 3.20: Non-Hydrogen atom coordinates, Isotropic thermal parameters and Occupancies 
in NH6 
Atom X Y Z Ueq( Å2) Occupancy 
Pd(1) 0.34051(9) 0.63753(8) 0.39812(9) 0.01716(4) 1 
N(1) 0.2958(6) 0.4788(5) 0.4807(6) 0.0195(11) 1 
N(2) 0.2224(7) 0.2771(6) 0.5013(6) 0.0232(12) 1 
C(1) 0.3127(9) 0.4754(7) 0.6181(7) 0.0231(14) 1 
C(2) 0.2665(10) 0.3486(7) 0.6322(9) 0.0291(16) 1 
C(3) 0.1654(9) 0.1504(8) 0.4639(7) 0.0317(16) 1 
C(4) 0.1172(11) 0.0972(8) 0.3301(10) 0.0424(19) 1 
C(5) 0.1399(11) 0.1783(9) 0.2308(9) 0.041(2) 1 
C(6) 0.1973(8) 0.3072(7) 0.2665(6) 0.0245(14) 1 
C(7) 0.2394(7) 0.3591(7) 0.4118(6) 0.0179(12) 1 
N(3) 0.1232(6) 0.6521(6) 0.3014(6) 0.0196(12) 1 
N(4) -0.0962(7) 0.7174(5) 0.2623(6) 0.0207(11) 1 
C(8) 0.0358(8) 0.6022(7) 0.1666(7) 0.0238(14) 1 
C(9) -0.0993(6) 0.6404(7) 0.1426(7) 0.0243(15) 1 
C(10) -0.2114(8) 0.7807(7) 0.2900(9) 0.0241(15) 1 
C(11) -0.1834(9) 0.8533(7) 0.4172(7) 0.0262(14) 1 
C(12) -0.0409(9) 0.8576(8) 0.5148(9) 0.0358(18) 1 
C(13) 0.0710(7) 0.7961(7) 0.4855(7) 0.0242(14) 1 
C(14) 0.0429(7) 0.7231(7) 0.3585(7) 0.0183(12) 1 
N(5) 0.3889(7) 0.7978(6) 0.3198(6) 0.0212(12) 1 
N(6) 0.4615(7) 0.9984(6) 0.2912(7) 0.0252(13) 1 
C(15) 0.3650(9) 0.8031(8) 0.1820(8) 0.0290(16) 1 
C(16) 0.4080(9) 0.9211(8) 0.1615(7) 0.0286(15) 1 
C(17) 0.5174(9) 1.1320(7) 0.3372(9) 0.0363(18) 1 
C(18) 0.5507(10) 1.1781(8) 0.4741(10) 0.0359(15) 1 
C(19) 0.5382(10) 1.1002(7) 0.5707(9) 0.0317(17) 1 
C(20) 0.4819(9) 0.9708(7) 0.5248(8) 0.0286(16) 1 
C(21) 0.4446(7) 0.9192(7) 0.3885(7) 0.0218(14) 1 
N(7) 0.5542(7) 0.6222(6) 0.4913(6) 0.0192(11) 1 
N(8) 0.7820(6) 0.5581(6) 0.5370(6) 0.0212(12) 1 
C(22) 0.6386(8) 0.6752(7) 0.6234(8) 0.0253(14) 1 
C(23) 0.7804(8) 0.6381(7) 0.6553(7) 0.0299(17) 1 
C(24) 0.8898(8) 0.4948(9) 0.5088(9) 0.0300(17) 1 
C(25) 0.8606(9) 0.4248(8) 0.3846(9) 0.0340(18) 1 
C(26) 0.7198(6) 0.4119(7) 0.2761(7) 0.0217(13) 1 
C(27) 0.6107(7) 0.4776(6) 0.3024(6) 0.0209(13) 1 
C(28) 0.6438(7) 0.5512(6) 0.4384(7) 0.0177(12) 1 
Cl(1) 0.4064(2) 0.81605(19) 0.8001(2) 0.0405(5) 1 
Cl(2) 0.2716(2) 0.4549(2) 0.9966(2) 0.0409(5) 1 
O(1) 0.4316(8) 0.2067(7) 1.0217(8) 0.0568(18) 1 
O(2) 0.5639(7) 0.6091(8) 0.9717(8) 0.0534(18) 1 
O(3) 0.1162(7) 0.6673(8) 0.8130(7) 0.0441(15) 1 
O(4) 0.2460(7) 0.0738(5) 0.7689(6) 0.0414(14) 1 
N(1IA) 0.9900(10) 0.0396(9) 0.8564(11) 0.036(2) 0.5 
N(2IA) 0.7984(8) 0.0748(8) 0.9242(9) 0.039(2) 0.5 
C(1IA) 0.9408(9) -0.0667(6) 0.9101(9) 0.0212(15) 0.5 
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C(2IA) 0.8253(17) -0.0409(15) 0.9444(14) 0.036(3) 0.5 
C(3IA) 0.7044(13) 0.1892(13) 0.9358(12) 0.038(2) 0.5 
C(4IA) 0.7216(13) 0.3194(12) 0.9023(11) 0.038(2) 0.5 
C(5IA) 0.8411(14) 0.3415(12) 0.8441(12) 0.042(3) 0.5 
C(6IA) 0.9340(16) 0.2542(14) 0.8307(15) 0.053(4) 0.5 
C(7IA) 0.9104(12) 0.1434(11) 0.8655(11) 0.028(2) 0.5 
N(1IB) 0.6825(8) 0.2496(9) 0.9259(11) 0.031(2) 0.5 
N(2IB) 0.8751(7) 0.1749(7) 0.8806(7) 0.0229(13) 0.5 
C(1IB) 0.7595(13) 0.3404(8) 0.8757(16) 0.057(4) 0.5 
C(2IB) 0.8741(16) 0.2979(15) 0.8510(15) 0.049(4) 0.5 
C(3IB) 0.9845(12) 0.1159(10) 0.8554(10) 0.038(2) 0.5 
C(4IB) 0.9838(10) -0.0121(11) 0.8894(9) 0.0295(15) 0.5 
C(5IB) 0.8785(13) -0.0647(10) 0.9370(10) 0.0373(19) 0.5 
C(6IB) 0.7696(16) 0.0104(14) 0.9605(14) 0.043(3) 0.5 
C(7IB) 0.7705(11) 0.1533(10) 0.9237(10) 0.028(2) 0.5 
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Table 3.21: Hydrogen atom coordinates, Isotropic thermal parameters and Occupancies in 
NH6 
Atom X Y Z Ueq( Å2) Occupancy 
H(1) 0.3497 0.5476 0.6910 0.028 1 
H(2) 0.2656 0.3177 0.7151 0.035 1 
H(3) 0.1592 0.0985 0.5324 0.038 1 
H(4) 0.0698 0.0097 0.3010 0.051 1 
H(5) 0.1135 0.1394 0.1366 0.050 1 
H(6) 0.2088 0.3595 0.2001 0.029 1 
H(8) 0.0670 0.5490 0.1014 0.029 1 
H(9) -0.1812 0.6188 0.0594 0.029 1 
H(10) -0.3065 0.7730 0.2216 0.029 1 
H(11) -0.2573 0.8995 0.4393 0.031 1 
H(12) -0.0211 0.9050 0.6049 0.043 1 
H(13) 0.1667 0.8045 0.5530 0.029 1 
H(15) 0.3228 0.7307 0.1102 0.035 1 
H(16) 0.4033 0.9479 0.0754 0.034 1 
H(17) 0.5314 1.1880 0.2746 0.044 1 
H(18) 0.5845 1.2690 0.5050 0.043 1 
H(19) 0.5677 1.1353 0.6662 0.038 1 
H(20) 0.4687 0.9163 0.5889 0.034 1 
H(22) 0.6046 0.7301 0.6852 0.030 1 
H(23) 0.8597 0.6622 0.7401 0.036 1 
H(24) 0.9849 0.5003 0.5767 0.036 1 
H(25) 0.9374 0.3805 0.3661 0.041 1 
H(26) 0.7033 0.3593 0.1891 0.026 1 
H(27) 0.5165 0.4749 0.2336 0.025 1 
H(1OA) 0.3605 0.1662 0.9417 0.068 1 
H(1OB) 0.5084 0.2187 1.0052 0.068 1 
H(2OA) 0.5618 0.6961 0.9589 0.064 1 
H(2OB) 0.5331 0.5998 1.0355 0.064 1 
H(3OA) 0.1668 0.6103 0.8689 0.053 1 
H(3OB) 0.1744 0.7303 0.8170 0.053 1 
H(4OA) 0.2632 -0.0133 0.7701 0.050 1 
H(4OB) 0.1568 0.0776 0.7463 0.050 1 
H(1IA) 0.9858 -0.1468 0.9202 0.025 0.5 
H(2IA) 0.7709 -0.0997 0.9787 0.043 0.5 
H(3IA) 0.6256 0.1713 0.9691 0.045 0.5 
H(4IA) 0.6613 0.3862 0.9161 0.046 0.5 
H(5IA) 0.8520 0.4244 0.8143 0.050 0.5 
H(6IA) 1.0125 0.2736 0.7973 0.064 0.5 
H(1IB) 0.7301 0.4259 0.8610 0.069 0.5 
H(2IB) 0.9417 0.3440 0.8192 0.059 0.5 
H(3IB) 1.0531 0.1548 0.8195 0.045 0.5 
H(4IB) 1.0587 -0.0647 0.8793 0.035 0.5 
H(5IB) 0.8796 -0.1537 0.9544 0.045 0.5 
H(6IB) 0.6991 -0.0240 0.9969 0.052 0.5 
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Table 3.22: Anisotropic thermal parameters ( Å2) in NH6 
 Atom   U(1,1)   U(2,2)   U(3,3)   U(1,2)   U(1,3)   U(2,3) 
Pd(1)  0.01568(7)  0.01585(7)  0.01821(7)  0.00081(5)  0.00384(5)  0.00147(5) 
N(1)  0.018(2)  0.011(2)  0.024(2)  -
0.0038(16)  
0.0024(18)  -
0.0042(16) 
N(2)  0.019(2)  0.022(3)  0.025(3)  -
0.0023(19)  
0.005(2)  -
0.0002(19) 
C(1)  0.031(3)  0.023(3)  0.017(3)  0.006(2)  0.007(2)  0.008(2) 
C(2)  0.038(4)  0.020(3)  0.032(3)  -0.002(2)  0.016(3)  0.011(2) 
C(3)  0.041(4)  0.030(3)  0.024(3)  0.001(3)  0.009(2)  0.010(2) 
C(4)  0.049(4)  0.022(3)  0.046(4)  -0.010(2)  0.002(3)  0.014(3) 
C(5)  0.051(5)  0.035(4)  0.025(3)  0.003(3)  -0.004(3)  0.003(3) 
C(6)  0.031(3)  0.020(3)  0.015(2)  -0.001(2)  0.001(2)  -
0.0050(19) 
C(7)  0.018(3)  0.022(3)  0.013(2)  0.003(2)  0.004(2)  0.006(2) 
N(3)  0.013(2)  0.020(3)  0.026(3)  0.0052(19)  0.007(2)  0.002(2) 
N(4)  0.023(3)  0.016(2)  0.024(3)  0.0050(18)  0.010(2)  0.0004(19) 
C(8)  0.022(3)  0.030(3)  0.013(2)  -0.002(2)  0.0018(19)  -0.008(2) 
C(9)  0.012(2)  0.032(3)  0.023(3)  0.010(2)  -0.003(2)  0.005(2) 
C(10)  0.016(3)  0.022(3)  0.036(4)  0.008(2)  0.010(3)  0.004(3) 
C(11)  0.028(3)  0.026(3)  0.025(3)  0.005(2)  0.012(2)  -0.004(2) 
C(12)  0.053(4)  0.027(3)  0.028(3)  0.000(3)  0.017(3)  0.001(3) 
C(13)  0.014(2)  0.028(3)  0.032(3)  0.004(2)  0.007(2)  0.012(2) 
C(14)  0.012(2)  0.019(3)  0.018(3)  -
0.0036(19)  
-
0.0023(19)  
0.005(2) 
N(5)  0.023(3)  0.027(3)  0.019(2)  0.006(2)  0.009(2)  0.0114(19) 
N(6)  0.030(3)  0.019(3)  0.032(3)  0.004(2)  0.013(2)  0.016(2) 
C(15)  0.032(4)  0.025(3)  0.027(3)  -0.002(3)  0.010(3)  -0.004(2) 
C(16)  0.034(3)  0.036(3)  0.016(3)  0.007(3)  0.007(2)  0.004(2) 
C(17)  0.032(3)  0.012(2)  0.059(4)  -0.008(2)  0.007(3)  0.011(2) 
C(18)  0.038(3)  0.021(3)  0.041(3)  -0.006(2)  0.008(3)  -0.006(2) 
C(19)  0.040(4)  0.015(3)  0.033(4)  -0.006(2)  0.006(3)  -0.004(2) 
C(20)  0.029(3)  0.024(3)  0.035(4)  0.004(3)  0.011(3)  0.013(2) 
C(21)  0.017(3)  0.014(3)  0.034(3)  -0.001(2)  0.009(2)  0.003(2) 
N(7)  0.020(2)  0.019(3)  0.014(2)  -0.004(2)  0.0010(19)  0.0005(18) 
N(8)  0.0088(19)  0.027(3)  0.022(3)  -
0.0023(17)  
-
0.0020(17)  
0.005(2) 
C(22)  0.021(3)  0.026(3)  0.028(3)  0.009(2)  0.004(2)  0.006(2) 
C(23)  0.035(3)  0.031(3)  0.018(3)  -0.007(2)  0.006(2)  -0.009(2) 
C(24)  0.019(3)  0.037(4)  0.032(4)  0.001(3)  0.003(3)  0.008(3) 
C(25)  0.022(3)  0.031(3)  0.056(4)  0.008(2)  0.021(3)  0.011(3) 
C(26)  0.0146(19)  0.023(3)  0.027(3)  0.0004(17)  0.0098(19)  -0.005(2) 
C(27)  0.029(3)  0.018(2)  0.0112(18)  -0.006(2)  0.0055(18)  -
0.0079(16) 
C(28)  0.018(3)  0.015(3)  0.024(3)  0.0041(19)  0.011(2)  0.003(2) 
Cl(1)  0.0553(14)  0.0422(10)  0.0282(10)  0.0228(9)  0.0155(10)  0.0084(8) 
Cl(2)  0.0356(10)  0.0620(14)  0.0324(11)  0.0134(9)  0.0181(9)  0.0125(10) 
O(1)  0.050(4)  0.062(4)  0.053(4)  -0.008(3)  0.012(3)  0.010(3) 
O(2)  0.024(3)  0.070(4)  0.056(3)  0.001(3)  0.000(2)  0.013(3) 
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O(3)  0.031(3)  0.058(4)  0.042(3)  0.018(3)  0.003(2)  0.022(2) 
O(4)  0.041(3)  0.025(2)  0.047(3)  0.013(2)  -0.004(2)  0.013(2) 
 
Table 3.23: Non Hydrogen bond lengths ( Å) in NH6 
First atom   Second 
atom  
 Distance   First atom   Second 
atom  
 Distance 
Pd(1)  N(7)  1.996(6)  Pd(1)  N(5)  2.013(6) 
Pd(1)  N(1)  2.014(6)  Pd(1)  N(3)  2.031(6) 
N(1)  C(7)  1.330(8)  N(1)  C(1)  1.380(9) 
N(2)  C(3)  1.341(9)  N(2)  C(7)  1.364(9) 
N(2)  C(2)  1.376(11)  C(1)  C(2)  1.390(10) 
C(3)  C(4)  1.338(12)  C(4)  C(5)  1.457(12) 
C(5)  C(6)  1.363(11)  C(6)  C(7)  1.443(9) 
N(3)  C(14)  1.317(9)  N(3)  C(8)  1.387(9) 
N(4)  C(9)  1.374(9)  N(4)  C(14)  1.378(9) 
N(4)  C(10)  1.407(8)  C(8)  C(9)  1.336(9) 
C(10)  C(11)  1.365(10)  C(11)  C(12)  1.409(12) 
C(12)  C(13)  1.378(11)  C(13)  C(14)  1.364(10) 
N(5)  C(21)  1.343(9)  N(5)  C(15)  1.373(10) 
N(6)  C(16)  1.390(10)  N(6)  C(21)  1.408(9) 
N(6)  C(17)  1.409(9)  C(15)  C(16)  1.321(11) 
C(17)  C(18)  1.360(13)  C(18)  C(19)  1.381(11) 
C(19)  C(20)  1.371(10)  C(20)  C(21)  1.362(11) 
N(7)  C(28)  1.363(9)  N(7)  C(22)  1.365(9) 
N(8)  C(24)  1.347(10)  N(8)  C(28)  1.380(9) 
N(8)  C(23)  1.391(9)  C(22)  C(23)  1.386(11) 
C(24)  C(25)  1.325(12)  C(25)  C(26)  1.438(10) 
C(26)  C(27)  1.363(9)  C(27)  C(28)  1.437(9) 
N(1IA)  C(7IA)  1.358(14)  N(1IA)  C(1IA)  1.4073 
N(2IA)  C(2IA)  1.255(17)  N(2IA)  C(3IA)  1.538(14) 
N(2IA)  C(7IA)  1.574(13)  C(1IA)  C(2IA)  1.307(17) 
C(3IA)  C(4IA)  1.432(16)  C(4IA)  C(5IA)  1.484(17) 
C(5IA)  C(6IA)  1.329(19)  C(6IA)  C(7IA)  1.262(18) 
N(1IB)  C(7IB)  1.340(12)  N(1IB)  C(1IB)  1.4073 
N(2IB)  C(7IB)  1.249(11)  N(2IB)  C(3IB)  1.327(12) 
N(2IB)  C(2IB)  1.331(16)  C(1IB)  C(2IB)  1.299(16) 
C(1IB)  C(7IB)  2.037(12)  C(3IB)  C(4IB)  1.398(15) 
C(4IB)  C(5IB)  1.378(15)  C(5IB)  C(6IB)  1.402(17) 
C(6IB)  C(7IB)  1.557(17)    
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Table 3.24: Non Hydrogen bond angles ( º ) in NH6 
First  atom Second atom Third atom Angle 
N(7) Pd(1) N(5) 90.9(2) 
N(7) Pd(1) N(1) 88.1(2) 
N(5) Pd(1) N(1) 178.7(3) 
N(7) Pd(1) N(3) 179.4(3) 
N(5) Pd(1) N(3) 89.1(2) 
N(1) Pd(1) N(3) 92.0(2) 
C(7) N(1) C(1) 107.3(6) 
C(7) N(1) Pd(1) 126.3(4) 
C(1) N(1) Pd(1) 126.4(4) 
C(3) N(2) C(7) 124.6(6) 
C(3) N(2) C(2) 127.1(6) 
C(7) N(2) C(2) 108.3(6) 
N(1) C(1) C(2) 108.6(7) 
N(2) C(2) C(1) 105.8(6) 
C(4) C(3) N(2) 120.1(7) 
C(3) C(4) C(5) 117.6(7) 
C(6) C(5) C(4) 123.2(8) 
C(5) C(6) C(7) 115.7(7) 
N(1) C(7) N(2) 109.9(6) 
N(1) C(7) C(6) 131.3(6) 
N(2) C(7) C(6) 118.8(7) 
C(14) N(3) C(8) 107.8(6) 
C(14) N(3) Pd(1) 123.2(5) 
C(8) N(3) Pd(1) 128.8(5) 
C(9) N(4) C(14) 108.5(5) 
C(9) N(4) C(10) 128.4(6) 
C(14) N(4) C(10) 123.2(6) 
C(9) C(8) N(3) 109.4(6) 
C(8) C(9) N(4) 106.3(6) 
C(11) C(10) N(4) 118.5(7) 
C(10) C(11) C(12) 117.7(7) 
C(13) C(12) C(11) 123.1(7) 
C(14) C(13) C(12) 119.2(7) 
N(3) C(14) C(13) 133.6(6) 
N(3) C(14) N(4) 108.1(6) 
C(13) C(14) N(4) 118.3(6) 
C(21) N(5) C(15) 107.0(6) 
C(21) N(5) Pd(1) 127.7(5) 
C(15) N(5) Pd(1) 125.2(5) 
C(16) N(6) C(21) 107.4(6) 
C(16) N(6) C(17) 133.6(7) 
C(21) N(6) C(17) 118.9(7) 
C(16) C(15) N(5) 111.7(7) 
C(15) C(16) N(6) 106.3(6) 
C(18) C(17) N(6) 117.8(7) 
C(17) C(18) C(19) 123.7(7) 
C(20) C(19) C(18) 118.1(7) 
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C(21) C(20) C(19) 120.9(7) 
N(5) C(21) C(20) 131.8(7) 
N(5) C(21) N(6) 107.6(6) 
C(20) C(21) N(6) 120.6(7) 
C(28) N(7) C(22) 106.0(6) 
C(28) N(7) Pd(1) 126.9(4) 
C(22) N(7) Pd(1) 127.0(5) 
C(24) N(8) C(28) 120.8(6) 
C(24) N(8) C(23) 131.5(6) 
C(28) N(8) C(23) 107.6(6) 
N(7) C(22) C(23) 111.0(7) 
C(22) C(23) N(8) 105.4(6) 
C(25) C(24) N(8) 118.8(7) 
C(24) C(25) C(26) 124.1(7) 
C(27) C(26) C(25) 117.7(6) 
C(26) C(27) C(28) 117.4(6) 
N(7) C(28) N(8) 109.9(6) 
N(7) C(28) C(27) 128.8(6) 
N(8) C(28) C(27) 121.2(6) 
C(7IA) N(1IA) C(1IA) 110.4(5) 
C(2IA) N(2IA) C(3IA) 147.9(10) 
C(2IA) N(2IA) C(7IA) 112.2(9) 
C(3IA) N(2IA) C(7IA) 99.8(8) 
C(2IA) C(1IA) N(1IA) 111.2(7) 
N(2IA) C(2IA) C(1IA) 108.3(11) 
C(4IA) C(3IA) N(2IA) 127.7(10) 
C(3IA) C(4IA) C(5IA) 114.6(10) 
C(6IA) C(5IA) C(4IA) 124.9(12) 
C(7IA) C(6IA) C(5IA) 115.0(14) 
C(6IA) C(7IA) N(1IA) 124.4(11) 
C(6IA) C(7IA) N(2IA) 137.8(12) 
N(1IA) C(7IA) N(2IA) 97.8(7) 
C(7IB) N(1IB) C(1IB) 95.7(5) 
C(7IB) N(2IB) C(3IB) 140.8(10) 
C(7IB) N(2IB) C(2IB) 107.9(9) 
C(3IB) N(2IB) C(2IB) 111.4(9) 
C(2IB) C(1IB) N(1IB) 114.6(7) 
C(2IB) C(1IB) C(7IB) 73.7(8) 
N(1IB) C(1IB) C(7IB) 40.9(3) 
C(1IB) C(2IB) N(2IB) 104.3(11) 
N(2IB) C(3IB) C(4IB) 109.9(9) 
C(5IB) C(4IB) C(3IB) 122.4(9) 
C(4IB) C(5IB) C(6IB) 121.4(10) 
C(5IB) C(6IB) C(7IB) 116.4(11) 
N(2IB) C(7IB) N(1IB) 117.5(9) 
N(2IB) C(7IB) C(6IB) 109.1(10) 
N(1IB) C(7IB) C(6IB) 133.3(10) 
N(2IB) C(7IB) C(1IB) 74.1(5) 
N(1IB) C(7IB) C(1IB) 43.4(4) 
C(6IB) C(7IB) C(1IB) 176.7(9) 
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Table 3.25: Torsion angles  ( º ) in NH6 
First atom Second atom Third atom Fourth atom Angle 
C(7) N(1) C(1) C(2) 0.8(9) 
Pd(1) N(1) C(1) C(2) 178.5(5) 
C(3) N(2) C(2) C(1) -178.0(8) 
C(7) N(2) C(2) C(1) -1.0(9) 
N(1) C(1) C(2) N(2) 0.1(9) 
C(7) N(2) C(3) C(4) -1.6(13) 
C(2) N(2) C(3) C(4) 174.9(9) 
N(2) C(3) C(4) C(5) 4.7(14) 
C(3) C(4) C(5) C(6) -5.0(15) 
C(4) C(5) C(6) C(7) 1.9(14) 
C(1) N(1) C(7) N(2) -1.5(8) 
Pd(1) N(1) C(7) N(2) -179.2(5) 
C(1) N(1) C(7) C(6) 178.9(7) 
Pd(1) N(1) C(7) C(6) 1.2(12) 
C(3) N(2) C(7) N(1) 178.6(7) 
C(2) N(2) C(7) N(1) 1.5(8) 
C(3) N(2) C(7) C(6) -1.7(11) 
C(2) N(2) C(7) C(6) -178.8(7) 
C(5) C(6) C(7) N(1) -179.0(8) 
C(5) C(6) C(7) N(2) 1.4(11) 
C(14) N(3) C(8) C(9) -1.4(9) 
Pd(1) N(3) C(8) C(9) -176.7(5) 
N(3) C(8) C(9) N(4) 1.2(9) 
C(14) N(4) C(9) C(8) -0.6(8) 
C(10) N(4) C(9) C(8) -179.7(8) 
C(9) N(4) C(10) C(11) -179.8(7) 
C(14) N(4) C(10) C(11) 1.3(11) 
N(4) C(10) C(11) C(12) -1.6(12) 
C(10) C(11) C(12) C(13) 2.4(13) 
C(11) C(12) C(13) C(14) -2.7(12) 
C(8) N(3) C(14) C(13) -178.6(8) 
Pd(1) N(3) C(14) C(13) -3.0(11) 
C(8) N(3) C(14) N(4) 1.0(8) 
Pd(1) N(3) C(14) N(4) 176.6(4) 
C(12) C(13) C(14) N(3) -178.4(8) 
C(12) C(13) C(14) N(4) 2.1(10) 
C(9) N(4) C(14) N(3) -0.3(8) 
C(10) N(4) C(14) N(3) 178.8(7) 
C(9) N(4) C(14) C(13) 179.4(6) 
C(10) N(4) C(14) C(13) -1.5(10) 
C(21) N(5) C(15) C(16) 2.2(10) 
Pd(1) N(5) C(15) C(16) -179.9(6) 
N(5) C(15) C(16) N(6) -0.6(10) 
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C(21) N(6) C(16) C(15) -1.1(9) 
C(17) N(6) C(16) C(15) -177.5(9) 
C(16) N(6) C(17) C(18) 175.2(9) 
C(21) N(6) C(17) C(18) -0.8(12) 
N(6) C(17) C(18) C(19) 2.7(14) 
C(17) C(18) C(19) C(20) -3.5(15) 
C(18) C(19) C(20) C(21) 2.4(14) 
C(15) N(5) C(21) C(20) 176.7(8) 
Pd(1) N(5) C(21) C(20) -1.2(13) 
C(15) N(5) C(21) N(6) -2.7(8) 
Pd(1) N(5) C(21) N(6) 179.4(5) 
C(19) C(20) C(21) N(5) 179.9(8) 
C(19) C(20) C(21) N(6) -0.8(12) 
C(16) N(6) C(21) N(5) 2.4(8) 
C(17) N(6) C(21) N(5) 179.4(7) 
C(16) N(6) C(21) C(20) -177.1(7) 
C(17) N(6) C(21) C(20) 0.0(11) 
C(28) N(7) C(22) C(23) -0.3(9) 
Pd(1) N(7) C(22) C(23) 176.7(5) 
N(7) C(22) C(23) N(8) -0.3(9) 
C(24) N(8) C(23) C(22) 179.9(8) 
C(28) N(8) C(23) C(22) 0.8(8) 
C(28) N(8) C(24) C(25) -0.4(12) 
C(23) N(8) C(24) C(25) -179.5(8) 
N(8) C(24) C(25) C(26) 0.2(13) 
C(24) C(25) C(26) C(27) 1.1(12) 
C(25) C(26) C(27) C(28) -2.1(10) 
C(22) N(7) C(28) N(8) 0.9(8) 
Pd(1) N(7) C(28) N(8) -176.1(5) 
C(22) N(7) C(28) C(27) -178.8(7) 
Pd(1) N(7) C(28) C(27) 4.2(10) 
C(24) N(8) C(28) N(7) 179.7(7) 
C(23) N(8) C(28) N(7) -1.1(8) 
C(24) N(8) C(28) C(27) -0.6(11) 
C(23) N(8) C(28) C(27) 178.6(6) 
C(26) C(27) C(28) N(7) -178.5(7) 
C(26) C(27) C(28) N(8) 1.9(10) 
C(7IA) N(1IA) C(1IA) C(2IA) 4.8(14) 
C(3IA) N(2IA) C(2IA) C(1IA) -175.8(14) 
C(7IA) N(2IA) C(2IA) C(1IA) 0.4(14) 
N(1IA) C(1IA) C(2IA) N(2IA) -3.1(15) 
C(2IA) N(2IA) C(3IA) C(4IA) 175.8(17) 
C(7IA) N(2IA) C(3IA) C(4IA) -0.7(13) 
N(2IA) C(3IA) C(4IA) C(5IA) 2.8(16) 
C(3IA) C(4IA) C(5IA) C(6IA) -4.3(17) 
C(4IA) C(5IA) C(6IA) C(7IA) 3(2) 
C(5IA) C(6IA) C(7IA) N(1IA) 178.3(12) 
C(5IA) C(6IA) C(7IA) N(2IA) -1(2) 
C(1IA) N(1IA) C(7IA) C(6IA) 176.9(12) 
C(1IA) N(1IA) C(7IA) N(2IA) -3.9(11) 
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C(2IA) N(2IA) C(7IA) C(6IA) -178.7(16) 
C(3IA) N(2IA) C(7IA) C(6IA) -0.7(17) 
C(2IA) N(2IA) C(7IA) N(1IA) 2.3(12) 
C(3IA) N(2IA) C(7IA) N(1IA) -179.7(10) 
C(7IB) N(1IB) C(1IB) C(2IB) -0.4(16) 
N(1IB) C(1IB) C(2IB) N(2IB) 1.6(18) 
C(7IB) C(1IB) C(2IB) N(2IB) 1.4(9) 
C(7IB) N(2IB) C(2IB) C(1IB) -2.3(15) 
C(3IB) N(2IB) C(2IB) C(1IB) 177.7(11) 
C(7IB) N(2IB) C(3IB) C(4IB) -0.9(17) 
C(2IB) N(2IB) C(3IB) C(4IB) 179.1(9) 
N(2IB) C(3IB) C(4IB) C(5IB) 2.1(13) 
C(3IB) C(4IB) C(5IB) C(6IB) -3.2(15) 
C(4IB) C(5IB) C(6IB) C(7IB) 2.6(16) 
C(3IB) N(2IB) C(7IB) N(1IB) -177.7(11) 
C(2IB) N(2IB) C(7IB) N(1IB) 2.3(14) 
C(3IB) N(2IB) C(7IB) C(6IB) 0.5(17) 
C(2IB) N(2IB) C(7IB) C(6IB) -179.5(11) 
C(3IB) N(2IB) C(7IB) C(1IB) -178.5(13) 
C(2IB) N(2IB) C(7IB) C(1IB) 1.5(10) 
C(1IB) N(1IB) C(7IB) N(2IB) -1.2(13) 
C(1IB) N(1IB) C(7IB) C(6IB) -178.8(12) 
C(5IB) C(6IB) C(7IB) N(2IB) -1.2(14) 
C(5IB) C(6IB) C(7IB) N(1IB) 176.5(11) 
  
130 
 
Table 3.26: Hydrogen bond geometry in NH6 
Donor Hydrogen Acceptor  D-H( Å) H-A( Å) D-A( Å) DHA 
Angle( º) 
C(1) H(1) Cl(1)  0.95 2.80 3.673(8) 153.9 
C(2) H(2) O(4)  0.95 2.63 3.323(9) 129.7 
C(3) H(3) O(4)  0.95 2.36 3.193(9) 146.5 
C(6) H(6) Cl(2) 1_554 0.95 2.65 3.574(8) 165.9 
C(8) H(8) Cl(2) 1_554 0.95 2.71 3.590(8) 154.0 
C(9) H(9) O(2) 1_454 0.95 2.32 3.129(9) 142.6 
C(13) H(13) Cl(1)  0.95 2.81 3.737(7) 164.5 
C(15) H(15) Cl(2) 1_554 0.95 2.88 3.751(8) 153.7 
C(17) H(17) O(1) 1_564 0.95 2.51 3.284(11) 139.2 
C(20) H(20) Cl(1)  0.95 2.74 3.667(8) 165.3 
C(22) H(22) Cl(1)  0.95 2.70 3.582(8) 155.7 
C(23) H(23) O(3) 1_655 0.95 2.34 3.096(10) 136.4 
C(27) H(27) Cl(2) 1_554 0.95 2.77 3.704(7) 168.6 
O(1) H(1OA) O(4)  0.92 1.87 2.774(3) 169.1 
O(1) H(1OB) N(1IB)  0.82 2.12 2.932(10) 169.9 
O(2) H(2OA) Cl(1)  0.92 2.35 3.073(8) 135.5 
O(2) H(2OB) Cl(2)  0.82 2.74 3.258(8) 122.6 
O(3) H(3OA) Cl(2)  0.92 2.26 3.174(7) 174.3 
O(3) H(3OB) Cl(1)  0.82 2.43 3.165(8) 149.9 
O(4) H(4OA) Cl(1) 1_545 0.92 2.28 3.131(5) 154.9 
O(4) H(4OB) N(1IA) 1_455 0.82 2.30 2.914(9) 132.5 
C(3IA) H(3IA) O(1)  0.95 2.15 3.050(14) 157.3 
C(4IA) H(4IA) O(2)  0.95 2.59 3.513(13) 164.3 
C(3IB) H(3IB) O(4) 1_655 0.95 2.27 2.977(13) 131.0 
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Table 3.27: Hydrogen bond lengths ( Å) in NH6 
First  atom Second 
atom 
Distance First atom Second 
atom 
Distance 
C(1) H(1) 0.9500 C(2) H(2) 0.9500 
C(3) H(3) 0.9500 C(4) H(4) 0.9500 
C(5) H(5) 0.9500 C(6) H(6) 0.9500 
C(8) H(8) 0.9500 C(9) H(9) 0.9500 
C(10) H(10) 0.9500 C(11) H(11) 0.9500 
C(12) H(12) 0.9500 C(13) H(13) 0.9500 
C(15) H(15) 0.9500 C(16) H(16) 0.9500 
C(17) H(17) 0.9500 C(18) H(18) 0.9500 
C(19) H(19) 0.9500 C(20) H(20) 0.9500 
C(22) H(22) 0.9500 C(23) H(23) 0.9500 
C(24) H(24) 0.9500 C(25) H(25) 0.9500 
C(26) H(26) 0.9500 C(27) H(27) 0.9500 
O(1) H(1OA) 0.9172 O(1) H(1OB) 0.8195 
O(2) H(2OA) 0.9171 O(2) H(2OB) 0.8194 
O(3) H(3OA) 0.9172 O(3) H(3OB) 0.8195 
O(4) H(4OA) 0.9172 O(4) H(4OB) 0.8195 
C(1IA) H(1IA) 0.9500 C(2IA) H(2IA) 0.9500 
C(3IA) H(3IA) 0.9500 C(4IA) H(4IA) 0.9500 
C(5IA) H(5IA) 0.9500 C(6IA) H(6IA) 0.9500 
C(1IB) H(1IB) 0.9500 C(2IB) H(2IB) 0.9500 
C(3IB) H(3IB) 0.9500 C(4IB) H(4IB) 0.9500 
C(5IB) H(5IB) 0.9500 C(6IB) H(6IB) 0.9500 
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Table 3.28: Hydrogen bond angles ( º ) in NH6 
First atom Second atom Third atom Angle 
N(1) C(1) H(1) 125.7 
C(2) C(1) H(1) 125.7 
N(2) C(2) H(2) 127.1 
C(1) C(2) H(2) 127.1 
C(4) C(3) H(3) 120.0 
N(2) C(3) H(3) 120.0 
C(3) C(4) H(4) 121.2 
C(5) C(4) H(4) 121.2 
C(6) C(5) H(5) 118.4 
C(4) C(5) H(5) 118.4 
C(5) C(6) H(6) 122.2 
C(7) C(6) H(6) 122.2 
C(9) C(8) H(8) 125.3 
N(3) C(8) H(8) 125.3 
C(8) C(9) H(9) 126.9 
N(4) C(9) H(9) 126.9 
C(11) C(10) H(10) 120.8 
N(4) C(10) H(10) 120.8 
C(10) C(11) H(11) 121.2 
C(12) C(11) H(11) 121.2 
C(13) C(12) H(12) 118.5 
C(11) C(12) H(12) 118.5 
C(14) C(13) H(13) 120.4 
C(12) C(13) H(13) 120.4 
C(16) C(15) H(15) 124.1 
N(5) C(15) H(15) 124.1 
C(15) C(16) H(16) 126.9 
N(6) C(16) H(16) 126.9 
C(18) C(17) H(17) 121.1 
N(6) C(17) H(17) 121.1 
C(17) C(18) H(18) 118.2 
C(19) C(18) H(18) 118.2 
C(20) C(19) H(19) 121.0 
C(18) C(19) H(19) 121.0 
C(21) C(20) H(20) 119.5 
C(19) C(20) H(20) 119.5 
N(7) C(22) H(22) 124.5 
C(23) C(22) H(22) 124.5 
C(22) C(23) H(23) 127.3 
N(8) C(23) H(23) 127.3 
C(25) C(24) H(24) 120.6 
N(8) C(24) H(24) 120.6 
C(24) C(25) H(25) 118.0 
C(26) C(25) H(25) 118.0 
C(27) C(26) H(26) 121.1 
C(25) C(26) H(26) 121.1 
C(26) C(27) H(27) 121.3 
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C(28) C(27) H(27) 121.3 
H(1OA) O(1) H(1OB) 108.0 
H(2OA) O(2) H(2OB) 108.0 
H(3OA) O(3) H(3OB) 108.0 
H(4OA) O(4) H(4OB) 108.0 
C(2IA) C(1IA) H(1IA) 124.4 
N(1IA) C(1IA) H(1IA) 124.4 
N(2IA) C(2IA) H(2IA) 125.9 
C(1IA) C(2IA) H(2IA) 125.9 
C(4IA) C(3IA) H(3IA) 116.1 
N(2IA) C(3IA) H(3IA) 116.1 
C(3IA) C(4IA) H(4IA) 122.7 
C(5IA) C(4IA) H(4IA) 122.7 
C(6IA) C(5IA) H(5IA) 117.5 
C(4IA) C(5IA) H(5IA) 117.5 
C(7IA) C(6IA) H(6IA) 122.5 
C(5IA) C(6IA) H(6IA) 122.5 
C(2IB) C(1IB) H(1IB) 122.7 
N(1IB) C(1IB) H(1IB) 122.7 
C(7IB) C(1IB) H(1IB) 163.6 
C(1IB) C(2IB) H(2IB) 127.9 
N(2IB) C(2IB) H(2IB) 127.9 
N(2IB) C(3IB) H(3IB) 125.0 
C(4IB) C(3IB) H(3IB) 125.0 
C(5IB) C(4IB) H(4IB) 118.8 
C(3IB) C(4IB) H(4IB) 118.8 
C(4IB) C(5IB) H(5IB) 119.3 
C(6IB) C(5IB) H(5IB) 119.3 
C(5IB) C(6IB) H(6IB) 121.8 
C(7IB) C(6IB) H(6IB) 121.8 
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Figure 3.23: ORTEP representation of NH6 
3.5 Anticancer activity of the compounds 
and phytochemicals  
 
MTT reduction assay was performed to determine the antitumour activity of the designed 
palladiums, clinically used platinum drugs and selected phytochemicals against various 
tumour models. Initially, all of the designed palladiums were tested against ovarian cancer 
cell lines (A2780, A2780CisR and A2780ZD0473R) where cisplatin (Cis) was taken as reference 
compound to compare the activity. The compounds were investigated for activity against 
colorectal cancer cell lines (HT-29 and CACO-2) where oxaliplatin (Ox) was used as clinical 
standard. Later on IC50 values of the selected phytochemicals (Eme, Pat, Cur, EGCG and 6-
SG) were determined in ovarian and colorectal cancer cell lines. The most active palladiums 
and phytochemicals were then further investigated for their activity in breast (MCF-7) and 
cervical (Hela) cancer cell lines. 
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3.5.1 Cytotoxicity in ovarian tumour models 
 
The summary of IC50 values in three ovarian cancer cell lines for all tested compounds is 
shown in Table 3.29. Resistance factor (RF) values for corresponding compounds in 
applicable cases are also shown. 
Table 3.29: IC50 values (µM) in ovarian cancer cell lines 
Compound A2780 A2780CisR Resistance 
Factor 
A2780ZD0473R Resistance 
Factor 
Cis 1.12 ± 0.13 11.54 ± 0.98 10.30 10.03 ± 1.02 8.95 
NH1 5.44 ± 0.70 7.56 ± 0.71 1.38 6.64 ± 0.36 1.22 
NH2 317.63 ± 17.46 217.51 ± 15.22 0.68 194.36 ± 15.54 0.61 
NH3 0.107 ± 0.008 0.127 ± 0.01 1.18 0.125 ± 0.01 1.16 
NH4 148.22 ± 11.85 164.43 ± 11.49 1.10 >200 >1.34 
NH5 19.39 ± 1.43 15.32 ± 1.08 0.79 19.45 ± 1.51 1.00 
NH6 104.19 ± 9.85 97.07 ± 10.92 0.93 102.96 ± 10.56 0.98 
Eme 0.023 ± 0.0009 0.018 ± 0.0009 0.78 0.022 ± 0.001 0.95 
Pat 1.47 ± 0.12 1.28 ± 0.08 0.87 1.44 ± 0.10 0.97 
Cur 6.80 ± 1.63 9.70 ± 4.66 1.42 Not done Not applicable 
EGCG 6.87 ± 2.72 6.67 ± 3.61 0.97 Not done Not applicable 
6-SG 9.45 ± 0.47 7.50 ± 0.76 0.79 Not done Not applicable 
 
It is evident from the Table 3.29 that, one of the designed palladiums (NH3) is much more 
active than clinical standard Cis. NH1 is more active than Cis in resistant cancer cells while 
showed higher IC50 value in parent A2780 cell line. NH5 showed comparable activity with 
Cis in all tested ovarian cancer cells with lower RF values than Cis. But NH2, NH4 and NH6 
showed insignificant antitumour activity. The overall trend of activity for the designed 
palladiums and Cis in A2780 cell line was NH3>Cis>NH1>NH5>NH6>NH4>NH2. In case 
of A2780cisR cell line the activity order was NH3> NH1>Cis>NH5>NH6>NH4>NH2. The 
same trend as A2780cisR was also observed in A2780ZD0473R cell that except that NH2 showed 
higher activity than NH4.  
Among the phytochemicals, Eme showed very high anticancer activity with IC50 values in 
nano-molar level in all three cancer cell lines. Pat, Cur, EGCG and 6-SG were found to be 
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more active than Cis in resistant cell lines but less in parent cell line. The detail discussion of 
the results is given in chapter four. Figure 3.24 is the pictorial representation of the anticancer 
activity of the most active designed palladiums and phytochemicals against ovarian tumour 
cell lines in comparison with Cis. The cell survival fraction versus concentration plots for the 
most active palladiums and phytochemicals which were further used in combination study is 
provided in Figure 3.25 (A2780 cell line) and Figure 3.26 (A2780cisR cell line). 
   
Figure 3.24: IC50 values of compounds against ovarian tumour models 
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Figure 3.25: Plots of cell survival fractions against added concentrations of Cis, palladiums 
(NH1, NH3) and phytochemicals as applied to cell line A2780 
 
Figure 3.26: Plots of cell survival fractions against added concentrations of Cis, palladiums 
(NH1, NH3) and phytochemicals as applied to cell line A2780cisR 
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3.5.2 Cytotoxicity in colorectal, breast and cervical 
tumour models 
 
The summary of IC50 values in two colorectal cancer cell lines (HT-29 and CACO-2), breast 
cancer cell line (MCF-7) and cervical (Hela) for selected compounds is shown in Table 3.30. 
Table 3.30: IC50 values in colorectal, breast and cervical cancer cell lines 
Compound HT-29 CACO-2 MCF-7 Hela 
Cis 2.47 ± 0.14 7.02 ± 0.15 21.43 ± 2.94 4.11 ± 0.41 
Ox 0.54 ± 0.06 0.30 ± 0.02 Not done Not done 
NH1 5.67 ± 0.60 6.69 ± 0.53 4.88 ± 0.28 8.11 ± 0.56 
NH2 255.69 ± 18.53 314.27 ± 18.85 Not done Not done 
NH3 0.086 ± 0.008 0.30 ± 0.03 0.33 ± .02 0.44 ± 0.03 
NH4 80.58 ± 9.61 Not done Not done Not done 
NH5 17.15 ± 1.43 16.14 ± 1.08 Not done Not done 
NH6 87.95 ± 12.35 150.92 ± 11.4 Not done Not done 
Eme 0.026 ± 0.002 0.069 ± 0.006 Not done Not done 
Pat 0.97 ± 0.09 4.83 ± 0.43 Not done Not done 
Cur 17.25 ± 1.38 21.20 ± 1.69 Not done Not done 
EGCG 24.00 ± 1.8 61.30 ± 4.59 Not done Not done 
 
Among the designed palaldiums, NH3 showed higher activity than all other palladium 
compounds and clinical standard (Cis and Ox) against all tested cell lines. The highest 
antitumour activity was found in HT-29 cell line with IC50 value in nano-molar level. The 
order of anticancer activity from highest to lowest in colorectal cancer cell line (HT-29) was 
NH3>Ox>Cis>NH1>NH5>NH4>NH6>NH2. In CACO-2 cell line, the order of antitumour 
activity was NH3=Ox>NH1>Cis>NH6>NH2. The phytochemicals showed the same activity 
profile in both colorectal cancer cell lines which was Eme>Ox>Pat>Cis>Cur>EGCG. Only 
NH1and NH3 were tested against breast and cervical cancer model due to their promising 
activity in other tumour models. NH3 showed lower IC50  values in both MCF-7 and Hela 
cell lines compared to Cis while NH1 gave higher activity in MCF-7 but lower in Hela cell 
lines.  Figure 3.27 shows the graphical representation of the anticancer activity of selected 
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designed palladiums and phytochemicals against non-ovarian tumour cell lines in comparison 
with Cis and Ox. Plots of cell survival fraction versus concentration for the selected 
palladiums (NH1, NH3) and phytochemicals (Eme,Pat) against colorectal tumour models is 
given in Figure 3.28 (HT-29 cell line) and Figure 3.29 (CACO-2) cell line.  
 
Figure 3.27: IC50 values of compounds against non-ovarian tumour models 
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Figure 3.28: Plots of cell survival fractions against added concentrations of Cis, Ox, 
palladiums (NH1, NH3) and phytochemicals as applied to cell line HT-29 
 
Figure 3.29: Plots of cell survival fractions against added concentrations of Cis, Ox, 
palladiums (NH1, NH3) and phytochemicals as applied to cell line CACO-2 
From the IC50 values of the compounds (Table 3.29 and Table 3.30) it is evident that, among 
the designed palladiums NH1 and NH3 showed potential to be developed as anticancer 
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agents. For that reason for further studies (combination and mechanistic) only these two 
compounds were selected. Concentration versus cell survival fractions plots for these two 
compounds in all cell lines are shown only and the rest are not given. Figure 3.30 presents the 
concentration versus cell survival fractions plots for NH1 and NH3 in A2780ZD0473R, MCF-7 
and Hela cell lines. The plots for other cell lines for these two compounds have already been 
shown in Figure 3.25, Figure 3.26, Figure 3.28 and Figure 3.29.  
 
Figure 3.30: Plots of cell survival fractions against added concentrations of NH1 and NH3 as 
applied to cell lines: A2780ZD0473R, MCF-7 and Hela 
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3.6 Anticancer activity of the drugs in 
combination 
 
Combination therapy relates to the use of two or more drugs together for management or 
treatment of a certain disease condition. Since cancer is a multiple disease, combination 
therapy is frequently used by the clinicians for the benefit of the patients. For example first 
line chemotherapy for colorectal cancer patients is “FOLFIRI” (combination of folinic acid, 
fluorouracil and irinotecan) or “FOLFOX” (combination of folinic acid, fluorouracil and Ox).  
The rationale of combination therapy is that the drugs used in combination will act through 
different mechanism of action and thus provide better efficacy than single drug therapy. But 
the drugs to be used for combined therapy should be chosen very carefully so that they do not 
antagonize each other or augment adverse effects. In this study platinums (Cis/Ox) or novel 
palladiums (NH1 and NH3) were combined with selected phytochemical to find out the 
synergism, antagonism or additiveness against ovarian and colorectal cancer model. As 
iterated before, during combination studies cells were treated with combinations of drugs at 
constant ratios of their IC50 values. Three modes of administration employed were: 0/0 h, 0/4 
h and 4/0 h, where 0/0 h or bolus addition means that both the compounds were added at the 
same time. Both 0/4 h and 4/0 h are termed as sequential additions - 0/4 h means that 
platinum or palladium drug was added first followed by the phytochemical 4 h later and 4/0 h 
means that platinum or palladium drug was added 4 h later after the addition of 
phytochemical.  
Nature of the combined drug effects is expressed in terms of dose response curves and 
combination index (CI) values. Dose response curve is the graphical representation of dose 
effect of the drugs at different exposure (concentrations, sequences) which is automatically 
generated by Calcusyn software on the basis of the data used in combination study. Although 
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dose response curves are visually appealing, interpretation and conclusions drawn from dose 
response curves can be misleading when the combining drugs differ much in potency. On the 
other hand, CI gives quantitative and more appropriate measure of the combined drug action 
in terms of synergism, additiveness and antagonism. That is why the results of combination 
studies are described in the following subsections by focusing on CI values not dose response 
curves. Table 3.31 defines the ranges of CI values in terms of degree of combined drug action 
(Chou 2006).  
Table 3.31: CI value related to combined drug effect 
Range of CI Description of Effect Range of CI Description of Effect 
Less than 0.1 Very strong 
Synergism 
1.10 to 1.20 Slight antagonism 
 
0.1 to 0.3 Strong Synergism 1.20 to 1.45 Moderate antagonism 
0.3 to 0.7 Synergism 1.45 to 3.3 Antagonism 
0.7 to 0.85 Moderate Synergism 3.3 to 10 Strong antagonism 
0.85 to 0.90 Slight Synergism Greater than 
10 
Very strong antagonism 
0.90 to 1.10 
 
Additive  
 
3.6.1 Combination study in ovarian tumour models 
 
Among three different ovarian cancer cells used in determination of cytotoxicity of individual 
compounds, only parent ovarian carcinoma A2780 cell line and Cis resistant A2780cisR cell 
line were used in combination study.  For this study only following combinations were 
investigated-Cis with Eme; Cis with Pat; NH3 with Cur; NH3 with EGCG; NH1 with Cur 
and NH1 with 6-SG. 
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3.6.1.1 A2780 cell line 
 
Table 3.32 gives the dose effect values (affected cell fractions) at three different 
concentrations of Cis or palladium drugs (NH1 and NH3) and selected phytochemicals (Eme, 
Pat, Cur, EGCG and 6-SG) added alone and in combination according to 3 different modes of 
administration (Pt or Pd/Phytochemical h): (bolus), (0/4 h), (4/0 h) to ovarian cancer A2780 
cell line. CI values calculated at ED50, ED75 and ED90 applying to the binary combinations of 
Cis or palladium drugs (NH1 and NH3) and selected phytochemicals (Eme, Pat, Cur, EGCG 
and 6-SG) for different additions in the A2780 ovarian cancer cell line is placed in Table 
3.33. Pictorial presentation of CI values at ED50 for all the combinations is shown in Figure 
3.31. It has been observed that among the six investigated combinations, only Cis with Eme 
produced synergism at all tested sequences (bolus, 0/4 and 4/0) and concentrations (ED50, 
ED75 and ED90) in A2780 cell line. NH3 with Cur also showed synergism at all additions in 
ED50 and ED75 level. Strongest synergism was displayed by NH1 with 6-SG especially at 
lower concentration among all studied combinations in A2780 cell line. In terms of 
synergistic outcome the investigated combinations showed the following trend at ED50 level 
in A2780 cell line: 
NH1+6-SG > NH3+Cur > Cis+Eme >NH3+EGCG > Cis+Pat.  
Combination of NH1 with Cur displayed antagonism at ED50 level irrespective of sequences 
of addition. Details discussion of the results is given in chapter four.   
  
145 
 
Table 3.32: Dose effect analysis applying to combinations of Cis/NH1/NH3 and selected 
phytochemicals (Eme, Pat, Cur, EGCG and 6-SG) in ovarian cancer cell line A2780 
Drug concentrations (μM) treated alone, effect means fraction cell kill 
Cis(µM) Effect Eme(µM) Effect Pat(µM) Effect 
0.18 0.02±0.002 0.01 0.01±0.001 0.27 0.24±0.02 
0.9 0.54±0.03 0.04 0.84±0.10 1.37 0.89±0.13 
4.48 0.65±0.06 0.21 0.85±0.01 6.84 0.93 ±0.04 
NH1(µM) Effect Cur(µM) Effect 6-SG (µM) Effect 
1.09 0.01±0.001 1.36 0.01±0.001 1.89 0.19±0.01 
4.35 0.45±0.05 5.44 0.037±0.02 7.56 0.04±0.003 
17.41 0.86±0.06 21.76 0.724±0.11 30.24 0.93±0.08 
NH3(µM) Effect Cur(µM) Effect EGCG(µM) Effect 
0.008 0.001±0.00 0.54 0.02±0.002 0.55 0.09±0.01 
0.085 0.60±0.03 5.44 0.43±0.04 5.5 0.19±0.01 
0.85 0.89±0.08 54.4 0.89±0.06 54.96 0.88±0.08 
Drug concentrations (μM) treated in combination, effect means fraction cell kill 
Drug concentrations (µM) (0/0 h) (0/4 h) (4/0 h) 
Cis Eme Effect Effect Effect 
0.09 
0.45 
2.24 
0.004 
0.02 
0.1 
0.01±0.001 
0.35±0.03 
0.92±0.03 
0.18±0.005 
0.42±0.02 
0.91±0.03 
0.01±0.000 
0.49±0.04 
0.92±0.04 
Cis Pat    
0.09 
0.45 
2.24 
0.13 
0.68 
3.41 
0.13±0.004 
0.76±0.08 
0.93±0.08 
0.16±0.01 
0.69±0.06 
0.92±0.05 
0.18±0.02 
0.76±0.08 
0.93±0.03 
NH1 Cur    
0.55 
2.18 
8.71 
0.68 
2.70 
10.80 
0.01±0.001 
0.12±0.01 
0.75±0.05 
0.01±0.001 
0.30±0.03 
0.68±0.06 
0.17±0.01 
0.19±0.01 
0.71±0.12 
NH1 6-SG    
0.55 
2.18 
8.71 
0.95 
3.77 
15.0 
0.42±0.04 
0.49±0.05 
0.82±0.08 
0.54±0.03 
0.74±0.07 
0.83±0.11 
0.45±0.09 
0.69±0.17 
0.85±0.10 
NH3 Cur    
0.004 
0.04 
0.42 
0.27 
2.71 
27.19 
0.10±0.01 
0.47±0.04 
0.89±0.08 
0.26±0.02 
0.53±0.05 
0.89±0.07 
0.14±0.01 
0.53±0.05 
0.89±0.08 
NH3 EGCG    
0.004 
0.04 
0.42 
0.27 
2.74 
27.47 
0.23±0.01 
0.35±0.05 
0.88±0.05 
0.001±0.000 
0.42±0.03 
0.88±0.06 
0.001±0.000 
0.26±0.02 
0.89±0.06 
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Table 3.33: Combination indices (CI) for binary combinations of Cis/NH1/NH3 and 
phytochemicals Eme/Pat/Cur/EGCG/6-SG for different modes of administration in A2780 
ovarian cancer cell line (Dm, m and r indicate respectively median effect dose, curve shape 
and reliability coefficient) 
 
Drug Sequence 
(h) 
Molar 
Ratio 
CI values at  
ED50 ED75 ED90 Dm m r 
Cis   
 
 
1:0.04 
N/A N/A N/A 1.88 1.40 0.91 
Eme  N/A N/A N/A 0.05 2.01 0.84 
Cis+Eme 0/0 0.96 0.84 0.75 0.68 2.20 1.00 
Cis+Eme 0/4 0.53 0.70 0.94 0.38 1.20 0.97 
Cis+Eme 4/0 0.86 0.76 0.67 0.61 2.22 0.99 
Cis   
 
 
1:1.53 
N/A N/A N/A 1.88 1.40 0.91 
Pat  N/A N/A N/A 0.47 1.18 0.92 
Cis+Pat 0/0 1.06 0.93 0.82 0.28 1.40 0.98 
Cis+Pat 0/4 1.09 1.03 0.97 0.29 1.29 1.00 
Cis+Pat 4/0 0.93 0.88 0.83 0.25 1.29 0.99 
NH1   
 
 
1:1.24 
N/A N/A N/A 6.69 2.31 0.98 
Cur  N/A N/A N/A 17.01 2.01 0.96 
NH1+Cur 0/0 1.16 1.19 1.23 5.21 2.08 1.00 
NH1+Cur 0/4 1.08 1.15 1.23 4.84 1.94 0.97 
NH1+Cur 4/0 1.05 2.22 4.69 4.73 0.88 0.89 
NH1   
 
 
1:1.73 
N/A N/A N/A 6.69 2.31 0.98 
6-SG  N/A N/A N/A 11.35 1.45 0.70 
NH1+6-SG 0/0 0.37 1.05 3.03 1.23 0.67 0.93 
NH1+6-SG 0/4 0.11 0.46 2.00 0.36 0.54 0.99 
NH1+6-SG 4/0 0.21 0.54 1.44 0.69 0.70 1.00 
NH3   
 
 
1:63.55 
N/A N/A N/A 0.18 1.97 0.94 
Cur  N/A N/A N/A 8.63 1.25 1.00 
NH3+Cur 0/0 0.59 0.92 1.48 0.05 0.93 1.00 
NH3+Cur 0/4 0.30 0.71 1.74 0.02 0.69 0.99 
NH3+Cur 4/0 0.46 0.80 1.42 0.04 0.86 1.00 
NH3   
 
 
1:64.2 
N/A N/A N/A 0.18 1.97 0.94 
EGCG  N/A N/A N/A 10.34 0.94 0.95 
NH3+EGCG 0/0 0.44 0.89 1.97 0.04 0.71 0.94 
NH3+EGCG 0/4 1.22 0.93 0.77 0.10 1.95 0.97 
NH3+EGCG 4/0 1.34 1.02 0.84 0.11 1.97 0.99 
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Figure 3.31: CI at ED50 level observed for different combinations in A2780 ovarian cancer 
cell line 
3.6.1.2 A2780cisR cell line 
 
Table 3.34 gives the dose effect values (affected cell fractions) at three different 
concentrations of Cis or palladium drugs (NH1 and NH3) and selected phytochemicals (Eme, 
Pat, Cur, EGCG and 6-SG) added alone and in combination according to 3 different modes of 
administration (Pt or Pd/Phytochemical h): (bolus), (0/4 h), (4/0 h) to A2780cisR ovarian 
cancer cell line. CI values calculated at ED50, ED75 and ED90 applying to the binary 
combinations of Cis or palladium drugs (NH1 and NH3) and selected phytochemicals (Eme, 
Pat, Cur, EGCG and 6-SG) for different additions in the A2780cisR ovarian cancer cell line is 
placed in Table 3.35. Pictorial presentation of CI values at ED50 for all the combinations is 
shown in Figure 3.32. It has been observed that among the six investigated combinations only 
NH3 with Cur produced synergism at all tested sequences (bolus, 0/4 and 4/0) and 
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concentrations (ED50, ED75 and ED90) in A2780
cisR cell line. Cis with Eme also showed 
synergism at all concentrations during 0/4 and 4/0 additions. In terms of synergistic outcome 
the investigated combinations showed the following trend at ED50 level in A2780
cisR cell line: 
NH3+Cur > Cis+Pat > Cis+Eme >NH3+EGCG > NH1+6-SG > NH1+Cur. 
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Table 3.34: Dose effect analysis applying to combinations of Cis/NH1/NH3 and selected 
phytochemicals (Eme, Pat, Cur, EGCG and 6-SG) in ovarian cancer cell line A2780cisR 
Drug concentrations (μM) treated alone, effect means fraction cell kill 
Cis(µM) Effect Eme(µM) Effect Pat(µM) Effect 
1.85 0.17±0.01 0.01 0.06±0.005 0.41 0.23±0.02 
9.23 0.51±0.02 0.03 0.82±0.07 2.06 0.82±0.17 
46.16 0.93±0.26 0.17 0.89±0.05 10.28 0.94±0.05 
NH1(µM) Effect Cur(µM) Effect 6-SG (µM) Effect 
1.53 0.01±0.001 1.94 0.01±0.000 1.5 0.58±0.05 
6.13 0.2±0.01 7.76 0.06±0.01 6 0.20±0.04 
24.51 0.87±0.14 31.04 0.68±0.07 24 0.89±0.37 
NH3(µM) Effect Cur(µM) Effect EGCG(µM) Effect 
0.01 0.001±0.000 0.78 0.01±0.001 0.53 0.1±0.01 
0.1 0.3±0.24 7.76 0.17±0.09 5.34 0.21±0.18 
1.02 0.93±0.33 77.6 0.93±0.39 53.36 0.89±0.23 
Drug concentrations (μM) treated in combination, effect means fraction cell kill 
Drug concentrations (µM) (0/0 h) (0/4 h) (4/0 h) 
Cis Eme Effect Effect Effect 
0.93 
4.62 
23.08 
0.003 
0.016 
0.08 
0.005±0.001 
0.53±0.03 
0.88±0.16 
0.12±0.01 
0.56±0.04 
0.95±0.12 
0.09±0.007 
0.71±0.09 
0.94±0.13 
Cis Pat    
0.93 
4.62 
23.08 
0.20 
1.02 
5.12 
0.36±0.001 
0.74±0.06 
0.94±0.14 
0.01±0.001 
0.64±0.03 
0.94±0.08 
0.19±0.01 
0.81±0.11 
0.94±0.08 
NH1 Cur    
0.77 
3.07 
12.26 
0.97 
3.86 
15.44 
0.07±0.01 
0.17±0.01 
0.78±0.06 
0.01±0.001 
0.11±0.02 
0.73±0.04 
0.01±0.001 
0.05±0.003 
0.75±0.06 
NH1 6-SG    
0.77 
3.07 
12.26 
0.75 
3.00 
12.01 
0.11±0.02 
0.44±0.09 
0.81±0.08 
0.15±0.03 
0.30±0.04 
0.78±0.06 
0.35±0.04 
0.50±0.08 
0.78±0.05 
NH3 Cur    
0.005 
0.05 
0.51 
0.38 
3.80 
38.79 
0.001±0.000 
0.66±0.38 
0.92±0.18 
0.02±0.01 
0.64±0.36 
0.92±0.24 
0.001±0.000 
0.65±0.44 
0.91±0.24 
NH3 EGCG    
0.005 
0.05 
0.51 
0.26 
2.61 
26.67 
0.001±0.000 
0.44±0.19 
0.91±0.25 
0.001±0.000 
0.76±0.36 
0.91±0.26 
0.04±0.01 
0.21±0.09 
0.91±0.27 
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Table 3.35: Combination indices (CI) for binary combinations of Cis/NH1/NH3 and 
phytochemicals Eme/Pat/Cur/EGCG/6-SG for different modes of administration in A2780cisR 
ovarian cancer cell line (Dm, m and r indicate respectively median effect dose, curve shape 
and reliability coefficient) 
Drug Sequence 
(h) 
Molar 
Ratio 
CI values at  
ED50 ED75 ED90 Dm m r 
Cis   
 
 
1:0.004 
N/A N/A N/A 7.07 1.30 0.99 
Eme  N/A N/A N/A 0.03 1.56 0.86 
Cis+Eme 0/0 1.89 1.41 1.06 7.19 2.25 0.97 
Cis+Eme 0/4 0.91 0.84 0.79 3.47 1.57 1.00 
Cis+Eme 4/0 0.86 0.79 0.72 3.28 1.60 0.99 
Cis   
 
 
1:0.22 
N/A N/A N/A 7.07 1.30 0.99 
Pat  N/A N/A N/A 0.89 1.26 0.98 
Cis+Pat 0/0 0.63 0.75 0.90 1.62 1.06 1.00 
Cis+Pat 0/4 2.14 1.45 0.99 5.47 2.31 0.97 
Cis+Pat 4/0 0.88 0.84 0.81 2.24 1.34 0.98 
NH1   
 
 
1:1.26 
N/A N/A N/A 10.95 2.34 1.00 
Cur  N/A N/A N/A 23.78 1.94 0.99 
NH1+Cur 0/0 0.86 1.13 1.50 5.94 1.41 0.97 
NH1+Cur 0/4 1.10 1.18 1.26 7.62 1.92 1.00 
NH1+Cur 4/0 1.23 1.27 1.30 8.55 2.08 0.97 
NH1   
 
 
1:0.98 
N/A N/A N/A 10.95 2.34 1.00 
6-SG  N/A N/A N/A 3.27 0.64 0.51 
NH1+6-SG 0/0 1.48 1.00 0.97 3.80 1.28 1.00 
NH1+6-SG 0/4 1.74 1.36 1.52 4.46 1.09 0.97 
NH1+6-SG 4/0 0.86 1.22 2.49 2.19 0.68 0.98 
NH3   
 
 
1:76.07 
N/A N/A N/A 0.23 2.05 0.99 
Cur  N/A N/A N/A 16.74 1.56 1.00 
NH3+Cur 0/0 0.83 0.77 0.72 0.09 2.02 0.94 
NH3+Cur 0/4 0.55 0.66 0.80 0.06 1.37 0.97 
NH3+Cur 4/0 0.86 0.81 0.76 0.10 1.99 0.94 
NH3   
 
 
1:64.2 
N/A N/A N/A 0.23 2.05 0.99 
EGCG  N/A N/A N/A 8.90 0.93 0.95 
NH3+EGCG 0/0 1.15 0.85 0.69 0.11 1.99 0.97 
NH3+EGCG 0/4 0.91 0.67 0.55 0.09 1.99 0.92 
NH3+EGCG 4/0 0.95 1.01 1.20 0.09 1.19 0.98 
  
151 
 
 
Figure 3.32: CI at ED50 level observed for different combinations in A2780
cisR ovarian cancer 
cell line 
 
3.6.2 Combination study in colorectal tumour models 
3.6.2.1  HT-29 cell line 
 
Table 3.36 gives the dose effect values (affected cell fractions) at three different 
concentrations of Ox or NH3 and Eme/Pat/Cur/EGCG added alone and in combination 
according to 3 different modes of administration (Ox or NH3/Phytochemical h): (bolus), (0/4 
h), (4/0 h) to HT-29 colorectal cancer cell line. CI values calculated at ED50, ED75 and ED90 
applying to the binary combinations of Ox or NH3 and selected phytochemicals (Eme, Pat, 
Cur and EGCG) for different additions in the HT-29 colorectal cancer cell line is placed in 
Table 3.37. Pictorial presentation of CI values at ED50 for all the combinations is shown in 
Figure 3.33. It has been observed that among the four investigated combinations only NH3 
with Cur produced synergism mostly compared to others in HT-29 cell line. NH3 with EGCG 
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showed synergism in all sequences of additions at the highest tested concentrations (ED90). 
At ED50 level most of the combinations produced antagonism. The detail discussion of the 
results is given in chapter four.  
Table 3.36: Dose effect analysis applying to combinations of Ox/NH3 and selected 
phytochemicals (Eme, Pat, Cur and EGCG) in colorectal cancer cell line HT-29 
Drug concentrations (μM) treated alone, effect means fraction cell kill 
Ox(µM) Effect Eme(µM) Effect Pat(µM) Effect 
0.09 0.08±0.007 0.004 0.01±0.001 0.16 0.01±0.001 
0.43 0.23±0.01 0.02 0.16±0.01 0.78 0.24±0.02 
2.16 0.76±0.07 0.1 0.79±0.07 3.88 0.91±0.06 
NH3(µM) Effect Cur(µM) Effect EGCG(µM) Effect 
0.0069 0.001±0.000 1.38 0.02±0.003 1.92 0.48±0.07 
0.069 0.01±0.000 13.8 0.67±0.06 19.2 0.58±0.09 
0.69 0.85±0.01 137.98 0.9±0.08 192 0.84±0.03 
Drug concentrations (μM) treated in combination, effect means fraction cell kill 
Drug concentrations (µM) (0/0 h) (0/4 h) (4/0 h) 
Ox Eme Effect Effect Effect 
0.05 
0.22 
1.08 
0.002 
0.01 
0.04 
0.09±0.008 
0.27±0.01 
0.67±0.06 
0.01±0.001 
0.24±0.02 
0.71±0.07 
0.01±0.001 
0.23±0.01 
0.74±0.05 
Ox Pat    
0.05 
0.22 
1.08 
0.08 
0.39 
1.93 
0.08±0.007 
0.50±0.04 
0.83±0.08 
0.01±0.001 
0.23±0.02 
0.79±0.02 
0.01±0.001 
0.33±0.03 
0.85±0.05 
NH3 Cur    
0.003 
0.03 
0.34 
0.69 
6.9 
69 
0.04±0.004 
0.26±0.02 
0.94±0.04 
0.07±0.01 
0.22±0.03 
0.87±0.07 
0.21±0.01 
0.50±0.04 
0.94±0.06 
NH3 EGCG    
0.003 
0.03 
0.34 
0.95 
9.59 
95.99 
0.11±0.01 
0.17±0.02 
0.91±0.04 
0.01±0.000 
0.17±0.01 
0.86±0.03 
0.03±0.001 
0.22±0.01 
0.86±0.04 
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Table 3.37: Combination indices (CI) for binary combinations of Ox/NH3 and 
phytochemicals Eme/Pat/Cur/EGCG for different modes of administration in HT-29 
colorectal cancer cell line (Dm, m and r indicate respectively median effect dose, curve shape 
and reliability coefficient) 
Drug Sequence 
(h) 
Molar 
Ratio 
CI values at  
ED50 ED75 ED90 Dm m r 
Ox   
 
 
1:0.05 
N/A N/A N/A 0.91 1.13 0.99 
Eme  N/A N/A N/A 0.05 1.84 1.00 
Ox+Eme 0/0 1.11 1.60 2.40 0.54 0.96 1.00 
Ox+Eme 0/4 1.15 0.98 0.86 0.56 1.79 0.99 
Ox+Eme 4/0 1.10 0.92 0.79 0.54 1.84 0.99 
Ox   
 
 
1:1.79 
N/A N/A N/A 0.91 1.13 0.99 
Pat  N/A N/A N/A 1.32 2.18 1.00 
Ox+Pat 0/0 0.67 0.78 0.96 0.27 1.31 0.99 
Ox+Pat 0/4 1.20 1.07 1.00 0.49 1.93 0.99 
Ox+Pat 4/0 1.74 1.52 1.39 0.71 1.99 0.99 
NH3   
 
 
1:199.97 
N/A N/A N/A 0.38 2.06 0.98 
Cur  N/A N/A N/A 16.63 1.25 0.97 
NH3+Cur 0/0 0.98 0.86 0.77 0.07 1.62 1.00 
NH3+Cur 0/4 1.21 1.29 1.40 0.08 1.27 0.99 
NH3+Cur 4/0 0.50 0.57 0.68 0.03 1.16 1.00 
NH3   
 
 
1:278.26 
N/A N/A N/A 0.38 2.06 0.98 
EGCG  N/A N/A N/A 3.67 0.39 0.96 
NH3+EGCG 0/0 5.69 1.02 0.46 0.07 1.29 0.96 
NH3+EGCG 0/4 9.00 1.33 0.50 0.11 1.67 1.00 
NH3+EGCG 4/0 7.54 1.24 0.52 0.10 1.43 1.00 
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Figure 3.33: CI at ED50 level observed for different combinations in HT-29 colorectal cancer 
cell line 
3.6.2.2 CACO-2 cell line 
 
Table 3.38 gives the dose effect values (affected cell fractions) at three different 
concentrations of Ox or NH3 and Eme/Pat/Cur/EGCG added alone and in combination 
according to 3 different modes of administration (Ox or NH3/Phytochemical h): (bolus), (0/4 
h), (4/0 h) to CACO-2 colorectal cancer cell line. CI values calculated at ED50, ED75 and 
ED90 applying to the binary combinations of Ox or NH3 and selected phytochemicals (Eme, 
Pat, Cur and EGCG) for different additions in the CACO-2 colorectal cancer cell line is 
placed in Table 3.39. Pictorial presentation of CI values at ED50 for all the combinations is 
shown in Figure 3.34. It has been observed that combination of Oxa with Pat produced 
synergism in all cases irrespective of sequences of addition and concentrations in CACO-2 
cell line. However, combination of Oxa with Eme did the opposite. Both combinations of 
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NH3 with Cur and NH3 with EGCG showed synergism in all sequences of addition at the 
lowest tested concentrations (ED50).  
Table 3.38: Dose effect analysis applying to combinations of Ox/NH3 and selected 
phytochemicals (Eme, Pat, Cur and EGCG) in colorectal cell line CACO-2 
Drug concentrations (μM) treated alone, effect means fraction cell kill 
Ox(µM) Effect Eme(µM) Effect Pat(µM) Effect 
0.19 0.03±0.005 0.01 0.01±0.001 0.77 0.01±0.001 
0.96 0.48±0.04 0.06 0.31±0.03 3.86 0.20±0.01 
4.8 0.62±0.05 0.32 0.81±0.07 19.32 0.91±0.1 
NH3(µM) Effect Cur(µM) Effect EGCG(µM) Effect 
0.02 0.001±0.000 1.7 0.05±0.004 4.9 0.008±0.001 
0.27 0.66±0.04 16.96 0.49±0.03 49.04 0.56±0.07 
2.76 0.89±0.08 169.56 0.88±0.13 490.4 0.79±0.06 
Drug concentrations (μM) treated in combination, effect means fraction cell kill 
Drug concentrations (µM) (0/0 h) (0/4 h) (4/0 h) 
Ox Eme Effect Effect Effect 
0.1 
0.48 
2.4 
0.06 
0.31 
1.59 
0.19±0.02 
0.55±0.03 
0.80±0.07 
0.27±0.01 
0.57±0.04 
0.75±0.05 
0.30±0.02 
0.47±0.04 
0.81±0.1 
Ox Pat    
0.1 
0.48 
2.4 
0.40 
1.93 
9.66 
0.27±0.02 
0.52±0.04 
0.90±0.09 
0.15±0.02 
0.49±0.04 
0.88±0.03 
0.18±0.02 
0.51±0.04 
0.90±0.1 
NH3 Cur    
0.01 
0.13 
1.38 
0.85 
8.45 
84.77 
0.19±0.02 
0.58±0.06 
0.91±0.09 
0.04±0.004 
0.47±0.03 
0.88±0.04 
0.08±0.01 
0.46±0.05 
0.90±0.06 
NH3 EGCG    
0.014 
0.138 
1.384 
2.48 
24.44 
245.19 
0.06±0.01 
0.71±0.02 
0.86±0.1 
0.15±0.02 
0.63±0.07 
0.86±0.25 
0.02±0.002 
0.47±0.03 
0.83±0.05 
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Table 3.39: Combination indices (CI) for binary combinations of Ox/NH3 and 
phytochemicals Eme/Pat/Cur/EGCG for different modes of administration in CACO-2 
colorectal cancer cell line (Dm, m and r indicate respectively median effect dose, curve shape 
and reliability coefficient) 
Drug Sequence 
(h) 
Molar 
Ratio 
CI values at  
ED50 ED75 ED90 Dm m r 
Ox   
 
 
1:0.67 
N/A N/A N/A 2.20 1.23 0.93 
Eme  N/A N/A N/A 0.12 1.08 1.00 
Ox+Eme 0/0 2.66 4.72 8.41 0.45 0.90 1.00 
Ox+Eme 0/4 2.31 6.24 16.97 0.39 0.67 0.99 
Ox+Eme 4/0 2.24 5.42 13.17 0.38 0.72 0.98 
Ox   
 
 
1:4.02 
N/A N/A N/A 2.20 1.23 0.93 
Pat  N/A N/A N/A 6.76 2.15 1.00 
Ox+Pat 0/0 0.33 0.51 0.82 0.31 1.00 0.98 
Ox+Pat 0/4 0.47 0.62 0.85 0.45 1.17 1.00 
Ox+Pat 4/0 0.40 0.52 0.70 0.39 1.20 1.00 
NH3   
 
 
1:61.25 
N/A N/A N/A 0.56 1.96 0.93 
Cur  N/A N/A N/A 21.90 1.08 1.00 
NH3+Cur 0/0 0.38 0.65 1.19 0.08 0.81 1.00 
NH3+Cur 0/4 0.89 1.06 1.33 0.19 1.11 1.00 
NH3+Cur 4/0 0.71 0.93 1.28 0.15 1.01 1.00 
NH3   
 
 
1:177.17 
N/A N/A N/A 0.56 1.96 0.93 
EGCG  N/A N/A N/A 107.58 1.32 0.94 
NH3+EGCG 0/0 0.45 0.69 1.09 0.13 0.98 0.95 
NH3+EGCG 0/4 0.34 0.73 1.58 0.10 0.77 0.99 
NH3+EGCG 4/0 0.90 1.15 1.49 0.26 1.19 0.98 
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Figure 3.34: CI at ED50 level observed for different combinations in CACO-2 colorectal 
cancer cell line 
 
3.7 DNA damage study 
 
This is a qualitative study which provides information on DNA damage due to interaction of 
compounds with DNA. This study was conducted to obtain the mechanistic information for 
the novel palladium compounds about whether they mediate cytotoxicity through interacting 
with DNA or not. A2780 and A2780cisR ovarian cancer cells and HT-29 colorectal cancer 
cells were used to collect DNA and determine the interactions of the compounds with that. 
From the six palladiums only NH3, NH4, NH5 and NH6 were chosen for DNA damage 
study.  
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3.7.1 DNA damage in ovarian A2780 cell line 
 
Figure 3.35 portrays the DNA bands obtained from agarose gel electrophoresis of DNA 
extracted from A2780 cells. Table 3.40 provides DNA bands mobility and intensity, while 
Figure 3.36 and Figure 3.37 give visual representations of the DNA bands mobility and 
intensity, respectively. 
 
Figure 3.35: Electrophoretograms applying to interaction of A2780DNA with selected drugs 
Table 3.40: Mobilty and fluorescence of DNA extracted from A2780 cell line  
Treatment group Band mobility (mm) DNA fluorescence 
Blank 2.87 18447.5 
Cis 2.79 8929.71 
NH3 2.37 22276.2 
NH4 2.87 9491.03 
NH5 2.2 22461.1 
NH6 2.37 29538.2 
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Figure 3.36: DNA mobility observed from interaction of A2780DNA with selected drugs 
 
Figure 3.37: DNA fluorescence observed from interaction of A2780DNA with selected 
drugs 
0
0.5
1
1.5
2
2.5
3
 Blank Cis
NH3
NH4
NH5
NH6
M
o
b
il
it
y
 (
m
m
)
Mobility of A2780 DNA  
0
10000
20000
30000
40000
 Blank Cis NH3 NH4 NH5 NH6
D
N
A
 F
lu
o
re
sc
en
ce
Net Intensity of A2780 DNA  
160 
 
It has been observed from the above results that all of the investigated drugs interacted with 
DNA extracted from A2780 cell line. NH4 caused most damage to DNA than other 
palladiums and even cisplatin. NH6 found to cause least damage towards DNA. So, it is 
conceivable that like cisplatin, novel palladiums display their anticancer activity through 
interaction with DNA in A2780 ovarian cancer cell. 
3.7.2 DNA damage in ovarian A2780cisR cell line 
 
Figure 3.38 portrays the DNA bands obtained from agarose gel electrophoresis of DNA 
extracted from A2780cisR cells. Table 3.41 provides DNA bands mobility and intensity, while 
Figure 3.39 and Figure 3.40 give visual representations of the DNA bands mobility and 
intensity, respectively. 
            
Figure 3.38: Electrophoretograms applying to interaction of A2780cisRDNA with selected 
drugs 
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Table 3.41: Mobilty and fluorescence of DNA extracted from A2780cisR cell line 
Treatment group Band mobility (mm) DNA fluorescence 
Blank 2.7 24496.1 
Cis 3.13 13069.7 
NH3 3.3 14615.6 
NH4 3.72 20150 
NH5 3.13 24661.9 
NH6 3.38 34070.8 
 
 
Figure 3.39: DNA mobility observed from interaction of A2780cisRDNA with selected drugs 
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Figure 3.40: DNA fluorescence observed from interaction of A2780cisRDNA with selected 
drugs 
It has been observed from the above results that all of the investigated drugs interacted with 
DNA extracted from A2780cisR cell line. NH4 and Cis caused similar damage to DNA which 
is more than other palladiums. Alike the damage in parent A2780 cell line, NH6 found to 
cause least damage in DNA of A2780cisR cell line.  
3.7.3 DNA damage in colorectal HT-29 cell line 
 
Figure 3.41 portrays the DNA bands obtained from agarose gel electrophoresis of DNA 
extracted from HT-29 cells. Table 3.42 provides DNA bands mobility and intensity, while 
Figure 3.42 and Figure 3.43 give visual representations of the DNA bands mobility and 
intensity, respectively. The result clearly indicated that similar to ovarian cancer cell lines, 
NH3 produced significant DNA damage in HT-29 cell line which further supports that 
cytotoxicity produced by NH3 is through interaction with DNA. 
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Figure 3.41: Electrophoretograms applying to interaction of HT-29DNA with selected drugs 
Table 3.42: Mobilty and fluorescence of DNA extracted from HT-29 cell line 
Treatment group Band mobility (mm) DNA fluorescence 
Blank 3.21 19203.4 
NH3 3.38 17326 
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Figure 3.42: DNA mobility observed from interaction of HT-29DNA with selected drugs 
 
Figure 3.43: DNA fluorescence observed from interaction of HT-29DNA with selected drugs 
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3.8 Cellular accumulation 
 
Since it was found from previous DNA damage study that all the palladiums and platinums 
mediate their anticancer activity through interaction with DNA, attempts were made to 
determine the cellular accumulation of the drugs which is prerequisite for binding with DNA. 
Although most of the drug molecules are deactivated before binding with DNA (only 1% of 
cisplatin molecules accumulated into the cells actually bind with DNA), it is logical to think 
that increased intracellular accumulation can lead to increased cytotoxicity. That is why 
cellular uptake of platinum/palladium can be a key determinant of activity of the drugs. In 
this study, cellular accumulation of platinum is used as a measure of the cellular 
accumulation of the reference compound cisplatin in ovarian cancer cells and oxaliplatin in 
colorectal cancer cells. Likewise, intracellular palladium content is determined to serve as a 
measure of the cellular accumulation of the most active designed palladium compounds NH1 
and NH3. Cellular accumulations of palladium are also determined as applied to the 
combinations of phytochemicals (curcumin and EGCG) with NH3, with a view to finding any 
correlation between the values and the nature of the combined drug action. The results are 
detailed as follows. 
3.8.1 Accumulations in ovarian cancer cell lines 
 
Table 3.43 gives the total intracellular platinum/palladium levels from selected treatments in 
the A2780 and A2780cisR cell lines. Figure 3.44 gives the corresponding graphical 
representations. 
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Table 3.43: Platinum and palladium accumulations in A2780 and A2780cisR cell lines (the 
symbol within parenthesis indicates the metal to which it applies)   
Drug/Drug in combination A2780 (nmol /5 X 106 cells)  
 
A2780cisR (nmol /5 X 106 cells) 
Cisplatin (Pt) 8.67±0.01 6.31±3.4 
NH1 (Pd) 1.74±0.93 Not done 
NH3 (Pd) 0.89±0.07 2.77±0.40 
NH3+Cur, 0/4 (Pd) 1.00±0.13 4.55±0.31 
NH3+EGCG, 0/0 (Pd) 1.53±0.73 Not done 
NH3+EGCG, 0/4 (Pd) Not done 1.03±0.55 
 
 
 
 
Figure 3.44: Platinum/palladium accumulations in the ovarian cancer cell lines 
The results above indicate that uptake of platinum for cisplatin is greater in the parent A2780 
cell line than resistant A2780cisR cell line. But in case of single addition of palladium drug 
NH3, cellular accumulation of palladium is more in resistant cell line. When phytochemicals 
were added as synergistic combination with NH3, only the combination of NH3 and Cur 
displayed higher uptake of palladium into the cells compared to that of single addition of 
NH3 in ovarian tumour models. 
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3.8.2 Cellular uptake in colorectal cancer cell lines 
Table 3.44 gives the total intracellular platinum/palladium levels from selected treatments in 
the HT-29 and CACO-2 cell lines. Figure 3.45 gives the corresponding graphical 
representations. 
Table 3.44: Platinum and palladium accumulations in HT-29 and CACO-2 cell lines (the 
symbol within parenthesis indicates the metal to which it applies)   
Drug/Drug in combination HT-29 (nmol /5 X 106 cells)  
 
CACO-2 (nmol /5 X 106 cells) 
Oxaliplatin (Pt) 0.41±0.008 0.24±0.09 
NH3 (Pd) 1.02±0.07 3.19±0.19 
NH3+Cur, 4/0 (Pd) 1.22±0.07 Not done 
NH3+EGCG, 0/4 (Pd) Not done 0.52±0.08 
 
 
Figure 3.45: Platinum/palladium accumulations in the colorectal cancer cell lines 
It is evident from above results that platinum uptake for oxaliplatin  in HT-29 cell line is 
more than CACO-2 cell line. But palladium uptake for NH3 in CACO-2 cell line is greater 
than that observed in HT-29 cell line. When cur is combined with NH3 in HT-29 cell line 
then uptake of palladium displayed more than that of NH3 alone. However, the converse is 
true for combination of EGCG with NH3 in CACO-2 cell line.  
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3.9 DNA binding study 
 
The aim of this study was to determine whether any correlation existed between the level of 
DNA binding and the drug action. In this study, the levels of PtDNA and PdDNA binding 
(expressed as nanomoles of Pt or Pd per mg of DNA) applying to cisplatin (that is used as a 
reference compound in ovarian cancer cells), oxaliplatin (that is used as a reference 
compound in colorectal cancer cells) and selected designed palladium compounds have been 
determined. The levels PdDNA binding are also determined applying to the binary 
combinations involving NH3 and the selected phytochemicals (Cur and EGCG). The results 
are given in following subsections. 
3.9.1 DNA binding levels in ovarian cancer cell lines 
Table 3.45 gives the PtDNA or PdDNA levels from selected treatments in the A2780 and 
A2780cisR cell lines. Figure 3.46 gives the corresponding graphical representations. 
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Table 3.45: PtDNA or PdDNA binding levels in A2780 and A2780cisR cell lines (the 
symbol within parenthesis indicates the metal to which it applies)   
Compound/Drug combination [Pt or Pd (nmol) /DNA(mg)] 
A2780 cell line A2780cisR cell line 
Cisplatin (Pt) 10.29±3.08 7.58±5.15 
NH1 (Pd) 10.23±0.81 Not done 
NH3 (Pd) 23.02±4.60 44.43±19.99 
NH3+Cur, 0/4 (Pd) 9.94±1.39 29.94±5.38 
NH3+EGCG, 0/0 (Pd) 26.16±1.83 Not done 
NH3+EGCG, 0/4 (Pd) Not done 85.29±12.79 
 
 
Figure 3.46: Platinum/palladium-DNA binding levels in the ovarian cancer cell lines 
The results above show that PtDNA binding level for oxaliplatin is greater in parent cell line 
than its resistant counterpart. But palladium compound NH3 displayed the converse in case of 
PdDNA binding levels. No specific trend was found regarding the combined drug action of 
NH3 with phytochemical and PdDNA binding levels. 
  
0
20
40
60
80
100
120
P
t/
P
d
 (
n
m
o
l/
m
g
 D
N
A
)
Pt/Pd-DNA levels in ovarian tumour model
A2780
A2780cisR
170 
 
3.9.2 DNA binding levels in colorectal cancer cell lines 
 
Table 3.46 gives the PtDNA or PdDNA levels from selected treatments in the HT-29 and 
CACO-2 cell lines. Figure 3.47 gives the corresponding graphical representations. 
Table 3.46: PtDNA or PdDNA binding levels in HT-29 and CACO-2 cell lines (the 
symbol within parenthesis indicates the metal to which it applies)   
Drug/Drug in combination HT-29 (nmol /5 X 106 cells)  
 
CACO-2 (nmol /5 X 106 cells) 
Oxaliplatin (Pt) 3.56±0.42 6.15±3.56 
NH3 (Pd) 6.41±1.53 13.68±2.18 
NH3+Cur, 4/0 (Pd) 18.37±4.59 Not done 
NH3+EGCG, 0/4 (Pd) Not done 10.63±4.46 
 
  
 
Figure 3.47: Platinum/palladium-DNA binding levels in the colorectal cancer cell lines 
The results above show that PtDNA binding level is greater in HT-29 cell line than CACO-
2 cell line. But palladium compound NH3 displayed the converse in case PdDNA binding 
levels. Simiar to what was in ovarian cancer model, no specific trend was found regarding the 
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combined drug action of NH3 with phytochemical and PdDNA binding levels in colorectal 
cancer model. 
3.10 Proteomic study 
 
Recently  proteomics study has become a powerful tool to conduct high-throughput studies 
allowing detection of altered expression of proteins in response to drug treatment. Two 
dimensional gel electrophoresis combined with mass spectrometry (2DE–MS) is the tested, 
mature technology that can be said as gold-standard in proteomic study (Oliveira, Coorssen et 
al. 2014). Proteins are resolved according to their isoelectric point (pI), using isoelectric 
focusing (IEF) in the first dimension since proteins migrate on a stabilized pH gradient in a 
polyacrylamide gel to the point at which their net charge is zero. Further resolution of the 
proteins is performed  through SDS-PAGE in the second dimension. As mentioned earlier, 
the objective of this study is to get mechanistic information concerning the changes in 
expression of proteins observed in ovarian and colorectal cancer cell lines after drug 
treatments (alone or in combination). In A2780 cell line, the investigation was conducted 
related to treatment with NH3 alone; NH3 in combination with Cur using 0/4 sequence of 
administration; NH3 in combination with EGCG given as a bolus; NH1 in combination with 
6-SG using 0/4 sequence of administration and Cis in combination with Eme also using 0/4 
sequence of administration. In A2780cisR cell line, treatments with NH3 alone; 
NH3+Cur(0/4); NH3+EGCG(0/4); Cis+Eme(4/0) and Cis+Pat(4/0) were chosen. The 
expression of the proteins in cisplatin resistant cell line were compared to those observed in 
parent A2780 cell line before and after treatment to identify the proteins responsible for drug 
resistance. In HT-29 colorectal cancer cell line the selected treatments were that with NH1 
alone and NH3 alone; NH3 in combination with Cur using 4/0 sequence of admiministration 
and Oxa with Pat administered as a bolus. Combination treatments of NH3 with EGCG (0/4) 
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and Ox with Pat (0/0) were investigated in CACO-2 colorectal cancer cell line. All of the 
combination treatments selected for proteomics produced synergistic outcomes. 
3.10.1 Two dimensional gel protein profile 
 
At the very beginning of the analysis, gel images were categorized into matched groups on 
the basis of the hypothesis to be investigated. In the present study, 20 matched groups were 
created with containing duplicate gel images. All of the matched groups were then assembled 
into four classes (two in ovarian and two in colorectal) based on cell lines. Grouping of the 
gel matching is shown in Figure 3.48 and 3.49. Later each class, the corresponding gel 
images were matched and assigned common matched ID numbers for individual protein spot 
using the Melanie software. In the gels obtained from A2780 untreated cell line, a total of  
308 spots were detected by the software. Whereas A2780cisR reference gels produced 107 
spots; HT-29 reference gels displayed 148 spots and CACO-2 reference gels showed a total 
of 224 spots.   
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Figure 3.48: Grouping of gels during proteomic study in ovarian tumour models 
 
Figure 3.49: Grouping of gels during proteomic study in colorectal tumour models 
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NH1 alone
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For differential protein expression analysis, 1.5 fold change in the expression of a protein 
across the matched groups was used as the cut-off. The number of proteins with significant 
changes in expression varied from treatment to treatment and cell line. For example, among 
308 spots annotated in the gel of untreated A2780 cell line, only 62 displayed significant 
changes in expression due to treatment with NH3 alone. However, the number was 72 due to 
treatment with NH3+Cur(0/4) but was 59 due to treatment with NH3+EGCG(0/0). Similarly 
gels obtained from treatment with NH3 alone in A2780cisR cell line showed significant 
changes in expression for only 26 protein spots out of 107 observed in reference untreated 
gel; but treatment with NH3+Cur(0/4) resulted in 28 spots. Among 148 spots in the reference 
gel of HT-29 cell line, treatment with NH3 displayed significant changes in 45 spots; 
treatment with NH3+Cur(4/0) presented 52 spots with significant changes in expression. 
Treatment of NH3+EGCG (0/4) caused significant changes in 35 spots out of 224 spots 
observed in reference untreated gels of CACO-2 cell line. Figure 3.50 (A2780 untreated), 
Figure 3.51 (A2780cisR untreated), Figure 3.52  (HT-29 untreated) and Figure 3.53 (CACO-2 
untreated) represent the image of annotated reference gels used in the study. Figure 3.54 
displays the images of treatment gels for A2780 class where (a)=NH3 alone; (b)= 
NH3+Cur(0/4); (c)=NH3+EGCG(0/0); (d)=NH1+6-SG(4/0) and (e)=Cis+Eme(4/0). Figure 
3.55 displays the images of treatment gels for A2780cisR class where (a)=NH3 alone; 
(b)=NH3+Cur(0/4); (c)=NH3+EGCG(0/4); (d)=Cis+Eme(4/0) and (e)=Cis+Pat(4/0). Figure 
3.56 displays the images of treatment gels for HT-29 class where (a)=NH1 alone; (b)= NH3 
alone; (c)=NH3+Cur(4/0); and (d)=Ox+Pat(4/0). Figure 3.57 displays the images of treatment 
gels for CACO-2 class where (a)=NH3+EGCG(0/4) and (b)=Ox+Pat(0/0) 
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Figure 3.50: Annotated A2780 reference gel 
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Figure 3.51: Annotated A2780cisR reference gel 
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Figure 3.52: Annotated HT-29 reference gel 
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Figure 3.53: Annotated CACO-2 reference gel 
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(a) NH3 alone     (b) NH3+Cur(0/4) 
    
(c) NH3+EGCG(0/0)    (d) NH1+6-SG(0/4) 
 
   (e) Cis+Eme(0/4) 
Figure 3.54: Drug treated gels administered alone and in combination in A2780 cells 
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  (a) NH3 alone     (b) NH3+Cur(0/4) 
     
(c) NH3+EGCG(0/0)    (d) Cis+Eme(4/0) 
 
(e) Cis+Pat(4/0) 
Figure 3.55: Drug treated gels administered alone and in combination in A2780cisR cells 
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(a) NH1 alone     (b) NH3 alone 
     
(c) NH3+Cur(4/0)    (d) Ox+Pat(0/0) 
Figure 3.56: Drug treated gels administered alone and in combination in HT-29 cells 
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(a) NH3+EGCG(0/4) 
 
 
(b) Ox+Pat(0/0)   
Figure 3.57: Drug treated gels administered alone and in combination in CACO-2 cells  
 
In this study, 47 protein spots that underwent significant changes among different classes of 
matched groups due to treatment with drugs administered alone or/and combination were 
chosen for characterization through MALDI-MS technique. The corresponding masses of 
partial or fully fragmented peptides from MS/MS scans were exported to E3 database and the 
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proteins were identified based on Mascot score (less than 56 is insignificant), protein mass 
(Mr), iso-electric point (pI), number of matched peptides and % of sequence coverage. Table 
3.47 shows the selected protein spots that underwent significant changes is expression after 
different treatments with drugs alone or in combination in A2780 ovarian cancer cell line and 
Table 3.48 provides the important information concerning the identity of the proteins. 
Table 3.47: Drug treatments and changes in expression of proteins with untreated A2780 cell 
line being used as reference (U=upregulated; D=downregulated; NC=no change in 
expression; NF=not found, may be due to extreme downregulation) 
 
 
 
 
Spot 
No 
Changes in protein expression in A2780 cell line (Fold) 
Drug treatments 
NH3 NH3+Cur (0/4) NH3+EGCG (0/0) NH1+6SG (0/4) Cis+Eme (0/4) 
6 D (4.8) NC NC U (1.54) NC 
12 D (1.63) D (1.83) NC NC D (2.0) 
13 D (3.23) U (1.67) NF NF NF 
18 D (4.56) NC NF NC D (3.05) 
45 D (2.00) D (1.73) NF D (1.84) D (1.71) 
89 NC NF D (4.14) D (2.52) D (1.65) 
118 D (11.39) NC NF NF D (3.91) 
155 D (6.63) D (2.32) NF NF NF 
195 NF D (2.45) D (5.32) NF NF 
196 NF NF NF NF D (2.57) 
224 NF D (3.62) NF NF NF 
235 NF NF NF NF U (5.26) 
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Table 3.48: Proteins identified in A2780 cell line based on MALDI-MS, Mascot and Swiss-
Prot database 
Spot 
No 
Accession No  
(Protein ID) 
Protein name Mass(
Da)/ pI 
Mascot 
score 
No of 
matched 
peptides 
Sequence 
coverage  
(%) 
6  ACTB_HUMAN 
(P02570) 
Actin, 
cytoplasmic 1 
41710 / 
5.29 
520 16 30 
12 VIME_HUMAN 
(P08670) 
Vimentin 53619 / 
5.06 
739 6 45 
13 CH60_HUMAN 
(P10809) 
60 kDa heat 
shock protein, 
mitochondrial 
61016/ 
5.70 
518 19 24 
18 ENPL_HUMAN 
(P14625) 
Endoplasmin 92411/
4.76 
647 36 21 
45 GRP78_HUMAN 
(P11021) 
78 kDa 
glucose-
regulated 
protein 
72288/
5.07 
820 28 27 
89 CALR_HUMAN 
(P27797) 
Calreticulin 48112/
4.29 
112 8 17 
118 UBB_HUMAN 
(P0CG47) 
Polyubiquitin-
B 
25746 40 ٭ ٭ 
155 H33_HUMAN 
(P06351) 
Histone H3.3 15319/
11.27 
120 11 27 
195 ANXA1_HUMAN  
(P04083) 
Annexin A1 38690/
6.57 
651 28 45 
196 NACA_HUMAN 
(Q13765) 
Nascent 
polypeptide-
associated 
complex 
subunit alpha 
23370/
4.52 
110 12 32 
224 PPIA_HUMAN 
(P05092) 
Peptidyl-prolyl 
cis-trans 
isomerase A 
18001/
7.68 
306 19 57 
235 PPIA_HUMAN 
(P05092) 
Peptidyl-prolyl 
cis-trans 
isomerase A 
18001/
7.68 
483 21 68 
٭Mascot score is insignificant, information not provided. 
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Table 3.49 shows the selected protein spots that underwent significant changes is expression 
after different treatments with drugs alone or in combination in A2780cisR ovarian cancer cell 
line and Table 3.50 provides the important information concerning the identity of the 
proteins.  
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Table 3.49: Drug treatments and changes in expression of proteins with untreated A2780cisR 
cell line being used as reference (U=upregulated; D=downregulated; NC=no change in 
expression; NF=not found, may be due to extreme downregulation) 
 
Match 
ID 
Changes in protein  expression in A2780cisR cell line (Fold) 
Drug treatments 
NH3 NH3+Cur (0/4) NH3+EGCG (0/4) Cis+Eme (4/0) Cis+Pat 
(4/0) 
1 D (1.51) NC D (2.22) NC NC 
Cn9 D (2.98) NC NC U (3.04) NC 
Cn16 D (1.69) NC D (5.70) NF NC 
Cn23 U (2.47) NF NC NF NC 
Cn27 NF D (1.60) NF NF NC 
Cn34 D (7.86) NC D (1.76) NF NC 
Cn39 NC D (1.66) NF NF NC 
Cn41 D (2.93) NF D (2.02) NC U (2.27) 
Cn48 NC NC D (2.49) NF D (1.63) 
Cn51 NC D (2.50) D (2.57) NF NC 
Cn56 D (3.87) NC D (4.75) NC NC 
Cn65 NF D (3.00) D (5.36) NF D (3.40) 
Cn69 D (2.27) D (6.88) D (11.86) D (1.86) D (11.05) 
Cn78 NF NF NF NF NC 
Cn79 D (2.79) D (3.44) NF NF NF 
Cn90 NF NF NF NF NF 
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Table 3.50: Proteins identified in A2780cisR cell line based on MALDI-MS, Mascot and 
Swiss-Prot database 
 
Spot 
No. 
       Accession No  
(Protein ID) 
Protein name Mass(Da)/ pI Mascot 
score 
No of 
matched 
peptides 
Sequence 
coverage  
(%) 
1 ACTB_HUMAN 
(P02570) 
Actin, 
cytoplasmic 1 
41710 / 5.29 520 16 30 
Cn9 RSSA_HUMAN 
(P08865) 
40S ribosomal 
protein SA 
32833 / 4.79 130 10 17 
Cn16 HSP7C_HUMAN 
(P11142) 
Heat shock 
cognate 71 kDa 
protein 
70854 / 5.37 686 27 21 
Cn23 K2C1_HUMAN 
(P04264) 
Keratin, type II 
cytoskeletal 1 
65999 31 ٭ ٭ 
Cn27 PRDX6_HUMAN  
(P30041) 
Peroxiredoxin-6 25019/6.0 60 6 19 
Cn34 EFTU_HUMAN 
(P49411) 
Elongation 
factor Tu, 
mitochondrial 
49510 / 7.26 88 13 16 
Cn39 ACTB_HUMAN 
(P02570) 
Actin, 
cytoplasmic 1 
41710 / 5.29 87 10 14 
Cn41 CISY_HUMAN 
(Q71UT9) 
Citrate synthase, 
mitochondrial 
51680 / 8.45 97 14 16 
Cn48 VIME_HUMAN 
(P08670) 
Vimentin 53619 / 5.06 285 25 30 
Cn51 HSP7C_HUMAN 
(P11142) 
Heat shock 
cognate 71 kDa 
protein 
70854 / 5.37 110 12 15 
Cn56 TERA_HUMAN 
(P55072) 
Transitional 
endoplasmic 
reticulum 
ATPase 
89266 / 5.14 208 14 10 
Cn65 CH10_HUMAN 
(P61604) 
10 kDa heat 
shock protein, 
mitochondrial 
10925 / 8.89 78 9 33 
Cn69 COF1_HUMAN 
(P23528) 
Cofilin-1 18491/8.22 144 10 22 
Cn78 SERPH_HUMAN 
(P50454) 
Serpin H1 46411 / 8.75 75 12 24 
Cn79 ACTB_HUMAN 
(P02570) 
Actin, 
cytoplasmic 1 
41710 / 5.29 231 19 48 
Cn90 HSP7C_HUMAN 
(P11142) 
Heat shock 
cognate 71 kDa 
protein 
70854 / 5.37 64 5 6 
٭Mascot score is insignificant, information not provided. 
 
188 
 
Table 3.51 shows the selected protein spots that underwent significant changes in expression 
after treatment with drugs administered alone or in combination in HT-29 colorectal cancer 
cell line and Table 3.52 provides information concerning the identity of the proteins. 
Table 3.51: Drug treatments and changes in expression of proteins with untreated HT-29 cell 
line being used as reference (U=upregulated; D=downregulated; NC=no change in 
expression; NF=not found, may be due to extreme downregulation) 
Match ID Changes in protein expression in HT-29 cell line (Fold) 
Drug treatments 
NH1 NH3 NH3+Cur (4/0) Ox+Pat (0/0) 
1 NF NF NF D (2.16) 
Hn11 D (2.12) NC D (1.57) U (2.26) 
Hn14 D (4.83) NC NC D (1.59) 
Hn15 D (2.85) NC D (4.21) NC 
Hn43 U (1.66) NC NC U (1.65) 
Hn70 D (2.26) D (2.14) D (2.42) NF 
Hn89 NF D (1.85) D (3.22) NF 
Hn119 NF D (1.91) NF NF 
Hn142 NF NF D (1.80) NF 
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Table 3.52: Proteins identified in HT-29 cell line based on MALDI-MS, Mascot and Swiss-
Prot database 
S
p
o
t
 
N
o
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Accession No  
(Protein ID) 
Protein nameb Mass(Da)/ 
pI 
Mascot 
score 
No of 
matched 
peptides 
Sequence 
coverage  
(%) 
1 ACTG_HUMAN 
(P02571) 
Actin, 
cytoplasmic 2 
41766/ 5.31 292 23 40 
Hn11 PROF1_HUMAN 
(P07737) 
Profilin-1 15045/8.44 89 12 42 
Hn14 PPIA_HUMAN 
(P05092) 
Peptidyl-propyl 
cis-trans 
isomerase A 
18001/7.68 212 18 50 
Hn15 PPIA_HUMAN 
(P05092) 
Peptidyl-propyl 
cis-trans 
isomerase A 
18001/7.68 177 21 55 
Hn43 PDIA3_HUMAN 
(P30101) 
Protein 
disulfide-
isomerase A3 
56747/5.98 345 31 43 
Hn70 NDKB_HUMAN 
(P05092) 
Nucleoside 
diphosphate 
kinase B 
17287/8.52 308 5(4) 71 
Hn89 ANXA1_HUMAN  
P04083 
Annexin A1 38690/6.57 166 25 54 
Hn119 H4_HUMAN 
(P02304) 
Histone H4 11360/11.36 58 6 29 
Hn142 ALDH2_HUMAN 
(P05091) 
ALDH class 2 56346/6.63 118 18 22 
 
Table 3.53 shows the selected protein spots that underwent significant changes is expression 
after  treatments with drugs administered alone or in combination in CACO-2 colorectal 
cancer cell line and Table 3.54 provides information concerning the identity of the proteins. 
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Table 3.53: Drug treatments and changes in expression of proteins with untreated CACO-2 
cell line used as reference (U=upregulated; D=downregulated; NC=no change in expression; 
NF=not found, may be due to extreme downregulation) 
Match ID Changes in protein expression in CACO-2 cell line (Fold) 
Drug treatments 
NH3+EGCG (0/4) Ox+Pat (0/0) 
Can3 NF D (7.88) 
Can11 NF D (10.03) 
Can22 NF D (1.98) 
Can31 D (1.67) NC 
Can59 NF D (8.31) 
Can71 NF D (2.90) 
Can92 NC U (2.17) 
Can147 D (2.04) NF 
 
Table 3.54: Proteins identified in CACO-2 cell line based on MALDI-MS, Mascot and 
Swiss-Prot database 
Spot 
No. 
       
 
Accession No  
(Protein ID) 
Protein name Mass(Da)/ 
pI 
Mascot 
score 
No of 
matched 
peptides 
Sequence 
coverage  
(%) 
Can3 PROF1_HUMAN 
(P07737) 
Profilin-1 15045/8.4
4 
56 7 39 
Can11 COF1_HUMAN 
(P23528) 
Cofilin-1 18491/8.2
2 
318 19 71 
Can22 GSTP1_HUMAN 
(P09211) 
Glutathione S-
transferase P 
23341/5.4
3 
228 16 55 
Can31 ROA2_HUMAN 
(P22626) 
Heterogenous 
nuclear 
ribonucleoprotei
ns A2/B1 
37407/8.9
7 
349 22 38 
Can59 ALDOA_HUMAN 
(P04075) 
Fructose-
biphosphate 
aldolase A  
39395/8.3
0 
180 18 34 
Can71 TBA1C_HUMAN 
(Q9BQE3) 
Tubulin alpha-
1C chain 
49863/4.9
6 
50 5 12 
Can92 TBB5_HUMAN  
P07437 
Tubulin beta 
chain 
49639/4.7
8 
241 27 65 
Can147 PRDX6_HUMAN  
(P30041) 
Peroxiredoxin-6 25019/6.0 61 6 32 
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As stated earlier, a further objective of proteomic study was to find out  proteins related to 
drug resistance in A2780cisR ovarian cancer cell line and to determine changes in expression 
of the identified proteins in treated A2780cisR cells for which A2780 was used as reference 
and changes in expression in untreated and treated A2780cisR was determined. Since some 
proteins were not expressed in A2780 cell line but expressed in A2780cisR cell line, further 
matching of protein spots was done through different classes using A2780cisR as reference. 
Table 3.55 and Table 3.56 summarize changes in expression of selected protein spots in 
A2780cisR cell line due to drug treatments. 
The detail of the proteins (alternative names, genes, subcellular location, functions) identified 
from this study is summarized in Appendix III (proteins differentially expressed in ovarian 
cancer cell) and Appendix IV (proteins differentially expressed in colorectal cancer cell). 
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Table 3.55: Changes in protein expression in A2780CisR cell line after treatment with drugs 
administered alone and in combination  with untreated A2780 cell line used as reference 
(U=upregulation; D=downregulation; PR=partially restored; OR=over restored; FR=fully 
restored; FUR= further upregulated; FDR=further downregulated; NF=not found, may be due 
to extreme downregulation) 
 
  
Match ID Changes in protein expression in A2780cisR cell line 
A2780CisR 
Untreated 
(Fold) 
  
Drug treatments 
NH3 NH3+Cur 
(0/4) 
NH3+EGC
G (0/4) 
Cis+Eme 
(4/0) 
Cis+Pat 
(4/0) 
6  U (2.40) PR PR PR PR PR 
 
12 U (1.94) PR PR FUR FUR PR 
 
13 U (1.92) FUR FUR PR FUR FUR 
18 U (1.58) PR FUR FUR FUR PR 
45 NF OR OR FR NF OR 
89 NF OR OR FR NF NF 
118 NF PR OR PR NF OR 
155 NF PR NF NF NF NF 
195 NF NF PR OR NF NF 
196 U (8.14) PR NF NF NF NF 
224 NF OR OR OR NF NF 
235 NF NF PR FR NF PR 
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Table 3.56: Changes in protein in A2780CisR cell line after treatment with drugs administered 
alone and in combination with untreated A2780cisR being used as reference (U=upregulation; 
D=downregulation; PR=partially restored; OR=over restored; FR=fully restored; FUR= 
further upregulated; FDR=further downregulated; NF=not found, may be due to extreme 
downregulation) 
 
3.10.2 Protein expression and Mass spectral analysis 
Actin, cytoplasmic 1 (ACTB) 
Actin, cytoplasmic 1 (ACTB) protein was present in both A2780 and A2780cisR cell line and 
showed significant changes in expression after drug treatments. The protein appeared as most 
prominent spot (match ID 6) in untreated A2780 and annotated as marker 1. Similarly due to 
unique presence of this protein spot (match ID 1) in all treatment groups, it was also used as 
marker in A2780cisR class and annotated as marker 1. However it appeared at three different 
positions (match ID 1, Cn39 and Cn79) in A2780cisR reference gels, all of them showing 
significant changes among different matched groups. Treatments with synergistic drug 
combinations and NH3 administered alone caused significant downregulation of this protein 
in both A2780 and A2780cisR cell line (Table 3.47 and Table 3.49). The protein was 
Match ID Changes in protein expression in A2780cisR cell line 
A2780cisR 
Untreated 
(Fold) 
  
Drug treatments 
NH3 NH3+Cur 
(0/4) 
NH3+EGCG 
(0/4) 
Cis+Eme 
(4/0) 
Cis+Pat (4/0) 
1 U (2.40) PR PR PR PR PR 
Cn9 U (4.93) PR PR PR FUR PR 
Cn16 U (8.12) PR FUR PR NF FUR 
Cn23 U (1.80) FUR NF PR NF FUR 
Cn27 U (10.22) NF PR NF NF PR 
Cn34 U (3.47) OR PR PR NF PR 
Cn39 U (2.09) PR PR NF NF PR 
Cn41 U (22.0) PR NF PR FUR FUR 
Cn48 U (3.53) PR PR PR NF PR 
Cn51 U (23.16) PR PR PR NF FUR 
Cn69 U (5.33) PR OR OR PR OR 
Cn79 U (7.77) PR PR NF NF NF 
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upregulated in A2780cisR cell line and partially restored back to the levels found in parent 
A2780 cell line after treatment with drugs administered alone and in combination (Table 3.55 
and Table 3.56). As a representative of four spots of Actin, cytoplasmic 1 (ACTB) observed 
in this study; mass spectrum and sequence of matched peptides of match ID 1 (highest 
Mascot score) from A2780cisR are shown in Figure 3.58. 
 
 
 
Figure 3.58: Mass spectrum and matched peptides for ACTB 
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Vimentin (Vime) 
Vimentin was also significantly expressed in both ovarian cancer cell lines and appeared as 
spot 12 (marker 2) in A2780 while as spot Cn48 in A2780cisR class. The protein was 
downregulated due to all of the drug treatments in both ovarian cancer cell lines (Table 3.47 
and Table 3.49). Compared to untreated A2780 cells, the protein was upregulated in untreated 
A2780cisR cell line and partially restored back to the levels found in parent A2780 cell line 
after treatment with NH3 alone, NH3+Cur(0/4) and Cis+Pat(4/0). Mass spectrum and 
sequence of matched peptides of match ID Cn48 (highest Mascot score) from A2780cisR are 
shown in Figure 3.59. 
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Figure 3.59: Mass spectrum and matched peptides for VIME 
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60 kDa heat shock protein, mitochondrial (CH60) 
60 kDa heat shock protein (match ID 13) showed significant changes in expression in A2780 
cell line due to various treatment groups. It was downregulated due to treatment with NH3 
alone but upregulated due to treatment with combination of NH3 with Cur using (0/4) 
sequence. The protein was upregulated in untreated A2780cisR cell line compared to that in 
parent A2780 cell line. However most of the drug treatments caused further upregulation of 
the protein except that with NH3+EGCG(0/4) which partially restored back to the level found 
in A2780 cell line. Mass spectrum and sequence of matched peptides of CH60 is given in 
Figure 3.60. 
  
Figure 3.60: Mass spectrum and matched peptides for CH60 
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Endoplasmin (ENPL) 
Endoplasmin (match ID 18) was significantly downregulated in A2780 cell line due to 
treatment with NH3 alone and that with combination of Cis with Eme using (0/4) sequence. It 
also showed downregulation due to treatments with NH3+Cur (0/4) and NH1+6-SG (0/4) but 
the change was not judged significant (Table 3.47). Endoplasmin was upregulated in 
untreated cisplatin resistant A2780cisR cell line compared to the level observed in parent 
A2780 cell line. Following treatment with NH3 alone and the combination  of Cis+Pat(4/0) in 
A2780cisR cell line, the protein was partially restored back to the levels as found in A2780 cell 
line. But other drug treatments caused further upregulation of the protein. Mass spectrum and 
sequence of matched peptides of ENPL are given in Figure 3.61. 
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Figure 3.61: Mass spectrum and matched peptides for ENPL 
78 kDa glucose-regulated protein (GRP) 
78 kDa glucose-regulated protein (match ID 45) was significantly downregulated in A2780 
cell line due to all drug treatments (Table 3.47). But the protein was not detectable in 
untreated A2780cisR cell line. However most of the drug treatments restored back the protein 
(Table 3.55). Mass spectrum and sequence of matched peptides of GRP is given in Figure 
3.62. 
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Figure 3.62: Mass spectrum and matched peptides for GRP 
Calreticulin (CALR) 
Calreticulin (match ID 89) was significantly downregulated in A2780 cell line due to 
treatment wih NH3+EGCG(0/0); NH1+6-SG(0/4) and Cis+Eme(0/4). Treatment with NH3 
alone also downregulated the protein although the change was not judged to be significant. 
The protein was not detectable following  treatment with NH3+Cur(0/4). In untreated 
A2780cisR cell line, CALR did not express at all but was restored back (upregulated) due to 
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treatments with NH3 alone; NH3+Cur(0/4) and NH3+EGCG(0/4). Mass spectrum and 
sequence of matched peptides of CALR are given in Figure 3.63.  
 
 
Figure 3.63: Mass spectrum and matched peptides for CALR 
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Polyubiquitin-B (UBB) 
Polyubiquitin-B (match ID 118) was significantly downregulated in A2780 cell line due to 
threatments with NH3 alone (11.39 folds) and Cis+Eme(0/4). The protein was not detected in 
untreated cisplatin resistant A2780cisR cell line but all of the drug treatments either partially or 
over  restored the protein except that with Cis+Eme(4/0). However, Mascot score of UBB 
was not significant during MALDI-MS scan. That is why sequence of matched peptides is 
not given, only Mass spectrum of UBB is displayed in Figure 3.64. 
 
Figure 3.64: Mass spectrum for UBB 
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Histone H3.3 (H33) 
Histone H3.3 (match ID 155) was downregulated in A2780 cell line due to treatments with 
NH3 alone and NH3+Cur(0/4)  but did not express with other treatments. The protein was not 
expressed in A2780cisR cell line but restored back partially (upregulated) due to treatments 
with NH3 alone. Mass spectrum and sequence of matched peptides of H33 are given in 
Figure 3.65.  
 
 
Figure 3.65: Mass spectrum and matched peptides for H33 
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Annexin A1 (ANXA1) 
Annexin A1 (match ID 195 and Hn89) displayed significant changes in expression due to 
drug treatments compared to reference gel in A2780 and HT-29 class. In A2780 cell line, 
ANXA1 was significantly downregulated due to treatments with NH3+Cur(0/4) and 
NH3+EGCG(0/0). Downregulation of the protein was also observed in HT-29 cell line due to 
treatments with NH3 alone and combination NH3+Cur(4/0). The protein was not observed in 
untreated A2780cisR cell line but was over restored due to treatment with NH3+EGCG(0/4) 
and partially restored by NH3+Cur(0/4). Mass spectrum and sequence of matched peptides of 
ANXA1 is given in Figure 3.66.  
 
 
Figure 3.66: Mass spectrum and matched peptides for ANXA1 
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Nascent polypeptide-associated complex subunit alpha (NACA) 
Nascent polypeptide-associated complex subunit alpha (match ID 196) was significantly 
downregulated in A2780 cell line due to treatment with Cis+Eme(0/4) but the protein was not 
detectable following other treatments. NACA was highly upregulated in untreated A2780cisR 
cell line and partially restored back  due to treatment with NH3 alone. The protein was 
completely disappeared with all investigated combined treatments of drugs in A2780cisR cell 
line. Mass spectrum and sequence of matched peptides of NACA are given in Figure 3.67. 
 
 
Figure 3.67: Mass spectrum and matched peptides for NACA 
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Peptidyl-prolyl cis-trans isomerase A (PPIA) 
Peptidyl-prolyl cis-trans isomerase A (match ID 224, 235 and Hn15) was found to display 
significantly changes in expresssion in A2780 ovarian cancer cell line and HT-29 colorectal 
cancer cell line. The protein was not detectable after treatment of the cellswith NH3 alone; 
combination treatments: NH3+Cur(0/4); NH3+EGCG(0/0) and NH1+6-SG. But it was 
significantly upregulated due to treatment with Cis+Eme(0/4). In untreated A2780cisR cell 
line, the protein did not express at all but was restored back (upregulated) due to three 
combined treatments. In HT-29 cell, downregulation of PPIA resulted due to all treatments 
although it was judged to be significant only as applied to treatments with NH1 alone and the 
combination NH3+Cur(4/0). Mass spectrum and sequence of matched peptides of PPIA 
(match ID 235 having highest Mascot score) is given in Figure 3.68.  
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Figure 3.68: Mass spectrum and matched peptides for PPIA 
  
208 
 
40S ribosomal protein SA (RSSA) 
40S ribosomal protein SA (match ID Cn9) was significantly downregulated in A2780 cell line 
following treatment with NH3 alone; significantly upregulated due to treatment with 
Cis+Eme(4/0). All other treatments caused significant downregulation of RSSA in A2780 
cell line. The protein was upregulated in untreated A2780cisR cell line compared to the 
expression level observed in A2780 cell line. However, all the treatments in A2780cisR cell 
line restorted back the level of protein found in A2780 cell line except Cis+Eme(4/0) where 
further upregulation was observed (Table 3.56). Mass spectrum and sequence of matched 
peptides of RSSA are given in Figure 3.69. 
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Figure 3.69: Mass spectrum and matched peptides for RSSA 
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Heat shock cognate 71 kDa protein (HSP7C) 
Heat shock cognate 71 kDa protein appeared as three different spots (Cn16, Cn51 and Cn90) 
in untreated A2780cisR reference gel. The protein was significantly downregulated in A2780 
cell line following all except that with Cis+Eme(4/0) where the protein was found to 
disappear. Compared to the expression level of HSP7C in A2780 cell line, the protein was 
upregulated in untreated A2780cisR cell line. Treatments of A2780cisR cell line with NH3 alone 
and the combination NH3+EGCG(0/4) caused the protein to be restored back partially to the 
level observed in parent cell line. Mass spectrum and sequence of matched peptides of 
HSP7C (match ID Cn16) are given in Figure 3.70. 
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Figure 3.70: Mass spectrum and matched peptides for HSP7C 
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Keratin, type II cytoskeletal 1 (K2C1) 
Keratin, type II cytoskeletal 1 (Cn23) was significantly upregulated in A2780 cell line due to 
treatment with NH3 alone but was not detectable following treatments with NH3+Cur(0/4) 
and Cis+Eme(4/0). The protein was significantly upregulated in A2780cisR cell line compared 
to the level in parent A2780 cell line. It was partially restored back to the level detected in 
A2780 cell line only following treatment with the combination NH3+EGCG(0/4). However 
Mascot score of the protein was insignificant and matched peptides have not shown here. 
Mass spectrum of K2C1 is given in Figure 3.71. 
 
Figure 3.71: Mass spectrum for K2C1 
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Peroxiredoxin-6 (PRDX6) 
Peroxiredoxin-6 (match ID Cn27 and Can147) found to show significant changes in 
expression in A2780 cell line and CACO-2 cell line. In A2780 cell line it was significantly 
downregulated following treatment with NH3+Cur(0/4). Also in CACO2 cell line the 
protein was downregulated followoing treatment with NH3+EGCG(0/4). PRDX6 was highly 
upregulated (10.22 folds) in A2780cisR cell line compared to the level of expression in A2780 
cell line. It was partially restored back to the level as found in A2780 cell line after treatment 
with the combinations NH3+Cur(0/4) and Cis+Pat(4/0). Mass spectrum and sequence of 
matched peptides of PRDX6 (match ID Can147, highest Mascot score) are given in Figure 
3.72. 
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Figure 3.72: Mass spectrum and matched peptides for PRDX6 
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Elongation factor Tu, mitochondrial (EFTU) 
Elongation factor Tu, mitochondrial (match ID Cn34) was significantly downregulated in 
A2780 cell line following treatments with NH3 alone and the combination NH3+EGCG(0/4). 
EFTU was significantly upregulated in untreated A2780cisR cell line compared to its parent 
A2780 cell line. Most of the selected drug treatments restored back to the level of the protein 
as expressed in A2780 cell line. Mass spectrum and sequence of matched peptides of EFTU 
are given in Figure 3.73. 
 
 
Figure 3.73: Mass spectrum and matched peptides for EFTU 
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Citrate synthase, mitochondrial (CISY) 
Citrate synthase, mitochondrial (match ID Cn41) was downregulated in A2780 cell line 
following treatments with NH3 alone and the combination NH3+EGCG(0/4) but was 
upregulated following treatment with the combination Cis+Pat(4/0). CISY was extremely 
upregulated in untreated A2780cisR cell line when compared with the level of expression in 
A2780 cell line. It was partially restored back to the level as observed in A2780 cells after 
treatment with NH3 alone and  the combination NH3+EGCG(0/4). Mass spectrum and 
sequence of matched peptides of CISY are given in Figure 3.74. 
 
 
Figure 3.74: Mass spectrum and matched peptides for CISY 
  
217 
 
Transitional endoplasmic reticulum ATPase (TERA) 
 
Transitional endoplasmic reticulum ATPase (match ID Cn56) was downregulated in 
A2780cisR cell line following treatment with NH3 alone and the combinations: NH3+Cur(0/4) 
and NH3+EGCG(0/4) in A2780cisR cell line. TERA was absent in untreated parent A2780 
cell line. Mass spectrum and sequence of matched peptides of TERA are given in Figure 
3.75. 
 
 
Figure 3.75: Mass spectrum and matched peptides for TERA 
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10 kDa heat shock protein, mitochondrial (CH10) 
10 kDa heat shock protein, mitochondrial (match ID Cn65) was downregulated in A2780cisR 
cell line following treatment with the combinations NH3+Cur(0/4); NH3+EGCG(0/4) and 
Cis+Pat(4/0). The protein disappeared after treatment of A2780cisR cells with NH3 alone and 
the combination Cis+Eme(4/0). CH10 was not expressed at all in untreated parent A2780 cell 
line. Mass spectrum and sequence of matched peptides of CH10 are given in Figure 3.76. 
 
 
 
Figure 3.76: Mass spectrum and matched peptides for CH10 
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Cofilin-1 (COF1) 
Cofilin-1 (match ID Cn69 and Can11) revealed significant changes in expression in A2780 
ovarian and CACO-2 colorectal cancer cell line. The protein was downregulated in A2780 
cell line due to all of the selected treatments. COF1 showed upregulation in untreated 
A2780cisR cell line than the level observed in parent A2780 cell line. All of the selected drug 
treatments of A2780cisR cell line restored back the protein to the level found in A2780 cell 
line. Ten folds downregulation of the protein was observed following treatment with 
Ox+Pat(0/0) in CACO-2 cell line.  Mass spectrum and sequence of matched peptides of 
COF1 (match ID Can11, having highest Mascot score) are given in Figure 3.77. 
 
 
Figure 3.77: Mass spectrum and matched peptides for COF1 
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Serpin H1(SERPH) 
Serpin H1 (match ID Cn78) was marginally downregulated A2780cisR cell line following 
treatment with Cis+Pat(4/0). All other selected drug treatments of A2780cisR cell line caused 
the protein to disappaer completely. SERPH was not detectable in untreated A2780 cell line. 
Mass spectrum and sequence of matched peptides of SERPH are given in Figure 3.78. 
 
 
Figure 3.78: Mass spectrum and matched peptides for SERPH 
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Profilin-1 (PROF1) 
Profilin-1 (match ID Hn11 and Can3) exhibited significant changes in expression before and 
after treatment in both the colorecal cancer cell lines HT-29 and CACO-2. The protein was 
significantly downregulated in HT-29 cell line following treatment with NH1 alone and the 
combination NH3+Cur(4/0) but was upregulated following treatments with Ox+Pat (0/0). In 
CACO-2 cell line, treatment with Ox+Pat(0/0) caused greater downregulation of the protein 
than that observed in HT-29 cell line. PROF1 was not detectable in CACO-2 cell line 
following treatment with the combination NH3+EGCG(0/4). Mass spectrum and sequence of 
matched peptides of PROF1 (match ID Hn11, greater Mascot score) are given in Figure 3.79. 
 
 
Figure 3.79: Mass spectrum and matched peptides for PROF1 
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Protein disulfide-isomerase A3 (PDIA3) 
Protein disulfide-isomerase A3 (match ID Hn43) was upregulated in HT-29 cell line 
following all the selected drug treatments but the upregulation was judged to be significant 
only in treatments with NH1 alone and the combination Ox+Pat(0/0). Mass spectrum and 
sequence of matched peptides of PDIA3 are given in Figure 3.80. 
 
 
Figure 3.80: Mass spectrum and matched peptides for PDIA3 
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Nucleoside diphosphate kinase B (NDKB) 
Nucleoside diphosphate kinase B (match ID Hn70) was downregulated in HT-29 cell line 
following all of the selected drug treatments. Mass spectrum and sequence of matched 
peptides of NDKB are given in Figure 3.81. 
 
 
Figure 3.81: Mass spectrum and matched peptides for NDKB 
  
224 
 
Histone H4 (H4) 
Histone H4 (match ID Hn119) was downregulated in HT-29 cell line following all 
treatments. Mass spectrum and sequence of matched peptides of H4 are given in Figure 3.82. 
 
 
 
 
Figure 3.82: Mass spectrum and matched peptides for H4 
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ALDH class 2 (ALDH2) 
ALDH class 2 (match ID Hn142) was downregulated in HT-29 cell line following all 
treatments. Mass spectrum and sequence of matched peptides of ALDH2 are given in Figure 
3.83. 
 
 
Figure 3.83: Mass spectrum and matched peptides for ALDH2 
226 
 
Glutathione S-transferase P (GSTP1) 
Glutathione S-transferase P (match ID Can22) was downregulated in CACO-2 cell line 
following all treatments. Mass spectrum and sequence of matched peptides of GSTP1 are 
given in Figure 3.84. 
 
 
 
Figure 3.84: Mass spectrum and matched peptides for GSTP1 
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Heterogenous nuclear ribonucleoproteins A2/B1 (ROA2) 
Heterogenous nuclear ribonucleoproteins A2/B1 (match ID Can31) was downregulated in 
CACO-2 cell line following all the selected drug treatments. Mass spectrum and sequence of 
matched peptides of ROA2 are given in Figure 3.85. 
 
 
Figure 3.85: Mass spectrum and matched peptides for ROA2 
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Fructose-biphosphate aldolase A (ALDOA) 
Fructose-biphosphate aldolase A (match ID Can59) was markedly downregulated in CACO-2 
cell line following treatment with the combination Ox+Pat(0/0). The protein did not express 
at all following treatments with the combination NH3+EGCG(0/4) that may be considered as 
extreme downregulation. Mass spectrum and sequence of matched peptides of ALDOA are 
given in Figure 3.86. 
 
 
Figure 3.86: Mass spectrum and matched peptides for ALDOA 
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Tubulin alpha-1C chain (TBA1C) 
Tubulin alpha-1C chain (match ID Can71) was downregulated in CACO-2 cell line following 
treatment with the combinations Ox+Pat(0/0) and NH3+EGCG. Mass spectrum and sequence 
of matched peptides of TBA1C are given in Figure 3.87. 
 
 
Figure 3.87: Mass spectrum and matched peptides for TBA1C 
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Tubulin beta chain (TBB5) 
Tubulin beta chain (match ID Can92) was downregulated in CACO-2 cell line following 
treatments with the combinations: NH3+EGCG(0/4) and Ox+Pat(0/0). Mass spectrum and 
sequence of matched peptides of TBB5 are given in Figure 3.88. 
 
 
Figure 3.88: Mass spectrum and matched peptides for TBB5 
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CHAPTER FOUR 
4  DISCUSSION 
Palladium based tumour active compounds are gaining increasing attention due to promising 
activity of many synthesized palladium complexes found during in vitro and animal model 
studies. Enhanched activity in palladium complexes can be attained by introduction of bulkier 
ligands which will provide the complexes less labile but with sufficient distortion of DNA to 
bring about programmed cell death (Alam and Huq 2016). With this hypothesis, six 
palladium complexes (coded as NH1, NH2, NH3, NH4, NH5 and NH6) have been 
synthesized using bulky N-planaramine ligands. The designed compounds were characterized 
by elemental microanalysis, IR spectroscopy, proton-NMR spectroscopy and mass 
spectroscopy. In addition, single crystal X-ray characterization was performed for NH3, NH4 
and NH6. Cytotoxicity of the designed complexes was determined through MTT-reduction 
assay against ovarian, colorectal, breast and cervical cancer models. Another objective of this 
study was to exploit the anticancer potential of phytochemicals to overcome drug resistance. 
Designed palladium complexes and drugs used in the clinic (cisplatin and oxaliplatin) were 
combined with selected phytochemicals (curcumin, EGCG, emetine, patulin and 6-Shogaol) 
as a function of concentrations and sequence of addition against ovarian and colorectal cancer 
models.  
DNA damage study was performed to obtain information on the interaction of the designed 
complexes with DNA. Other mechanistic studies involved cellular accumulation of platinum, 
metalDNA binding and proteomics were carried out to obtain information about the 
underlying mechanisms for the antitumour activity of the complexes alone or in combination. 
This chapter discusses the results of all studies from synthesis of palladium complexes up to 
the changes in key proteins in cancer cells after drug treatments alone or in combination. 
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4.1 Synthesis and characterization 
 
Potassium terachloropalladate was used as the starting material for all of the palladium 
complexes synthesized in this study. Quinoline, benzimidazole and 8-hydroxyquinoline were 
used as ligands for synthesis of NH1, NH2 and NH3 respectively. Imidazo (1, 2-)pyridine 
was used as ligand during synthesis of NH4, NH5 and NH6. The general synthetic scheme of 
the complexes was similar with small variations in incubation period and reaction conditions. 
Figure 4.1 depicts the synthetic scheme for NH1, NH2 and NH3 while Figure 4.2 gives the 
same for NH4, NH5 and NH6.  
 
Figure 4.1: General synthetic scheme for NH1, NH2 and NH3 
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Figure 4.2: General synthetic scheme for NH4, NH5 and NH6 [L= Imidazo (1, 2-)pyridine] 
The percent yield for the all synthesized palladium complexes was high except for NH4. 
Highest yield was shown by NH1 with 94.47% where quinoline was used as ligand followed 
by NH2 (89.84%) where benzimidazole was used as ligand and NH3 (82.32%) for which 8-
hydroxyquinoline was used as ligand. Palladium complexes having quinoline moieties have 
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shown greater than 90% yields in previous report as well (Motswainyana, Onani et al. 2013). 
It can be said that the yield of NH1 from this study is similar to earlier findings. Seventy five 
to eighty five percent yields for palladium complexes possessing benzimidazole derivatives 
have been reported earlier (Abdel Ghani and Mansour 2011, Abdel Ghani and Mansour 
2012). Yield of NH2 from this study is little bit more than the previous reports of structurally 
similar compounds. Likewise yield of NH3 obtained from this study is higher than the 
previous reports of alike palladium complexes (Vranec, Potocnak et al. 2014). Among the 
complexes designed with imidazo (1, 2-)pyridine, the lowest yield was displayed by NH4 
(59.69%) and the highest by NH6 (79.15%). Such variation of yield is not uncommon in 
palladium and platinum complexes (Mazumder 2013, Arzuman 2014). Palladium compound 
NH5 was reported earlier but with a different synthetic protocol and with lower yield (54%) 
than that observed in this study (77.18%) (Mazumder 2013). Elemental composition of the 
compounds is given in Table 3.2 and it is evident from that, all of the compounds were 
synthesized with sufficient purity ranging from 95% to 99%. Three of them (NH3, NH4 and 
NH6) produced suitable single crystals.    
4.1.1 IR Spectra 
 
Infrared spectrum obtained for each compound has been displayed in Figure 3.2 to Figure 3.7 
and the important peaks have been listed in in Table 3.3. The IR peaks were assigned based 
on the previously reported spectra of the corresponding ligands and their palladium or 
platinum complexes (Huq, Tayyem et al. 2007, Mazumder, Beale et al. 2012, Arzuman, 
Beale et al. 2016).  
NH1: The peak at 1588 cm-1 may be due to C=N stretching vibrations and the peak at 1461 
cm-1 is thought to be due to aromatic ring stretch. The medium band at 1392 cm-1 is supposed 
to be due to CH bending vibrations. Strong band at 1316 cm-1 and medium band at 1210 cm-
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1 might be produced by C-N stretching vibrations. The peak at 1130 cm-1 is believed to be 
due to CC bending. The weak band produced at 869 cm-1 is considered to be due to CH 
aromatic stretching. Strong band observed at 753 cm-1 may be due to CH out of plane 
bending. Whereas strong band at 644 cm-1 is believed to be due to C=C bending. PdN 
vibration may be responsible for producing weak band at 514 cm-1.   
NH2: The weak band at 3072 cm-1 may be due to CH aromatic vibrations. The peaks at 1504 
cm-1 and 1435 cm-1 are considered to be due to aromatic ring stretch. The medium band at 
1263 cm-1 is supposed to be due to CN stretching vibrations. Strong bands observed at 819 
cm-1 and at 744 cm-1 may be due to aromatic out of plane bending and CH out of plane 
bending respectively. PdN bond vibrations may be responsible for producing weak band at 
516 cm-1.   
NH3: The weak band at 3055 cm-1 may be due to CH stretching. The peaks at 2360 cm-1, 
2341 cm-1, 1572 cm-1, 1497 cm-1 and 1461 cm-1 are considered to be due to ring stretch. The 
peak at 1572 cm-1 may be due to C=C stretching vibrations and the peak at 1461 cm-1 is 
thought to be due to aromatic ring stretch. The strong band at 1372 cm-1 is supposed to be due 
to OH bending vibrations. Medium bands at 1316 cm-1 and 1214 cm-1 might be produced by 
CN stretching vibrations. The strong peaks at 1283 cm-1 and 1172 cm-1 are believed to be 
due to CO stretching. Medium band at 1114 cm-1 is considered to be due to CC bending. 
Strong band observed at 824 cm-1 may be due to aromatic out of plane bending. Strong bands 
observed at 824 cm-1 and at 738 cm-1 may be due to aromatic out of plane bending and CH 
out of plane bending respectively. PdN vibration may be responsible for producing weak 
band at 529 cm-1.   
NH4: The weak band at 3369 cm-1 may be due to CH stretching. Weak bands at 3152 cm-1 
and 3061 cm-1 are considered to be due to CH aromatic vibrations. CH bending aromatic is 
believed to be responsible for producing weak bands at 1827 cm-1 and 1653 cm-1. The peaks 
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at 1635 cm-1 and 1510 cm-1 are considered to be due to ring stretch. Medium bands at 1319 
cm-1 and 1181 cm-1 might be produced by CN stretching vibrations. The strong peak at 738 
cm-1 may be due to aromatic CH out of plane bending. PdN vibrations may be responsible 
for producing weak bands at 569 cm-1 and 422 cm-1.   
NH5: The weak band at 3133 cm-1 may be due to CH stretching. The peaks at 1637 cm-1, 
1509 cm-1 and 1320 cm-1 are considered to be due to ring stretch. Medium band at 1163 cm-1 
might be produced by CN stretching vibration. The strong peaks at 1039 cm-1 and 746 cm-1 
may be due to aromatic CH in plane and out plane bending respectively. PdN vibrations 
may be responsible for producing weak bands at 552 cm-1 and 427 cm-1.   
NH6: The weak band at 3392 cm-1 may be due to CH stretching. Weak band at 3101 cm-1 is 
considered to be due to CH aromatic vibration. The peaks at 1636 cm-1 and 1505 cm-1 are 
considered to be due to ring stretch. Medium bands at 1319 cm-1 and 1170 cm-1 might be 
produced by CN stretching vibrations. The strong peak at 758 cm-1 may be due to aromatic 
CH out of plane bending. PdN vibrations may be responsible for producing weak bands at 
594 cm-1, 449 cm-1 and 424 cm-1.   
4.1.2 Mass Spectra 
 
The mass spectra of the synthesized palladium compounds presented various peaks and 
seemed to be rather difficult to explain. Only few peaks were considered to be derived from 
molecules or molecular fragments of the molecules.  Other peaks corresponded to species that 
might be formed in situ. Major peaks observed in mass spectra for NH1, NH2, NH3, NH4, 
NH5 and NH6 were given in Table 3.4. Only the prominent peaks for the mentioned 
complexes are discussed here.  
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NH1  
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=435.65): The peak at m/z=400.98 
corresponds to (MCl) where M stands for the molecule NH1 [Pd(C9H7N)2Cl2 ]. The peak at 
m/z=457.27 corresponds to (M+H2O+4H). The other peaks are considered to be formed in 
situ from the fragments produced after electron bombardment in spectrophotometer. For 
example peak m/z at 834.94 corresponds to (2MCl); peak m/z at 803.54 corresponds to 
(2MCl+3H); peak m/z at 485.30 corresponds to (M+LCl8H) where L stands for ligand, 
quinoline. 
NH2  
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=531.74): The peak at m/z=479.03 
corresponds to (MCl+H) where M stands for the molecule NH2 [Pd(C7H6N2)3Cl2 ]. The 
peak at m/z=579.10 corresponds to (MCl+L) where L stands for ligand benzimidazole. 
The peak at m/z=670.87 are considered to be formed in situ from the fragments produced 
after electron bombardment in spectrophotometer which corresponds to (M+L+H2O+3H). 
NH3  
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=394.73): The peak at m/z=395.00 
corresponds to (M) where M stands for the molecule NH3 [PdC18H12N2O2]. The peak at 
m/z=416.98 corresponds to (M+H2O+3H). The peak at m/z=445.35 corresponds to 
(M+Cl+H2O3H). The other peaks are considered to be formed in situ from the fragments 
produced after electron bombardment in spectrophotometer. For example peak m/z at 789.99 
corresponds to (2M); peak m/z at 811.97 corresponds to (2M++4H); peak m/z at 827.71 
corresponds to (2M+2+2H). 
NH4  
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=649.85): The peak at m/z=497.03 
corresponds to (MClL) where M stands for the molecule NH4 [Pd(C7H6N2)4Cl2 ] and L 
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stands for ligand, imidazo (1, 2-)pyridine. The peak at m/z=378.97 corresponds to 
(MCl2L); while peak at m/z=342.00 corresponds to (MCl2L). The presence of 
(M2Cl) [Pd(C7H6N2)4+] peak is difficult to explain although this may be produced from 
further fragmentation in the mass spectrometer. 
NH5  
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=413.6): The peak at m/z=378.97 
corresponds to (M-Cl) where M stands for the molecule NH5 [Pd(C7H6N2)2Cl2]. The peak at 
m/z=342.00 corresponds to (M2Cl) and peak at m/z=436.93 corresponds to (M+H2O5H). 
The peak at m/z=497.03 is considered to be formed in situ from the fragments produced after 
electron bombardment in spectrophotometer and corresponds to (M+LCl) where L stands 
for imidazo (1, 2-)pyridine. 
NH6 
Electro spray ionization –Mass spectra (ESI-MS) (m/z: M=840.05): The peak at m/z=378.97 
corresponds to (MCl3LH2O) where M stands for the molecule NH6 
[Pd(C7H6N2)4.4H2O.2Cl.2Cl. (C7H6N2)] and L stands for ligand, imidazo (1, 2-)pyridine. 
The peak at m/z=344.00 corresponds to (MCl3LH2O); peak at m/z=497.03 
corresponds to (MClLH2O) and peak at m/z=289.05 corresponds to (MLH2O). 
4.1.3 Proton-NMR Spectra 
 
Proton-NMR spectrum presents details the number and arrangement of 1H present in a 
compound and used as an important tool for characterization. The protons resonate at 
different frequencies on the basis of their chemical environment. The major peaks observed 
in 1H-NMR spectra for NH1, NH2, NH3, NH4, NH5, and NH6 were given in Table 3.5 and 
the numbering scheme adopted for the ligands present in the designed compounds is shown in 
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Figure 3.14. The following discussion is provided in support for the suggested structures of 
the designed compounds.  
NH1 
The resonance at δ=8.91 ppm (doublet) corresponds to C2H. The resonance at δ=8.69 ppm 
(seen as triplet) is believed to be due to C3H. The resonances at δ=8.38 ppm (doublet) and 
δ=8.14 ppm (doublet) are believed to be due to C4H and C5H respectively. The resonances at 
δ=8.02 ppm (multiplet), δ=7.85 (triplet) and δ=7.79 ppm (triplet) are due to C6H, C7H and 
C8H respectively. The resonances at δ=7.57 ppm (multiplet) could not be characterised. The 
resonance at δ=2.49 ppm (singlet) is believed to be due to DMSO.    
NH2 
The resonance at δ=8.53 ppm (singlet) is considered to be due to C2H. The resonance at 
δ=8.39 ppm (doublet) is believed to be due to C4H. The resonances at δ=8.23 ppm (singlet) is 
believed to be due to NH and δ=7.73 ppm (triplet) are believed to be due to C5H respectively. 
The resonances at δ=7.45 ppm (triplet) and δ=7.24 (triplet) are due to C6H and C7H 
respectively. The resonance at  δ=7.13 ppm (triplet) δ=6.89 ppm (singlet) could not be 
identified.  
NH3 
The resonance at δ=8.58 ppm (doublet) is believed to be due to C2H. The resonance at δ=8.47 
ppm (doublet) is considered to be due to C4H. The resonance at δ=7.67 ppm (quintet) is 
believed to be due to C6H. The resonances at δ=7.46 ppm (triplet), δ=7.11 (doublet) and 
δ=6.93 ppm (doublet) are due to C3H, C4H and C7H respectively. The resonances at δ=3.69 
ppm (singlet) and at δ= 2.49 (singlet) are believed to be due to water and DMSO.  
NH4 
 The resonance at δ=8.70 ppm (doublet) is believed to be due to C2H. The resonance at 
δ=8.38 ppm (doublet) is considered to be due to C3H. The resonance at δ=8.11 ppm (singlet) 
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could not be identified. The resonances at δ=7.94 ppm (multiplet) and δ=7.84 (doublet) is due 
to C6H and that at δ=6.53 ppm (doublet) could not be identified. The resonances at δ=7.46 
ppm (multiplet) is considered to be due to C7H. The resonances at δ=7.34 ppm (triplet) and 
δ=7.03 (triplet) and are believed to be due to impurities. The resonance at δ= 4.80 (singlet) is 
believed to be due to D2O. 
NH5 
The resonance at δ=8.73 ppm (doublet) is believed to be due to C2H. The resonance at δ=8.55 
ppm (doublet) is considered to be due to C3H. The resonance at δ=8.16 ppm (doublet) could 
not be identified. The resonances at δ=7.63 ppm (multiplet) and δ=7.50 ppm (doublet) are 
due to C6H. The resonances at δ=7.20 ppm (multiplet) is considered to be due to C7H. The 
resonance at δ= 8.02 ppm (singlet) is believed to be due to DMF. The resonance at δ= 3.50 
ppm (singlet) is believed to be due to water. Resonance at δ= 2.92 ppm (singlet) and δ= 2.75 
(singlet) also considered to be DMF. 
NH6 
The resonance at δ=8.40 ppm (quintet) is believed to be due to C2H due to free and bound 
ligands. The resonance at δ=7.84 ppm (doublet) is considered to be due to C2H. The 
resonance at δ=7.59 ppm (doublet) is believed to be due to C3H. The resonances at δ=7.41 
ppm (quintet) are due to C6H applying to bound and free ligands. The resonance δ=7.51 ppm 
(doublet) and resonance at δ=7.34 ppm (quintet) is considered to be due to C7H. The 
resonance at δ=7.03 ppm (triplet) is believed to be due to impurities. The resonance at δ= 
6.98 ppm (singlet) is believed to be due to impurity. The resonance at δ= 4.80 ppm (singlet) 
is believed to be due to D2O. 
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4.1.4 X-ray crystallography 
 
As stated earlier, only three of the designed palladiums provided suitable single crystals for 
analysis. The ORTEP structures of NH3, NH4 and NH6 were diplayed in Figure 3.21, Figure 
3.22 and Figure 3.23 respectively. The discussion on the crystal structures is given below. 
NH3 
A SuperNova Dual diffractometer equipped with an Atlas detector set for Cu K radiation 
was used for data collection. Least squares refinement based on 3,518 reflections located 
between 9 and 151º 2provided cell constants.  Data were collected at 150(1) K with  scans 
to 153º 2. Data processing was undertaken with CrysAlisPro software and a multi-scan 
absorption correction was applied. For subsequent computations, WinGX and ShelXle 
interfaces were used. Direct methods were employed to solve the structure in the space group 
P21/c(#14) using SHELXT; extended and refined using SHELXL-2014/7. Non-hydrogen 
atoms were modelled with anisotropic displacement parameters whereas a riding atom model 
with group displacement parameters was used for hydrogens.  
The similar crystal structure of NH3 has been first described by Prout & Wheeler in 1966 as 
8-hydroxyquinolatopalladium (II) (cambridge structural database code: HQUIPD01). But the 
presented crystal structure in this study differs from the earlier reported structures in the 
nature of the packing and hence unit cell constant (Prout and Wheeler 1966, Low, Xu et al. 
2011). Moreover, synthetic protocol used in this study differs from that of earlier studies. It 
has been observed that the palladium atom has a square planar co-ordination and the 
molecular dimensions do not vary from previously reported for this molecule in molecular 
complexes. There is no direct metal-to-metal interaction observed between molecules. The 
palladium (II) centre in NH3 adopts an approximately four-coordinated square planar 
geometry where two 8-hydroxyquinoline ligands arrange in the trans position. Pd–N and Pd–
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O bond lengths are in the range of 2.001–2.003 and 2.002–2.007 Å, respectively, which are 
within the normal range. 
NH4 
A SuperNova Dual diffractometer equipped with an Atlas detector set for MoKradiation 
was used for data collection. Least squares refinement based on 15,849 reflections located 
between 8 and 68º 2provided cell constants. Data were collected at 150(1) K with  scans 
to 61º 2. Data processing was undertaken with CrysAlisPro software that included Gaussian 
and a multi-scan absorption correction. Subsequent computations were carried out with the 
assistance of the WinGX and ShelXle interfaces. 
The structure was solved in the space group P1(#2) by direct methods with SHELXT and 
extended and refined with SHELXL-2014/7. The asymmetric unit contains half of the 
complex molecule, with the metal located on an inversion centre, and a chloride counter ion. 
Non hydrogen atoms in the asymmetric unit were modelled with anisotropic displacement 
parameters and a riding atom model with group displacement parameters was used for 
hydrogen atoms. A significant residual electron density peak of 2.875 e-Å-3 located 0.9 Å 
from the metal site is attributed to unresolved disorder.  The superscript refers to the 
inversion operation: (i) -x, 1-y, -z. 
The bond lengths and angles of the coordination sphere are typical of square planar palladium 
complexes. The dihedral angles formed between the least squares plane defined by the 
coordinated nitrogen atoms and the least squares planes of the two asymmetric unit ligands 
are 79.22(5) and 76.17(5)º.  The chloride counter ions ‘cap’ the complex cation through 
hydrogen bond interactions with the ligand. The Cambridge Structural Database currently 
contains a chloroform solvate of the same complex molecule (cambridge structural database 
code: LIHHAN) (Małecki 2013).  
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NH6 
A SuperNova Dual diffractometer equipped with an Atlas detector set for MoKradiation 
was used for data collection. Least squares refinement based on 23,793 reflections located 
between 6 and 69º 2provided cell constants. Data were collected at 150(1) K with scans 
71º 2. Data processing was undertaken with CrysAlisPro software that included application 
of a multi-scan absorption correction. Subsequent computations were carried out with the 
assistance of the WinGX and ShelXle interfaces. 
Direct methods were employed to solve the structure in the space group P1(#2) using 
SHELXT; extended and refined using SHELXL-2014/7. The asymmetric unit contains half of 
a tetrakis(imidazo[1,2-]pyridine)-palladium cation located on an inversion site and a 
chloride counter ion. The asymmetric unit also contains sites modelled as the partially 
occupied site of two partially imidazo[1,2-]pyridine molecules, each disordered about the 
same inversion site. The occupancies of the partially occupied sites of each were refined and 
then fixed at 0.3 and 0.2.  
The asymmetric also contains four sites that were each modelled as water oxygen sites, with 
two fully occupied. The occupancies for the sites treated as partially occupied were refined 
and then fixed at 0.3 and 0.2. The two partially occupied water sites are located amongst the 
sites of the disordered imidazopyridine molecule sites. Three of the four hydrogen sites for 
the two sites modelled as fully occupied water oxygen sites were inferred with respect to 
nearby chloride anions, while the fourth could not be located and is not represented in the 
model. Likewise hydrogen atoms are not included in the model for the sites treated as 
partially occupied water oxygen sites.  
The non-hydrogen atoms in the asymmetric unit were modelled with anisotropic 
displacement parameters and a riding atom model was used for the hydrogen atom sites. The 
superscript refers to the inversion operation: (i) -x, -y, 1-z. 
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The bond lengths and angles of the coordination sphere are typical of square planar palladium 
complexes. The dihedral angles formed between the least squares plane defined by the 
coordinated nitrogen atoms and the least squares planes of the two asymmetric unit ligands 
are 88.34(6) and 69.95(8)º. The chloride counter ions ‘cap’ the complex cation through 
hydrogen bond interactions with the ligand. The Cambridge Structural Database currently 
contains a chloroform solvate of the same complex molecule (cambridge structural database 
code:LIHHAN) (Małecki 2013).   
4.2 Antitumour activity alone 
 
Antitumour activity of the designed palladium compounds and phytochemicals against 
various cancer models was determined using MTT reduction assay. Cisplatin and oxaliplatin 
were used as standard in this study. Table 3.29 displays the IC50 values of the investigated 
compounds in ovarian cancer models, whereas Table 3.30 represents the same in colorectal, 
breast and cervical cancer models. It is evident from the results that, among the designed 
palladiums, NH3 is the most active against tested seven different cancer cell lines. NH3 
displayed greater activity compared to clinical standards cisplatin and oxaliplatin against all 
the cell lines. In parent ovarian A2780 cell line NH3 showed 10 times greater activity than 
cisplatin but in cisplatin resistant A2780cisR, NH3 was 96 times lower IC50 value than 
cisplatin. Lowest IC50 of NH3 was observed against HT-29 cell where the value was in 
nanomolar level. In another colorectal cancer model of CACO-2 cell line, NH3 exhibited 28 
times greater cytotoxicity compared cisplatin. In MCF-7 cell line of breast cancer model, IC50 
value of NH3 was 65 times lower than cisplatin. Against cervical cancer model of Hela cell 
line, cisplatin found to have 10 times greater IC50 value than NH3. 
This is the first report concerning the anticancer potential of NH3 [Bis(1,8 
quinolato)palladium(II)] against any tumour model. A number of studies have been 
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conducted earlier towards evaluation of anticancer activity of the ligand 8-hydroxyquinoline 
itself and its derivatives. The ligand displayed significant antitumour activity against Raji 
(lymphoma), Hela (cervical) and PC-3 (prostate) cancer cell line (Jiang, Taggart et al. 2011, 
Tardito, Barilli et al. 2012). However in a different study, the mentioned range of IC50 values 
was large (67 -195 µM) against five different cancer cell lines (Qin, Chen et al. 2015). Few 
derivatives of 8-hydroxyquinoline also displayed very high anticancer activity during in vivo 
and in vitro model study i.e. clioquinol (Ding, Liu et al. 2005), nitroxoline (Jiang, Taggart et 
al. 2011) and mannich bases of 8-hydroxyquinoline (SHEN, WU et al. 1999). Interestingly, 
chelation of metals with 8-hydroxyquinoline or its derivatives further increased antitumour 
activity. Six copper chelated compounds have been reported to show lower IC50 values (1.3 -
16 µM) against PC-3 and Hela cell lines (Tardito, Barilli et al. 2012). Promising antitumour 
activity of platinum chelated compounds also have been described from host laboratory and 
elsewhere (Arzuman, Beale et al. 2014, Qin, Chen et al. 2015). Palladium compounds 
containing clioquinol were also reported to possess significant anticancer activity against 
ovarian cancer model (Vranec, Potocnak et al. 2014). But NH3 is found to show superiority 
(in terms of IC50 values) over the all previously reported activity of 8-hydroxyquinoline, 
derivatives of 8-hydroxyquinoline, metal chelated 8-hydroxyquinoline or derivatives against 
various tumour models. It is worthy to mention that, a platinum compound coordinated with 
two 8-hydroxyquinoline which is structurally identical to NH3 but showed comparatively 
lesser activity than its palladium analogue. Structurally similar platinum and palladium 
complexes have shown varied antitumor activity where in some instances palladium 
compounds displayed higher activity than platinum counterparts and vice versa (Alam and 
Huq 2016). 
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The higher antitumour activity of NH3 can be partially attributed to the presence of the ligand 
8-hydroxyquinoline itself. Coordination of the ligand with palladium metal might have 
resulted in further increase in activity which has been observed in earlier studies with copper 
and platinum (Tardito, Barilli et al. 2012, Qin, Chen et al. 2015). Four-coordinated square 
planar geometry of NH3 where two 8-hydroxyquinoline ligands arrange in the trans position 
with palladium might be in the unique position to bind and DNA and display maximum cell 
killing in cancer cells.  The suggested bio-activation pathway of NH3 for its antitumour 
activity is given in Figure 4.3. Further molecular mechanism of NH3 relating to its anticancer 
action obtained from proteomics and other mechanistic study will be discussed in respective 
sections.   
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Figure 4.3: Proposed bio-transformation pathway of NH3 based on the reported mechanism 
of oxaliplatin (Panczyk 2014) 
 
Another palladium compound NH1 also demonstrated promising antitumour potential against 
the panel of ovarian, colorectal, breast and cervical cancer cell lines. Although NH1 is found 
to be less active than cisplatin against parent ovarian A2780 cell line, it has shown 
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significantly greater activity against resistant cell lines A2780cisR and A2780ZDO473R compared 
to cisplatin. Resistant factor value (RF) for NH1 in A2780cisR was 1.38 where cisplatin 
showed higher value of 10.30. Similarly in A2780ZDO473R cell line RF value for NH1 was 
1.22 whereas cisplatin showed the value of 8.95. It is evident from Table 3.30 that, NH1 was 
4.4 times more active than cisplatin against MCF-7 breast cancer cell line but less potent 
against Hela cervical cancer cell line. In colorectal cancer models, NH1 showed superiority 
over cisplatin against CACO-2 cell line but in contrast less potency against HT-29 cell line.  
Anticancer potential of quinolines and their derivatives is not new (SAKAI, MINODA et al. 
1955) and widely investigated in various cancers along with other diseases. Quinolines have 
been defined as privileged scaffold for development of new anticancer drugs (R Solomon and 
Lee 2011, Marella, Tanwar et al. 2013). A number of studies have been described the 
encouraging antitumour activity of quinoline derivatives against leukaemia (Beauchard, 
Jaunet et al. 2009); melanoma (Dalla Via, Gia et al. 2008); breast (Shi, Nguyen et al. 2008, 
Arafa, Hegazy et al. 2013), ovarian , cervical, hepatic, lung (Tseng, Chen et al. 2009) and 
colorectal cancer (Arafa, Hegazy et al. 2013) cell lines having IC50 values at lower micro 
molar range. In most of the cases ligation of quinolines with metals like copper, platinum, 
chromium and cobalt (Denny, Wilson et al. 2006) displayed greater cytotoxicity against 
cancer cells compared to clinical standards e.g. cisplatin, irinotecan, topotecan (Liu, Wang et 
al. 2010, Motswainyana, Onani et al. 2013, Arzuman, Beale et al. 2016). Palladium 
compounds having quinoline derivatives also reported to show higher activity compared to 
clinical drugs (Hamad Elgazwy, Shehata et al. 2013, Motswainyana, Onani et al. 2013). 
The findings of this study support the hypothesis that chelation of palladium with quionoline 
and its derivatives might lead towards developing novel anticancer drugs. Metabolic pathway 
of bio-activation and detoxification of NH1 inside the cell is believed to be similar to 
cisplatin.  
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Among the designed palladium compounds, NH5 is proved to be the third most active 
anticancer drug showing lower resistance factor in ovarian A2780cisR and A2780ZDO473R 
cancer cell line (Table 3.29). However the activity of NH5 is comparatively lower than 
cisplatin against investigated ovarian and colorectal cancer cell lines (Figure 3.24 and Table 
3.30). Although the similar activity of the same compound has been reported earlier 
(Mazumder, Beale et al. 2012) as EH4, but no activity was reported against colorectal cancer 
model. The anticancer activity of NH2, NH4 and NH6 are found to be insignificant as seen 
from higher IC50 values against tested cell lines (Table 3.29 and Table 3.30). Interestingly, it 
was observed that the designed palladiums were better able to overcome drug resistance in 
ovarian cancer models by having lower RF values compared to cisplatin. Insignificant 
antitumour activity of NH2, NH4 and NH6 could be attributed to steric hindrance of the 
bulky ligands attached with palladium. Three bulky benzimidazole ligands which are directly 
bonded to palladium metal in NH2, might not allow to form sufficient amount of mono-
functional adducts required for distortion of DNA. Moreover being an ionic compound, entry 
of NH2 into the cells would be dominated by active transport methods using carrier protein, 
rather than passive diffusion which might affect cellular accumulation into the cells and 
targeted DNA. Contrary to this findings, platinum monofunctional complex bearing three 
benzimidazole ligands demonstrated significant antitumour activity against ovarian cancer 
models (Arzuman, Beale et al. 2014). Insignificant activity of NH4 and NH6 could be due to 
the absence of any leaving groups into their structure which make the compounds unable to 
generate suitable species to interact with DNA covalently.  NH4 and NH6 might interact with 
DNA only by weaker non-covalent bonding such as: electrostatic or hydrogen bonding 
interactions which render the compounds to bind with DNA in a manner not unique for 
maximum cell killing. In addition to this, bulkiness of both NH4 and NH6 [4 imidazo(1,2-
α)pyridine ligands bonded with palladium] believed to retard their entry into the cells. 
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Among the phytochemicals emetine was found to be the most active against all different 
cancer cell lines tested in this study. The IC50 values of Eme were found to be in nanomolar 
range; lowest against ovarian A2780cisR cell line with 18 nM and highest in colorectal CACO-
2 cell line with 69 nM. Anticancer potential of Eme was discovered in late 1910s and entered 
into Phase-I and Phase-II clinical trial in 1970s (S Akinboye and Bakare 2011). However, it 
was withdrawn due to dose dependent muscle weakness and cardiotoxicity (Foreman, Jesse et 
al. 2014). Since the adverse effects are observed mainly at high doses, Eme has been 
considered for combination study with Cis and Oxa where required amount of each drug 
would be very little and considered to give activity with minimum side effects.  
The order of activity of other phytochemicals against ovarian A2780 cell line was 
Pat>Cur≈EGCG>6-SG, whereas against A2780cisR it was Pat>EGCG>6-SG>Cur. On the 
other hand, against colorectal cancer models the activity order was Pat> Cur>EGCG. Pat has 
not been studied much towards its anticancer potential, but this study demonstrates that Pat is 
a prospective compound having greater antitumour activity than cisplatin against A2780cisR, 
A2780ZDO473R, HT-29 and CACO-2 cell lines. The result of this study is supported by the 
earlier studies against HEK kidney cancer cell line (IC50 value 2.5 µM) and CHO-K1 ovarian 
cancer cell line (IC50 value 2.8 µM) (Pillay, Phulukdaree et al. 2015, Zouaoui, Mallebrera et 
al. 2016). Another in vivo model study reported that intraperitoneal administration of Pat 
caused significant reduction of tumour in B16F10 cell-implanted mice (Boussabbeh, Salem et 
al. 2016). The authors also mentioned that after 20 days no potential toxicity was observed 
among Pat administered mice. However several long term studies concluded that Pat can lead 
to immunotoxicity, genotoxicity, mutagenicity and neurotoxicity (Sarubbi, Formisano et al. 
2016). International Agency for Research on Cancer includes Pat in ‘Class- 3 agents’ which 
are not carcinogenic towards human. That is why Pat has been selected here for combination 
study.  
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IC50 values of Cur and EGCG found in this study are in accordance with the findings of 
others from host laboratory against ovarian cancer cell lines (Mazumder, Beale et al. 2012, 
Alamro 2015, Arzuman, Beale et al. 2016). Ginger component 6-SG is recently being 
considered as potential anticancer agent but less studied against ovarian cancer model. The 
IC50 values of 6-SG observed in the present study is lower than cisplatin against A2780
cisR 
cell line. Previous study against three gastric cancer cell lines also reported the IC50 values of 
6-SG ranging from 6 µM  to 10 µM which is matching to the observed value in this study 7.5 
µM  and 10.45 µM  (Ishiguro, Ando et al. 2007). However activity of 6-SG against lung 
cancer cell lines displayed higher IC50 values ranging from 25 µM to 55 µM (Hung, Hsu et 
al. 2009, Warin, Chen et al. 2014). No clear evidence of systemic toxicity after administration 
of Cur, EGCG and 6-SG in human or animal model study has been reported in literature. 
Molecular mechanisms concerning the anticancer activity of the selected phytochemicals will 
be further discussed in the next section.      
4.3 Combined drug action 
 
Selected phytochemicals were combined with platinum drugs (cisplatin or oxaliplatin) and 
designed palladium compounds against A2780, A2780cisR, HT-29 and CACO-2 cell lines. 
Combined drug in binary combination of Cis with Eme was investigated in A2780 and 
A2780cisR cell lines whereas combination of Ox with Eme was investigated in HT-29 and 
CACO-2 cell lines. Similarly combination of Cis with Pat was investigated in A2780 and 
A2780cisR cell lines while that of Ox with Pat was investigated in HT-29 and CACO-2 cell 
lines. Combination of NH1 with 6-SG was investigated against A2780 and A2780cisR cell 
lines only. Most active palladium NH3 in combination with Cur and EGCG was investigated 
in A2780, A2780cisR, HT-29 and CACO-2 cell lines. As stated earlier, combination indices as 
quantitative measures of combined drug action were determined using Calcusyn (Chou-
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Talalay method) at different concentrations (ED50, ED75 and ED90) in three added sequences: 
bolus, 0/4 and 4/0.  
4.3.1 Combination of Cis with Eme 
 
Cis in combination with Eme displayed synergism at all concentrations and for all added 
sequences in A2780 cell line (Table 3.33). Among three sequences, 0/4 addition exhibited the 
most synergistic effect with the highest at ED50 level. Gradual decrease in synergism was 
observed with the increase of added concentrations of drugs with 0/4 addition but the 
converse is true for 0/0 and 4/0 addition in A2780 cell line. 
On the other hand in A2780cisR cell line, Cis in combination with Eme showed synergistic 
effect when administered using the sequences 0/4 and 4/0. Bolus addition of Cis with Eme 
displayed antagonism. Interestingly, a clear trend was evident with the increase of added 
concentrations of drugs producing greater synergistic action for all sequences of 
administration (Table 3.35). 
Sun et.al also found that co-administration cisplatin and emetine increased the apoptotic cell 
death after 72 hours in SKOV ovarian cancer cell line (Sun, Yogosawa et al. 2015). The 
authors suggested that synergism is linked with activation of caspase-3, caspase-7 and 
caspase-8. Sensitization of cancer cells towards cisplatin was correlated with the 
downregulation of Bcl-xL by emetine.       
4.3.2 Combination of Ox with Eme 
 
Ox in binary combination with Eme showed additiveness in HT-29 cell line only at higher 
concentrations (ED75 and ED90) when administered using 0/4 or 4/0 sequences. But bolus 
addition produced antagonism in this study at all added concentrations in HT-29 cell line 
(Table 3.37). However, in CACO-2 cell line Ox in combination with Eme displayed strong 
antagonism for all sequences of administration and added concentrations (Table 3.39). 
253 
 
Similar to the outcome in HT-29 cell line of this study, Larrson et.al also found additiveness 
to synergism from combination of Ox with Eme at ED75 level against three neuroendocrine 
tumour cell lines (Larsson, Hassan et al. 2009). However variation in combined drug action is 
not unusual due to change in cell line of same cancer model (Alamro 2015), in regards to 
antagonism found in this study against CACO-2 cell line.   
4.3.3 Combination of Cis with Pat 
 
4/0 combination of Cis with Pat showed synergism at all added concentrations in A2780 cell 
line whereas 0/0 sequence displayed synergism only at ED90 level. But the same combination 
demonstrated additiveness at lower concentrations when administered as a bolus and also for 
all 0/4 sequence of administration against A2780 cell line (Table 3.33). In contrast, bolus and 
4/0 addition of Cis with Pat produced synergism at all added concentrations against A2780cisR 
cell line. But 0/4 sequence of administration was proved to be antagonistic to additive in 
A2780cisR cell line (Table 3.35). All told, it can be said that 4/0 combination of Cis with Pat is 
better than other sequences of administration pertaining to synergistic outcome in ovarian 
cancer and also in overcoming cisplatin resistance.    
4.3.4 Combination of Ox with Pat 
 
Combination of Ox with Pat demonstrated synergism only with bolus addition in HT-29 cell 
line while 0/4 nor 4/0 sequences of administration exhibited additiveness to antagonistic 
effect at all added concentrations against HT-29 cell line (Table 3.37). However in CACO-2 
cell line the same combination displayed strong synergism at all added concentrations and for 
all sequences of administration. Greater synergism was observed at lower concentrations 
(ED50 level) compared to higher concentrations (ED75 level or ED90 level) from the 
combination of Ox with Pat in both tested colorectal cancer models (Table 3.39). Since 
combination of Ox with Pat displayed strong synergism at lower concentration, the 
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combination has the potential for further in vivo animal model study for evaluation of safety 
and efficacy. The molecular mechanisms through which Pat can kill cancer cells and could 
give synergistic drug action in combination with other chemotherapeutics have been reported 
in literature: such as- ROS-dependent cytotoxicity involving ER stress and activation of 
mitochondrial apoptotic pathway (Boussabbeh, Ben Salem et al. 2015, Zhang, Peng et al. 
2015); induction of apoptosis by increasing p53 and Bax expressions, downregulation of Bcl2 
and elevation of caspase-3 activity (Boussabbeh, Salem et al. 2016). Antitumour activity of 
Pat also has been linked with phosphorylation of a transcription factor EGR-1 followed by 
elevated expression of ATF3, which in turn results in the cell cycle arrest and activation of 
apoptosis (Kwon, Soung et al. 2012).  
4.3.5 Combination of NH1 with Cur 
 
Studies on sequence and concentration dependent binary combinations of NH1 with Cur 
revealed that the combined drug action is mostly additive to antagonistic against ovarian 
cancer models. Synergism was observed only at ED50 level during bolus addition of NH1 
with Cur against A2780cisR cell line. However, a clear trend of increasing antagonism was 
shown with the increase of added concentrations (Table 3.33 and 3.35).    
4.3.6 Combination of NH1 with 6-SG 
 
Very strong synergism was found from combination of NH1 with 6-SG at lower 
concentrations (ED50 level) for all sequences of administration against A2780 cell line. 0/4 
addition produced greatest synergism followed by 4/0 addition and bolus displayed the least. 
Both, 0/4 and 4/0 sequences of administration exhibited strong synergism at ED75 level as 
well but bolus addition caused additiveness at the same concentration in A2780 cell line. 
However, against cisplatin resistant A2780cisR cell line synergism was observed only with 4/0 
sequence of administration at lower concentration (Table 3.33 and 3.35). Finally, it should be 
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stated that NH1 in combination with 6-SG displayed the strongest synergistic activity (CI 
value 0.11) against A2780 cell line among all investigated combinations in this study. So the 
combination can be evaluated further for safety and efficacy using suitable animal model. 
Anticancer mechanism of 6-SG has been correlated with oxidative stress mediated p53 
pathway of apoptosis (Warin, Chen et al. 2014); inhibition of cell proliferation through 
activation of peroxisomal proliferator activated receptor γ (Tan, Kang et al. 2013). TRAIL-
induced apoptosis through ROS-mediated cytochrome c release was also found to be linked 
with antitumour action of 6-SG (Han, Woo et al. 2015). Another study revealed that 6-SG 
caused G2/M cell cycle arrest by p53/p21-cdc2/cdc25A crosstalk (Qi, Zhang et al. 2015). In 
vivo study showed that 6-SG reduced interleukin (IL)-6–induced STAT3 activation and 
inhibited both and TNF-–induced NF- activity (Saha, Blando et al. 2014). Autophagic 
cell death through modulating notch signalling was also observed from 6-SG treatment (Ray, 
Vasudevan et al. 2015). Figure 4.4 depicts the suggested pathways for synergism observed 
from combination of NH1 with 6-SG. 
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Figure 4.4: Suggested mechanism for synergistic action: NH1 in combination with 6-SG 
4.3.7 Combination of NH3 with Cur 
 
The combination of NH3 with Cur has been investigated in both ovarian and colorectal 
cancer models using four different cell lines and found to the most promising among all 
combinations studied here. In A2780 cell line, at ED50 level all different sequences of 
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administration produced strong synergism with the greatest being observed for the 0/4 
sequence followed by 4/0 sequence. Similarly at ED75 level, all sequences of administration 
displayed synergistic following the same order observed at ED50 level. However, at ED90 
level the combined effect was antagonistic for all sequences of administration. In contrast, 
against cisplatin resistant A2780cisR cell line synergism was observed irrespective of 
concentrations and sequences of administration. But the degree of synergism observed in 
A2780cisR cell line is comparatively lower than that of observed against parent A2780 cell 
line. Degree of synergism found to increase with the increase of added concentrations for 0/4 
and 4/0 sequences of administration against A2780cisR cell line. But with bolus additions the 
converse result was observed (Table 3.33 and Table 3.35). Taking together, combination of 
NH3 with Cur at lower concentration was best for 0/4 sequence of administration followed by 
4/0 sequence in regards to synergistic outcome against ovarian cancer model. 
While NH3 in combination with Cur against HT-29 cell line displayed synergism at all added 
concentrations for 4/0 and bolus administrations. But antagonism was observed at all 
concentrations for 0/4 sequence of administration. Greater synergism was shown at lower 
concentrations compared to higher added concentrations for 4/0 sequence but the converse 
was true for bolus addition in HT-29 cell line. Against CACO-2 cell line, synergistic effect 
was produced at ED50 level irrespective sequences of administration. But at ED75 level the 
synergism effect was found to decrease for all sequences of administration and became 
additive for 0/4 addition of NH3 with Cur in CACO-2 cell line (Table 3.37 and Table 3.39). 
With further increase in concentration to ED90, all sequences of administration displayed 
antagonism. 
Potential benefits of concurrent addition of curcumin and cisplatin have been described 
against various cancers e.g. lymphoma (Valenzuela, Grabauskas et al. 2017), lung cancer 
(Chen, Li et al. 2015, Baharuddin, Satar et al. 2016) and bladder cancer in literature (Park, 
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Lim et al. 2016). Cur in combination with platinum drugs (cisplatin, oxaliplatin) was reported 
to show sequence and dose dependent synergism in ovarian cancer models in earlier studies 
from host laboratory as well (Nessa, Beale et al. 2012). Recently Ulukaya et al. reported 
synergism obtained from the combination of a tumour active palladium compound with 
curcumin (Tunc, Dere et al. 2017). As NH3 in combination with Cur has produced promising 
synergistic outcome against different cancer cell lines, the combination could be tested in 
xenograft rodent model for effectiveness and safety.  
The mechanism behind the synergistic outcome from combination of NH3 with Cur could be 
associated with the role of Cur as prooxidants (Hatcher, Planalp et al. 2008, Kuo, Wu et al. 
2011, Park, Lim et al. 2016). Due to prooxidants activity, oxidative stress would be generated 
after entry of curcumin into the cells through dysregulation of gluthathione and glutathione-
S- transferase levels. Oxidative stress would confer the cells to produce signals for MEK 
activation followed by ERK1/2 activation which would lead towards apoptotic and necrotic 
cell death (Park, Lim et al. 2016). Additionally, depletion of glutathione and GSTs would 
cause the reactive species (Figure 4.5) to interact with DNA in an efficient manner for 
maximum cell killing. The idea is supported from palladium-DNA binding study as well in 
HT-29 cell line where 3 folds increase in palladium-DNA binding level from combined 
treatment of NH3 with Cur was observed than single treatment of NH3 (Table 3.46). 
Literature suggests that prooxidant activity of Cur is predominant mainly at a lower 
concentration (Banerjee, Kunwar et al. 2008) which is also corroborated with the results from 
the present study where it has been observed that CI values were more synergistic at ED50 
level than ED75 and ED90 levels. Moreover generation of reactive species from metabolism of 
NH3 would cause oxidative stress from other side and would lead towards cell death using 
multiple signalling pathways. 
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Figure 4.5: Suggested mechanism for synergistic action: NH3 in combination with curcumin 
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4.3.8 Combination of NH3 with EGCG 
 
NH3 when combined with EGCG demonstrated significant synergism only at ED50 
for bolus administration against ovarian A2780 cancer cell line.  But moderate 
synergism was found at ED90 level for 0/4 and 4/0 sequences whereas bolus addition 
displayed antagonism (Table 3.33). Against A2780cisR cell line, 0/4 sequence of 
administration exhibited synergism irrespective of sequence of administration and the 
degree of synergism increased with the increase in concentration. Bolus addition of 
NH3 with EGCG also produced synergism at ED75 and ED90 level but antagonism 
was found at ED50 level in cisplatin resistant A2780
cisR cell line (Table 3.35). 
However, 4/0 sequence of addition displayed additiveness at all concentrations.  
In HT-29 colorectal cancer line, combination of NH3 with EGCG showed 
concentration dependent synergism. At ED90 level strong synergism was evident but 
strong antagonism was evident at ED50 for all sequences of administration (Table 
3.37). In other colorectal cancer cell line CACO-2, the combination of NH3 with 
EGCG displayed synergism at ED50 and ED75 for 0/0 and 0/4 sequences of 
administration. In contrast, 4/0 sequence gave additive to antagonistic effect 
irrespective of concentrations (Table 3.39).  
Current literature shows that EGCG inhibits cancer cells growth in vitro and in vivo 
synergistically in combination with ascorbic acid, curcumin, 6-gingerol, quercetin, 
sulforaphane, raphasatin, proanthocyanidins and other natural small molecules (Gan, 
Li et al. 2017). Synergism from combination with chemotherapeutics is also evident 
through the ability of EGCG to sensitise cancer cells towards chemotherapeutic drugs 
such as: cisplatin (Hagen, Chedea et al. 2013, Mayr, Wagner et al. 2015), bleomycin 
(Bimonte, Leongito et al. 2015), docetaxel, capecitabine, paclitaxel (Luo, Wang et al. 
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2010) and doxorubicin. Sequence and dose dependent synergism was also reported 
from the host laboratory from combination of EGCG with cisplatin and designed 
palladiums (Mazumder, Beale et al. 2012, Alamro 2015). A number of molecular 
pathways have been linked with the antitumour activity of EGCG, through which it 
display synergism in combination with other phytochemicals and chemotherapeutics 
(Min and Kwon 2014, Gan, Li et al. 2017).  Figure 4.6 visualizes the signalling 
mechanisms modulated by EGCG in carcinogenesis.  
 
Figure 4.6: Molecular mechanism for anticancer action of EGCG 
 
 262 
4.4 DNA damage study 
 
Only few selected palladium drugs (NH3, NH4, NH5 and NH6) were investigated for 
DNA damage study to get qualitative understanding of the anticancer mechanism of 
the drugs. Cisplatin was used as a reference standard to compare the qualitative 
damage caused by the designed palladiums. All the selected compounds were studied 
with the extracted DNA from ovarian A2780 cell line and its cisplatin resistant 
counterparts A2780cisR cell line. In addition, NH3 was further examined with the 
DNA obtained from HT-29 colorectal cancer cell line.  
It is evident from the study that all the investigated drugs interacted with DNA 
manifested as either change in mobility and/or intensity (DNA fluorescence). It was 
observed that NH4 caused the most damage to the DNA extracted from A2780 cell 
line greater than clinical drug cisplatin. The actual order (highest to lowest) of DNA 
damage caused by the compounds were NH4>Cis>NH3>NH5>NH6 (Table 3.40). 
However, in terms of anticancer activity the actual order from highest to lowest in 
A2780 cell line was NH3>Cis>NH5>NH6>NH4 (Table 3.29). Thus it can be seen 
that the compound causing most damage to DNA, does not necessarily produce 
greatest antitumour activity. While DNA damage can be a prerequisite for the activity, 
the anticancer action and DNA damage do not always correlate. This finding is in 
agreement with earlier investigations where many least active platinum or palladium 
compounds displayed highest DNA damage and compounds with greater antitumour 
activity revealed the least DNA damage (Huq, Tayyem et al. 2007, Arzuman 2014, 
Arzuman, Beale et al. 2016).  
Similar results were also observed with the investigated palladium complexes when 
the study was conducted using the DNA obtained from A2780cisR cell line. NH4 
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showed the highest increase in mobility among the studied compounds indicating 
highest DNA damage. NH3 and Cis caused similar extent of DNA damage in 
A2780cisR cell line where relatively greater change in mobility was caused by NH3 but 
lesser change in intensity compared to Cis. NH5 was found to be more damaging 
towards DNA than NH6 (least damaging) in A2780cisR cell line. However in regards 
to anticancer activity of the compounds in cisplatin resistant A2780cisR cell line, the 
order from highest to lowest was NH3>Cis>NH5>NH6>NH4 (Table 3.29). The 
results of this study further suggest that anticancer activity of a compound is 
predominantly due to the activation of various proteins recognized by the damage on 
to DNA not on the extent of DNA damage.  
A significant increase in mobility and decease in intensity were also observed in the 
DNA bands treated with NH3 as applied to HT-29 cell line (Table 3.42). The result 
reconfirmed that NH3 displayed its antitumour action through damaging DNA. 
4.5 Cellular uptake study 
 
Only NH1 and NH3 as a single drug were selected for this study with cisplatin as a 
reference standard in ovarian cancer models. A few combinations with NH3 which 
gave synergistic effects were also examined to get the ideas relating their mechanism 
of action. From the study in ovarian cancer models, it was noted that cellular 
accumulation of palladiums was comparatively lower than that of platinum (cisplatin). 
The similar phenomenon was also observed from the earlier studies in the host 
laboratory (Tayyem 2006, Mazumder 2013). Between two palladiums, NH1 showed 
better uptake in A2780 cell line than NH3. However, NH3 displayed far greater 
activity than NH1 and cisplatin. The results indicate that elevated entry into the cells 
does not necessarily make a compound highly active. Rather the interaction of a 
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compound with the target molecules and further activation of the downstream proteins 
which are related to specific signalling mechanism leading towards definite outcome 
is more important (Sadler 2009). 
As applied to synergistic combination of NH3 with Cur using 0/4 sequence of 
administration, increased accumulation of palladiums was found from the combined 
treatment than single drug treatment of NH3 in both A2780 and A2780cisR cell lines. 
Similar observation was also made from another synergistic combined treatment 
namely NH3 in combination with EGCG administered as a bolus addition in A2780 
cell line. On the other hand, additive to synergistic combination of NH3 with EGCG 
using 0/4 sequence of administration in A2780cisR cell line displayed reduced 
accumulation of palladium compared to the single drug treatment of NH3 (Table 
3.43).  
Oxaliplatin was considered as reference compound instead of cisplatin because 
oxaliplatin is clinically used to treat colorectal cancer. Study on colorectal cancer 
models showed that the accumulation of palladium from NH3 was greater than that of 
platinum from oxaliplatin. Similar to the finding of ovarian cancer models, synergistic 
combination of NH3 with Cur using 4/0 sequence of administration was found to 
cause significant increase in accumulation of palladium in HT-29 cells compared to 
single treatment of NH3. The discussed results proved that elevated cellular 
accumulation of palladium from combined treatment might be responsible for 
synergistic action. However the mechanisms through which co-administration of Cur 
or EGCG helped in increased entry of palladium into ovarian cancer cells have not 
been investigated. 
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4.6 MetalDNA binding study 
 
As a single drug, NH3 demonstrated the highest binding affinity towards DNA among 
the investigated compounds. NH1 and cisplatin showed the similar metalDNA 
binding capacity although NH1 has palladium as central metal ion whereas cisplatin 
has platinum. Against colorectal cancer models HT-29 and CACO-2 cell line, NH3 
showed higher binding with DNA than oxaliplatin. In general, it was observed that the 
trend in metalDNA binding is in agreement with the trend of anticancer activity of 
the compounds (NH3>Oxa>Cis>NH1). 
As applied to synergistic combinations of NH3 with Cur using 0/4 sequence of 
administration, level of palladiumDNA binding was lower for combined treatment 
compared to that for treatment of NH3 alone in both A2780 and A2780cisR cell lines. 
However synergistic combination of NH3 with EGCG administered as a bolus 
presented greater level of palladiumDNA binding than treatment with NH3 alone in 
A2780 cell line (Table 3.45). Furthermore, additive to synergistic combination of 
NH3 with EGCG using 0/4 sequence of administration also resulted in higher level of 
palladiumDNA binding than treatment with NH3 alone in A2780cisR cell line.  
Synergistic combination of NH3 with Cur using 4/0 sequence of administration in 
HT-29 colorectal cell line exhibited approximately 3 folds increase in 
palladiumDNA binding level than treatment with NH3 alone (Table 3.46). In 
contrast, in CACO-2 cell line synergistic combination of NH3 with EGCG using 0/4 
sequence of administration resulted in lower palladiumDNA binding level than 
treatment with NH3 alone. From above it is clear that there was no clear trend in 
palladiumDNA binding level associated with combined drug action. Results of 
earlier studies are found to be in agreement with the finding of this study where a 
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number of highly synergistic combinations displayed lower level of metalDNA 
binding than addition of drugs alone and the converse is for antagonistic combinations 
(Mazumder 2013, Nessa 2013). Once again it has been established that DNA binding 
is usually associated with the anticancer activity of platinum or palladium based 
compounds but the key determinant of cell kill is not the extent of binding, rather it is 
the recognition of the change in conformation of DNA by the downstream proteins 
responsible for inducing cell death.  
4.7 Proteomic study 
 
To obtain in depth information relating with the antitumour action of the drugs alone 
and in combination with phytochemicals, proteomic study was carried out. As stated 
before, 47 protein spots were selected for characterization through MALDI-MS 
applying to significantly expressed proteins in four different cell lines (ovarian 
A2780, ovarian A2780cisR, colorectal HT-29 and colorectal CACO-2). All of the 
identified proteins were categorized into eight major groups based on their most 
important functions. The proteins appeared as different spots in the same or different 
cell lines considered only once during functional classification of proteins. The groups 
are described as following: 
Class 1-Metastasis related cytoskeleton proteins: ACTB, VIME, PROF-1, COF-1, 
ACTG, TBA1C and TBB5.  
Class 2-Heat shock proteins: CH60, ENPL, GRP78, PPIA, HSP7C, CH10, PDIA3 
and SERPH.  
Class 3-Redox regulation proteins: PRDX6, GSTP1 and CISY. 
Class-4-Protein biosynthesis and RNA processing proteins: EFTU, RSSA and 
ROA2. 
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Class 5-Enzymes or catalytic proteins: ALDOA, TERA and NDKB. 
Class 6- Chromatin assembly proteins: H3.3 and H4. 
Class 7-Calcium binding proteins: ANXA1 and CALR. 
Class 8-Others: NACA and ALDH2. 
Figure 4.7 depicts the pie chart for the functional classification of proteins. However, 
it is appropriate to note that each protein has variety of functions and the choice of a 
specific group for the proteins was random.  
 
Figure 4.7: Pie chart of functional classification of identified proteins 
Detailed account of the functions of the significantly expressed proteins is discussed 
as follows to get valuable insight into the possible biochemical mechanisms 
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associated with the anticancer activity of the treated drugs alone and in combination 
with phytochemicals. 
4.7.1 Metastasis related cytoskeleton proteins 
 
The cytoskeletal system of eukaryotes is a dynamic structure composed of 
cytoskeleton proteins which can adapt with cells requirement with the capacity of 
rapid growth or disassemble at a particular time (Dos Remedios, Chhabra et al. 2003). 
These proteins are of only three classes such as: actin filaments, microtubules and 
intermediate filaments but control the interactions of cells with one another and to 
their environment. The coordinated formation of multiple actin based structures is 
also responsible for many biological processes e.g. cancer metastasis, inflammatory 
pathways, wound healing and embryonic development (Davidson and Wood 2016). In 
the present study, 23% of the selected differentially expressed proteins from the 
treatment of drugs either alone or in combination are found to belong in this group. 
ACTB (Actin, Cytoplasmic 1) 
Amongst the cytoskeleton proteins actin is the most abundant and highly conserved 
intracellular proteins, ubiquitous in all eukaryotes and mainly controls the cell shape 
and mechanics (Xu, Huff et al. 2017). ACTB or beta-actin is non-muscle variant with 
meshwork among the three different types found in human. Whereas, alpha-actin is 
muscle variant (skeletal, cardiac and smooth) with contractile structure and gamma-
actin is smooth muscle/non-muscle variant with stress fibre (Dominguez and Holmes 
2011). Functionally, actin proteins are responsible for cellular motility, development, 
maintenance, and pathogenesis (Artman, Dormoy-Raclet et al. 2014).    
Although, ACTB is being used as reference protein for quantification of changes in 
expression of proteins/genes in cells due to its constitutive housekeeping role with the 
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idea that the expression of beta-actin is unaltered with most experimental or 
physiological conditions. The use of ACTB for that purpose is now being challenged 
due to its involvement in cell migration, cell proliferation, wound repair, 
inflammatory immune response and gene expression (Kwon, Oh et al. 2009, Guo, Liu 
et al. 2013). Positive link between the tumour development and metastasis with the 
level of expression and polymerization of beta-actin has been reported (Nowak, 
Krawczenko et al. 2002). Significant increases in expression of beta-actin has been 
observed in multiple cancers such as: liver (Waxman and Wurmbach 2007), 
melanoma (SUZUKI, IIZUKA et al. 2010), renal (Jung, Ramankulov et al. 2007, Guo, 
Liu et al. 2013), gastric (Rho, Lee et al. 2010), lung (Gámez-Pozo, Sánchez-Navarro 
et al. 2009), pancreatic (Ohl, Jung et al. 2005, Rubie, Kempf et al. 2005), prostate 
(Ohl, Jung et al. 2005), oesophageal, breast, ovarian cancers (Li, Ye et al. 2009), and 
leukaemia (Guo, Liu et al. 2013).  
Overexpression of ACTB in ovarian cancer lines was also seen in the present study 
with greater elevation being observed in cisplatin resistant cell line. ACTB protein 
spot was very distinct in A2780 parent and cisplatin resistant A2780cisR cell line and 
was used as Marker 1 for both cell lines. In A2780 cell line the protein was 
significantly downregulated (4.8 folds) due to treatment with NH3 alone indicating 
that ACTB might have association with the anticancer mechanism of NH3. Since 
treatment of NH3 caused downregulation of ACTB protein which was found to be 
upregulated in various cancers and reported to involve in cell division and metastasis, 
it was assumed that high antitumour activity of NH3 against A2780 cell line is 
correlated with ACTB. The idea was also supported from the results of A2780cisR cell 
line where ACTB appeared as three different spots and all were downregulated with 
treatment of NH3. 
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None of the combinations administered to A2780 cell line caused significant change 
in expression of ACTB after treatment except NH1 with 6-SG using 0/4 sequence 
(which caused only 1.54 fold upregulation) (Table 3.47, spot 6). All other 
combinations caused downregulation of the protein but the effect was not significant. 
On the other hand in A2780cisR cell all the combinations caused either downregulation 
of ACTB or did not change expression of the protein (Table 3.49, spot1; spot Cn39 
and spot Cn79).The treatments where the expression of ACTB could not be seen were 
due to extreme downregulation. Prooxidant role by the phytochemical might be 
responsible for counterbalancing the downregulation of ACTB as observed from 
treatment with NH3 alone. Current literature suggests that generation of reactive 
oxygen species can increase actin polymerization and formation of stress fibres 
(Moldovan, Moldovan et al. 2000, Munnamalai and Suter 2009, Xu, Huff et al. 2017). 
Upregulation of ACTB observed with the treatment of NH1 with 6-SG in A2780 cell 
line could also be explained due to the well-established prooxidant role of 6-SG.  
With respect to the involvement of ACTB in conferring drug resistance in ovarian 
cancer, the present study shows that it has been upregulated by 2.40 fold in A2780cisR 
cell line compared to that expressed in A2780 cell line. All the treatments whether 
administered alone or in combination partially restored back the expression of ACTB 
to the level found in A2780 cell line (Table 3.55 and Table 3.56). Upregulation of 
ACTB in cisplatin resistant A2780cisR cell line and its restoration back to normalcy 
due to treatment with synergistic combinations was also reported earlier from our 
group (Nessa 2013). Thus it is proposed that ACTB is associated with drug resistance 
into ovarian cancer.  
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VIME (Vimentin) 
As stated earlier, intermediate filaments are one of the three major groups of 
cytoskeleton proteins. Among six different types of intermediate filaments, vimentin 
belongs to type III which is found mostly in mesenchymal cells. Structurally, 
vimentin is a polypeptide which is composed of 466 amino acids having a central rod 
with alpha-helical structure and a non-alpha helical N and C- terminal end (Satelli and 
Li 2011). Identical to other members of intermediate filaments, the vimentin network 
which spreads from the nucleus to the cell membrane and performs as a scaffold by 
providing mechanical and structural support to the cells, maintains cell and tissue 
integrity (Lundkvist, Reichenbach et al. 2004). Additionally, it serves a vital role in 
cellular adhesion; migration of cells; wound healing; lipid metabolism; cell survival 
and signalling. Vimentin possesses multiple kinase specific sites recognized by 
various kinases and functions after activation through phosphorylation (Lahat, Zhu et 
al. 2010). Vimentin plays a key role in epithelial to mesenchymal transition (EMT) 
where epithelial cells convert into mesenchymal phenotype and acquire the ability to 
move easily (Satelli and Li 2011). That is why vimentin is considered to be a 
canonical biomarker to differentiate between metastatic and non-metastatic breast 
cancer (Ngan, Yamamoto et al. 2007). Previous studies also suggested the elevated 
expression of vimentin in prostate (Wei, Xu et al. 2008), ovarian (Al-Eisawi 2013), 
lung (Al-Saad, Al-Shibli et al. 2008) and gastric cancers (Otsuki, Inokuchi et al. 
2011).  
In the present study, vimentin was found to be significantly downregulated due to 
treatment with NH3 alone, that with combination of NH3 using Cur 0/4 sequence of 
administration and combination of Cis with Eme also using 0/4 sequence of 
administration in A2780 cell line. However combination of NH3 with EGCG 
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administered as a bolus and that of NH1 with 6-SG using 0/4 sequence of 
administration did not change the expression level of the protein in the same cell line 
(Table 3.47, spot 12). In contrast, treatment with combination of NH3 and EGCG 
using 0/4 sequence of administration and that with combination of Cis and Pat using 
4/0 sequence of administration caused significant downregulation of vimentin in 
A2780cisR cell line. But expression of the protein was not changed after treatment with 
NH3 alone and combination of NH3 with Cur using 0/4 sequence of administration in 
A2780cisR cell line (Table 3.49, spot Cn48). The protein was not detectable after the 
treatment with combination of Cis with Eme using 4/0 sequence of administration in 
the same cell line. 
 The level of expression of vimentin is higher in A2780cisR cell line than in A2780 cell 
line. All the treatments are found to result in partial restoration of the protein to the 
level in the parent cell line (Table 3.56, spot Cn48). For treatment with combination 
of Cis with Eme using 4/0 sequence of administration, the protein is found to 
disappear completely indicating over restoration. From the above it can concluded 
that vimentin functions as an antiapoptotic protein that can be used as a biomarker for 
cisplatin resistant ovarian cancer and could be targeted to develop newer anticancer 
agents which might overcome drug resistance.  
PROF1 (Profilin-1) 
Profilins are omnipresent actin-monomer binding proteins which have unique ability 
to control actin polymerization in both positive and negative directions (Theriot and 
Mitchison 1993). Among the four isoforms of profilin discovered, Profilin-1 or 
PROF1 is universally present in all cells. Whereas Profilin-2 is predominant in 
neurons, Profilin-3 and Profilin-4 are restricted to nephron and testis (Zou, Ding et al. 
2010). Other than the controlling of cell motility via polymerization of actin, PROF1 
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also binds with WASP (Wiskott-Aldrich syndrome protein) and VASP 
(ena/vasodilator-stimulated phosphoprotein) (Zoidakis, Makridakis et al. 2012). 
Through binding with these proteins PROF1 is also linked with cellular signalling 
pathways, membrane transport, cell proliferation, apoptosis and cell cycle arrest 
(Adami, O'callaghan et al. 2017). The protein was reported to show reduced 
expression in bladder cancer (Adami, O'callaghan et al. 2017), breast (Janke, Schlüter 
et al. 2000), laryngeal (Adami, O'callaghan et al. 2017), and pancreatic  cancers (Yao, 
Ji et al. 2014). However, PROF1 was found to be upregulated in some other cancers 
such as: renal (Minamida, Iwamura et al. 2011), gastric (Cheng, Zhu et al. 2015) and 
colorectal carcinoma (Almeida, de Aquino et al. 2017).  
In the present study, PROF1 was significantly downregulated in HT-29 cell line due 
to treatments with NH1 and combination of NH3 with Cur using 4/0 sequence of 
administration. However combination of Ox with Pat administered as a bolus to HT-
29 cell line, caused upregulation of PROF1 (Table 3.51, spot Hn11). On the other 
hand, the protein disappeared after treatment of CACO-2 cell line with combination of 
NH3 with EGCG using 0/4 sequence of administration signifying extreme 
downregulation. Treatment of the same line with combination of Ox and Pat 
administered as a bolus also caused downregulation of PROF1 (by a factor of 7.88) 
(Table 3.53, spot Can3). It is evident from above that PROF1 could be a potential 
biomarker for colorectal cancer because it was highly expressed in two different types 
of colorectal cancer and significantly downregulated after drug treatments whether 
administered alone or in combination. In a study of clinical gastric carcinoma and 
adjacent tissues, the authors proposed that silencing of PROF1 can give antitumour 
benefit by modulating  integrin β1/focal adhesion kinase pathway (Cheng, Zhu et al. 
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2015). However, further studies are required to get more mechanistic information 
concerning the anticancer effect and downregulation of PROF1.  
COF1 (Cofilin-1) 
Cofilin belongs to a family of closely related low molecular weight proteins named as 
actin depolymerizing family (ADF). Among three members of cofilin family (ADF, 
Cofilin-1 and Cofilin-2), COF1 or Cofilin-1 is the most abundant consisting about 
95% of all expressed cofilin (Wang, Eddy et al. 2007). COF-1 can bind both 
monomeric actin (G-actin) and filamentous actin (F-actin), and is responsible for 
controlling actin dynamics at the cell membrane during cellular motility due to its 
capacity to sever actin filaments (Yamaguchi and Condeelis 2007). Moreover, COF1 
has been associated with apoptosis through its translocation into mitochondria and 
subsequent release of cytochrome-c (Bernstein and Bamburg 2010). Phospholipase 
D1 activation which is considered to be an integral part for chemotaxis has also been 
reported to be induced by COF1 (Han, Stope et al. 2007). Overexpression of COF1 
has been observed in a variety of cancers including: glioblastoma (Gunnersen, 
Spirkoska et al. 2000), lung (Keshamouni, Michailidis et al. 2006), pancreas (Sinha, 
Hütter et al. 1999), breast (Dowling, Meleady et al. 2007), oral (Turhani, 
Krapfenbauer et al. 2006), renal (Unwin, Craven et al. 2003) and ovary (Martoglio, 
Tom et al. 2000).  
In the present study, COF1 was expressed in cisplatin resistant A2780cisR cell line but 
was not detectable in the parent ovarian A2780 cell line. Treatment with most of the 
combinations caused extreme downregulation of the protein such that the spot was 
disappeared. However, combination of Cis with Pat did not change the expression of 
the protein significantly (Table 3.49, spot Cn78). The findings indicated that COF1 is 
possibly linked with resistance in ovarian cancer. 
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In CACO-2 cell line, COF1 is found to undergo 10.03 folds downregulation following 
treatment with combination of Ox with Pat at bolus addition. The protein was not able 
to be detected after combined treatment of NH3 with EGCG using 0/4 sequence of 
administration indicative of extreme downregulation. Thus downregulation of COF1 
could be a strategy to combat ovarian and colorectal cancer. Antitumour action of 
NH3 administered alone or in combination with phytochemicals could also be 
attributed with the downregulation of COF1. 
ACTG (Actin, Cytoplasmic 2) 
ACTG or G-actin is a 43 kDa monomeric and globular protein which is composed of 
a single polypeptide chain of 375 amino acids (Grzanka, Gagat et al. 2013). G-actin 
can be converted to F-actin by binding with ATP through polymerization and the 
reversal phenomenon can also happen via depolymerisation. G-actin is non-muscle 
variant among three types of actin which mainly forms the cortical network and thus 
controls shape, flexibility and motility of cells (Dugina, Zwaenepoel et al. 2009). 
Changes in expression of G-actin can alter cell motility pattern, cytoskeleton 
reorganization and thus contribute into diseases process using multiple signalling 
pathways including ROCK signalling (Shum, Pasquier et al. 2011). The protein was 
found to be upregulated in osteosarcoma (Li, Liang et al. 2010) and gall bladder 
cancer (Huang, Yao et al. 2014). However, decreased expression of G-actin was 
found in salivary gland adenocarcinoma (Suzuki, Nagata et al. 1998). 
In the present study, G-actin was significantly downregulated in HT-29 colorectal 
cancer cell line following treatment with combination of Ox and Pat administered as a 
bolus. The protein was undetectable in the same cell line following treatment with 
NH1, NH3 and combination of NH3 with Cur administered using 4/0 sequence 
believed to be due to extreme downregulation. Decrease in expression of G-actin 
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might cause suppression of interphase microtubule dynamics via decreasing 
microtubule shortening rates and increasing microtubule attenuation. Furthermore, 
decrease in G-actin would prolonged mitotic progression, block metaphase–anaphase 
transition and inhibit cell proliferation (Po'uha, Honore et al. 2013). This study 
suggests that partial downregulation of the protein is related to the antitumour action 
of NH1 and NH3.                 
TBA1C (Tubulin alpha-1C chain) 
Tubulin is the subunit protein of microtubules which is negatively charged and highly 
conserved and found in all nucleated cells (Sackett, Werbovetz et al. 2010). Tubulins 
are composed of two spherical proteins alpha tubulin and beta tubulin, having 
molecular weight of about 50 kDa each (Jordan, Hadfield et al. 1998). The structure 
of tubulins share considerable portion of common features among different species. In 
general, tubulin is an αβ heterodimer attached with two molecules of GTP. One of 
two GTP molecules is always attached with the dimer and the other one is 
exchangeable and critical for the functions of tubulin. In the presence of an additional 
GTP molecule the heterodimer forms protofilament by rearranging into head to tail 
format in a manner of alternating alpha tubulin and beta tubulin. After few minutes 
the protofilaments group together and form C sheet which later on curls into pipe like 
structures known as microtubules (Jordan, Hadfield et al. 1998). Antimitotic 
anticancer drugs such as: vincristine, colchicine, paclitaxel etc. show their antitumour 
action by binding with tubulin and microtubules which ultimately cause mitotic arrest 
and cell death (Giannakakou, Sackett et al. 2000).  
TBA1C remains mostly unexplored protein in regard to its role in disease process. 
However, it has been proposed that TBA1C is associated with translation related 
proteins, chaperones and signal transduction associated proteins (Kapustian, Dadlez et 
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al. 2016). Proteomics study after exposure of carcinogen in MCF-7 breast cancer cell 
line caused upregulation of TBAIC indicating possibility of increased expression of 
the protein in cancerous cell (Hooven and Baird 2008). Proteomics analysis from two 
different studies demonstrated that exosome-like vesicles derived from breast cancer 
cells contain TBA1C which further potentiates the link of the protein with cancer 
(Palazzolo, Albanese et al. 2012, Kruger, Elmageed et al. 2014).  
In this study it has been observed that combination of Ox with Pat administered as a 
bolus caused significant downregulation of the TBA1C. The disappearance of the 
protein after treatment with combination of NH3 and EGCG in CACO-2 colorectal 
cell line may be due to extreme downregulation. This study might be the first to claim 
that downregulation of TBA1C could be novel strategy to combat colorectal cancer. 
However further investigations are required to consider increased expression of 
TBA1C is a biomarker for cancer. 
TBB5 (Tubulin beta chain) 
Beta-tubulin is the integral part of αβ heterodimer of tubulin which forms the 
backbone of microtubules. The exchangeable GTP molecule is attached with beta-
tubulin which is very important for the functioning of tubulin. Beta-tubulin can exist 
as six different isoforms which are highly conserved across species. Aberrant 
expression of the particular beta-tubulin isotype is associated with emergence of 
resistance in solid cancers (Kavallaris 2010). Recently it has been discovered that 
tubulin isotype composition can alter microtubule assembly, drug resistance, drug 
binding and dynamics (Ghadari, Alavi et al. 2015). Most of the epithelial cells express 
the isoform tubulin beta chain 5, encoded by the gene TUBB5 (Kelley, Li et al. 2001). 
TBB5 is found to be upregulated in breast (Cortesi, Barchetti et al. 2009) and 
oesophageal cancer (Qi, Chiu et al. 2005). Previous study from the host laboratory 
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reported that TBB5 was downregulated in ovarian A2780cisR cell line compared to that 
of parent A2780 cell line (Alamro 2015). Several synergistic drug combinations over-
restored the protein back to the level of expression observed in A2780 cell line.  
In the present study, the expression of the protein was not significantly changed due to 
treatment with combination of NH3 and EGCG using 0/4 sequence of administration 
in colorectal CACO-2 cell line although treatment with synergistic combination of Ox 
and Pat administered as a bolus upregulated its expression. Similar to earlier findings 
from our group, the present study also suggests that TBB5 might be proapoptotic in 
action. The mechanism through which TBB5 provides proapoptotic activity needs to 
be explored in future studies. 
4.7.2 Heat shock proteins 
 
Heat shock proteins (Hsps) are also known as molecular chaperons or stress proteins 
which have no function of their own but are responsible for correcting function of 
other proteins. Hsps control the appropriate folding of other proteins or assist in 
assembly into oligomers but do not become components of final tertiary structures 
(Ellis 1990, Hendrick and Hartl 1993). There are few special chaperones which act as 
true catalysts by increasing the rate of the folding of proteins and called ‘folding 
catalysts’. Most of the stress proteins act by preventing incorrect folding of proteins 
and overall network functions in diverse aspects of protein quality control, and 
targeting terminally misfolded proteins for proteolytic degradation (Kim, Hipp et al. 
2013). Although chaperones are indispensable for living cells during their entire 
lifetime, they are much more needed after environmental stress which causes protein 
damage e.g. heat shock, poisoning, almost any abrupt change in the cellular 
environment, and mental stress as well. That is why molecular chaperones function as 
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key player in the aetiology of multiple disease conditions, with a rapidly increasing 
role in clinical practice being discovered (Csermely, Schnaider et al. 1998).   
ENPL (Endoplasmin) 
ENPL is also called glucose regulated protein -94 (GRP94) which is a paralog of 
Hsp90 and unique to multicellular eukaryotes (Nicchitta 1998). The protein is highly 
abundant in the lumen of endoplasmic reticulum. Structurally the protein is composed 
of three major domains: N-terminal domain, charged linker region, middle domain 
and C-terminal domain. N-terminal domain possesses a nucleotide binding pocket 
(Stebbins, Russo et al. 1997) and mainly responsible for the breakdown of ATP 
through hydrolysis.  ENPL is a well-known master immune chaperone involved in 
folding of several innate immune receptors e.g. toll like receptors, integrins, platelet 
glycoprotein, GARP and LRP6 (Wu, Hong et al. 2016). Other than the association 
with autoimmune and inflammatory diseases, GRP94 has also been linked with 
carcinogenesis and metastasis (Chen, Ha et al. 2014). Mitogenic and prosurvival 
factors for neoplasia e.g. secretion of insulin like growth factors were also reported to 
be controlled by GRP94 (Wanderling, Simen et al. 2007). Different studies using 
various tumour models have shown that ENPL is upregulated in cancer cells 
compared to normal cells.  Elevated expression of GRP94 has been reported in 
oesophageal cancer (Chen, Ding et al. 2002), gastric cancer (Bai, Ye et al. 2011), 
pancreatic cancer (Pan, Erkan et al. 2009), prostate cancer (O'Connell, Prencipe et al. 
2012) and lung cancer (Wang, He et al. 2005) Wu, Hong et al. proposed the role of 
ENPL in oncogenesis which is shown in figure 4.8 (Wu, Hong et al. 2016).  
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Figure 4.8: Role of ENPL (GRP94) in carcinogenesis  
In the present study, the protein was significantly downregulated in A2780 cell line 
following treatment with NH3 alone and combination of Cis and Eme administered 
using 0/4 sequence. The protein was not detectable in A2780 cell line following 
treatment with combination of NH3 and EGCG which was due to extreme 
downregulation. The protein was found to be upregulated in untreated A2780cisR cell 
line compared to the level observed in parent A2780 cell line. When A2780cisR cell 
was treated with NH3 alone and combination of Cis and Pat, expression of GRP94 
was found to decrease towards the level found in the parent cell line. However other 
combined treatments caused further upregulation of the protein in A2780cisR cell line. 
In an earlier study, it was shown that the depletion of GRP94 returned back the 
sensitivity of the Caenorhabditis elegans towards the antitumour action of cisplatin 
(Natarajan, Gaur et al. 2013). It is proposed that ENPL is antiapoptotic in action and 
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can serve as a potent biomarker of various cancers including cisplatin resistance 
ovarian cancer. High antitumour activity of NH3 in parent ovarian A2780 and 
A2780cisR cell line is mediated through downregulation of GRP94. 
GRP78 (78 kDa glucose-regulated protein) 
 GRP78 is also known as binding immunoglobulin protein (Bip) which was 
discovered in 1970s together with GRP94 and GRP58 as cellular proteins triggered by 
glucose starvation (Lee 2001). GRP78 accelerates folding and assembly of nascent 
proteins; prevents their misfolding and intermediate aggregation; eliminates misfolded 
proteins via proteasome degradation; binds with calcium and regulates the pathways 
for the initiation of the various arms of the unfolded protein response (Park, Eun Kim 
et al. 2017). Although GRP78 belongs to Hsp70 family, the primary location of the 
protein is not cytoplasm. Rather it is the most abundant protein of endoplasmic 
reticulum. In stress relieved conditions, GRP78 is bound with ER transmembrane 
sensor proteins PERK, IRE1, and ATF6 (Lee 2007). The magnitude of expression of 
GRP78 is maintained at low basal level in major adult organs however it is strongly 
induced in cancers due to stress signals include glucose starvation, calcium depletion 
and accumulation of misfolded proteins in the endoplasmic reticulum (Kaufman 2002, 
Li, Lee et al. 2006). Since the microenvironment of tumour cells are identical to 
physiologic endoplasmic reticulum stress, and the unfolded protein response is often 
turned on for cell survival which in turn would cause increased expression of GRP78 
(Wang, Wey et al. 2009). Strong evidence regarding the upregulation of GRP78 in 
neoplasia exists such as that in breast cancer (Gazit, Lu et al. 1999, Fernandez, 
Tabbara et al. 2000, Lee, Nichols et al. 2006), hepatic cancer (Shuda, Kondoh et al. 
2003), lung cancer (Uramoto, Sugio et al. 2005), and prostate cancer (Pootrakul, Datar 
et al. 2006, Daneshmand, Quek et al. 2007). Lee has described the mechanisms 
 282 
through which GRP78 in involved in tumour progression, cancer cell resistance and 
chemotherapy resistance (Lee 2007). Figure 4.9 depicts the proposed mechanisms 
discussed in that review related to cancer, endoplasmic reticulum stress and 
upregulation of GRP78.  
 
Figure 4.9: Role of GRP78 in cancer progression and resistance to chemotherapy 
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In the present study, GRP78 was found to be significantly downregulated in ovarian 
A2780 cancer cell line after treatment with the selected drugs administered alone or in 
combination with phytochemicals. However, combined treatment of NH3 with EGCG 
given as a bolus caused extreme downregulation of the protein so that it was not at all 
seen. Downregulation of GRP78 is due to synergistic action between NH3 and 
EGCG.  
The protein was absent in untreated A2780cisR cell line but significantly expressed 
after treatment with selected drugs administered alone or in combination. Combined 
treatment with NH3 and Cur using 0/4 sequence of administration caused 
upregulation of GRP78 in A2780cisR cell line than that in untreated A2780 cell line by 
a factor of 3. Similarly, treatment with combination of Cis with Pat using 4/0 
sequence of administration and that with NH3 alone caused upregulation of the 
protein by a factor of 2.5 and 2 respectively. Since most of investigated treatments 
expressed GRP78 significantly, absence of the protein spot in untreated A2780cisR cell 
line in this study may be an artefact. Missing of obvious protein spots in a gel during 
proteomics study using 2-DE is not uncommon and could be due to improper location 
of the spot in the gel, incorrect gel alignment or staining error (Grove, Hollung et al. 
2006).  
If we consider, the protein was genuinely downregulated to that extent that it was 
below detectable threshold then the protein should be pro-apoptotic in action; which 
would go against the nature of the protein proved from the study in A2780 cell line 
being antiapoptotic in action. Earlier studies from our group also found that GRP78 
significantly upregulated in A2780cisR cell line compared to parent counterpart (Al-
Eisawi 2013, Mazumder 2013, Nessa 2013, Alamro 2015). Additionally, the 
mechanism of antiapoptotic action of GRP78  in ovarian cancer has been described 
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elsewhere as well (Cohen, Dromard et al. 2010). Studies in other cancer models like 
breast (Dong, Ko et al. 2005); prostate (Daneshmand, Quek et al. 2007); bladder 
(Reddy, Mao et al. 2003) and glioma cells (Pyrko, Schönthal et al. 2007), have shown 
that upregulation of GRP78 was associated with resistance against different 
chemotherapy. From the above discussion it can be concluded that GRP78 is 
upregulated in ovarian cancer thus responsible cisplatin resistance and antiapoptotic in 
action. And also, the antitumour activity of NH3 could be linked with the 
downregulation of GRP78.  
CH60 (60 kDa heat shock protein) 
CH60 or Hsp60 is also known as chaperonin because it is one of the first discovered 
molecular chaperones or heat shock proteins. Most of the CH60 proteins reside in the 
matrix of mitochondria but it can appear in cell membrane and extracellular spaces as 
well (Cappello, Conway de Macario et al. 2008). Hsp60 protein is a heptamer having 
the shape of a ring which is composed of three domains namely: apical, intermediate 
and equatorial (Richardson, Landry et al. 1998). The principal function of CH60 in 
association with CH10 is to regulate the folding of polypeptides. Recent studies have 
shown that Hsp60 has a great role to play in diagnosis-prognosis, prevention and 
treatment of cancer. CH60 is involved in maintaining the environment required for 
growth of certain types of tumour cells or even in some cases it is essential for 
survival of cancer cells. Increased expression of Hsp60 provides tumour cells ability 
to sustain uncontrolled proliferation, survive apoptotic stimuli, loose replicative 
senescence and retain carcinogenesis process (Cappello, Conway de Macario et al. 
2008). CH60 was found to be upregulated in most of the cancers such as astroglyoma 
(Bajramović, Geutskens et al. 2000), oesophageal carcinoma (Kawahara, Yokota et al. 
1999), gastric maltoma (Kobayashi, Yokota et al. 1998), hepatic carcinoma 
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(Kuramitsu and Nakamura 2005), colorectal carcinoma (Cappello, Bellafiore et al. 
2003), prostate carcinoma (Castilla, Congregado et al. 2010), ovarian carcinoma 
(Hjerpe, Egyhazi et al. 2013) and breast carcinoma (Desmetz, Bibeau et al. 2008). 
However, decreased expression of CH60 was also reported in bladder (Lebret, Watson 
et al. 2003), bronchial (Cappello, Di Stefano et al. 2005) and tongue carcinoma (Ito, 
Kawabe et al. 1998). 
In the present study, Hsp60 was downregulated by a factor of 3.23 in A2780 cell line 
after treatment with NH3 alone. Treatment with combinations of NH3 with EGCG 
administered as a bolus, that with combination of NH1 and 6-SG, and combination of 
Cis with Eme using 0/4 sequence of administration caused the protein to disappear 
completely in A2780 ovarian cancer cell line. In contrast, significant upregulation was 
observed in A2780 cell line after treatment with combination of NH3 and Cur 
administered as a bolus addition. 
Hsp60 was significantly upregulated in untreated A2780cisR cell line compared to the 
level expressed in parent A2780 cell line. Treatment of A2780cisR cell line with 
synergistic combination of NH3 and EGCG using 0/4 sequence of administration 
partially restored back towards the level found in parent A2780 cell line. However, 
treatment with other selected combinations caused further upregulation of the protein 
in A2780cisR cell line. The results can be seen to indicate complex nature of drug 
actions with the involvement of multiple pathways to bring cell death.  
Based on the results from the present study, it could not be ascertained whether Hsp60 
acted as an antiapoptotic protein or a proapoptotic protein. However, it is obvious that 
Hsp60 is upregulated in ovarian cancer and further upregulated in the resistant cell 
line. The controversial role of Hsp60 was also noted in earlier studies where the 
protein was thought to be proapoptotic in nature via caspase activation (Samali, Cai et 
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al. 1999, Xanthoudakis, Roy et al. 1999), while being antiapoptotic in action via 
sequestration of Bax (Shan, Liu et al. 2003). Hence targeting Hsp60 to develop new 
anticancer drugs or biomarker of cancer should be considered with caution. 
CH10 (10 kDa heat shock protein, mitochondrial) 
As stated earlier, CH10 or Hsp10 is a co-chaperone which acts in a coordinated 
fashion with Hsp60 during protein folding. CH10 does not possess the usual 
mitochondrial-targeting sequence; rather N-terminal sequence of the protein forms an 
amphipathic α-helix. Stabilization of the α-helix is accomplished by acetylation of the 
first alanine residue and thus attaining capability to cross the mitochondrial membrane 
(David, Bucchieri et al. 2013). After discovery of selective expression of CH10 in 
myelocyte and megakaryocyte precursors in normal human bone marrow, it has been 
postulated that the function of CH10 is not limited to action only as co-chaperon. The 
protein has a role in differentiation and/or proliferation of normal cellular lineages 
(Cappello, David et al. 2005). Due to the elevated expression of CH10 in several 
tumour models, the protein is now being considered in carcinogenesis. Evidence of 
upregulation of CH10 has been described in uterine (Cappello, Bellafiore et al. 2003), 
colorectal (Cappello, Bellafiore et al. 2003), prostate (ZUMMO 2003), bladder 
(Cappello, David et al. 2006), bowel (Rappa, Sciume et al. 2014) and ovarian cancer 
(Akyol, Gercel-Taylor et al. 2006). However, in bronchial tumour the expression of 
CH10 found to be downregulated (Cappello, Di Stefano et al. 2006).  
In the present study, Hsp10 was significantly downregulated in A2780cisR cell line 
following all of the selected drug treatments administered either alone or in 
combination. The highest downregulation (11.86 folds) of the protein was caused by 
the combined treatment of NH3 with EGCG using 0/4 sequence, followed by that 
with Cis with Pat using 4/0 sequence (11.05 folds). Since the protein was highly 
 287 
expressed in cisplatin resistant cells and absent in parent A2780 cell line, it was 
considered that upregulation of CH10 was associated with increase in cisplatin 
resistance. The idea that an Hsp10 acts as antiapoptotic protein was further supported 
by treatment with NH3 alone and synergistic drug combinations that caused 
downregulation of the protein.   
HSP7C (Heat shock cognate 71 kDa protein) 
HSP7C also known as HSC70, belongs to HSP70 family proteins and is characterized 
by its constitutive expression and mild induction during stressed conditions. 
Structurally HSC70 is composed of mainly two parts; nucleotide binding domain and 
substrate binding domain (Stricher, Macri et al. 2013). Nucleotide binding domain is a 
44 kDa Nterminal adenosine triphosphatase (ATPase) domain, also known as the 
ATP-binding domain. Substrate binding domain consists of two subdomains i.e. 18 
kDa peptide binding domain and 10 kDa carboxyl-terminal domain which is 
necessary for association with some co-chaperones (Mosser, Caron et al. 2000, 
Sullivan and Pipas 2002). While ATP is attached to the protein, HSC70 protein 
displays very low affinity towards its substrate. But as soon as hydrolysis of ATP 
takes place, HSC70 would become sufficiently active to interact with substrate. 
ATPase activity of HSC70 is catalysed due to presence of some co-chaperones e.g. 
Dna J homologues. On the contrary, BAG domain proteins; HSPBP1 and HSP110 
stimulate the dissociation of bound ADP from HSC70 and reset the cycle (Liu, 
Daniels et al. 2012).  
Other than the ATPase activity, HSC70 is involved in protein folding (Siegers, Bölter 
et al. 2003), translocation of proteins (Sheffield, Shore et al. 1990), targeting 
misfolded proteins towards lysosomal degradation (Lu, Huang et al. 2010) and 
regulating cellular signalling functions (Shiota, Kusakabe et al. 2010). Moreover, the 
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role of HSC70 in apoptosis, embryonic development and aging has also been reported 
(Liu, Daniels et al. 2012). Elevated expression of HSC70 has been observed in 
colorectal (Kubota, Yamamoto et al. 2010), gastric, pancreatic and breast cancer cell 
lines (Maeda, Ohguro et al. 2000). 
In the present study, HSP7C underwent significant downregulation in A2780cisR cell 
line following treatment with NH3 alone and that with combination of NH3 and 
EGCG using 0/4 sequence. The protein spot disappeared after the treatment of 
A2780cisR cell line with combination of Cis with Eme using 4/0 sequence. Other 
treatments did not cause significant change in expression of the protein in the same 
cell line.  
Compared to untreated A2780 cell line, HSP7C is upregulated by a factor of 8.12 in 
untreated A2780cisR cell line. Treatment with NH3 alone, combination of NH3 with 
Cur and combination of NH3 with EGCG using 0/4 sequence partially restored back 
the expression observed towards that in A2780 cell line. The protein was not 
detectable in A2780cisR cell line following treatment with the combination of Cis with 
Eme using 4/0 sequence indicating over restoration. In contrast, treatment with 
combination of Cis and Pat using 4/0 sequence of administration caused further 
upregulation of HSP7C. On balance it can be said that HSP7C would be functioning 
as an antiapoptotic protein and could be targeted to develop new anticancer drug. 
Anticancer action of NH3 was also proved to be associated with the downregulation 
of HSP7C. 
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PPIA (Peptidyl-propyl cis-trans isomerase A) 
Cyclophilins are a family of omnipresent proteins which have peptidyl prolyl 
isomerase activity and are responsible for catalyzing the isomerizations of peptide 
bonds from trans form to cis form at proline residues and thus facilitate protein 
folding (Nigro, Pompilio et al. 2013). Seven types of cyclophilins with 16 unique 
proteins are present in human which are CypA, CypB, CypC, CypD, CypE, Cyp40 
and CypNK. Among these Cyclophilins, CypA or PPIA is the most abundant in 
human, contributing 0.1% to 0.6% of total cytosolic proteins (Dornan, Taylor et al. 
2003). PPIA is a 18 kDa low molecular weight protein composed of 165 amino acids, 
which has eight-stranded antiparallel –barrel structure. There are two  helices 
present in the structure which enclose the barrel from either side (Wang and Heitman 
2005). The main functions of PPIA are folding, trafficking and assembly of proteins; 
modulation of immune system and cellular signalling (Obchoei, Wongkhan et al. 
2009). The protein also has been reported to play a role in cell migration, proliferation 
and differentiation (Yang, Li et al. 2005). Upregulation of PPIA has been observed in 
different types of cancer e.g. non-small cell lung carcinoma (Campa, Wang et al. 
2003), hepatocellular carcinoma (Lim, Park et al. 2002), pancreatic adenocarcinoma 
(Mikuriya, Kuramitsu et al. 2007), colorectal cancer (Lee and Kim 2010), endometrial 
cancer (Li, Zhao et al. 2008), gastric cancer (Al-Ghoul, Brück et al. 2008), 
oesophageal cancer (Qi, He et al. 2008), glioblastoma (Lee and Kim 2010) and 
metastatic melanoma (Al-Ghoul, Brück et al. 2008).  
In the present study, two spots in ovarian A2780 cell line (spot 224 and spot 235) and 
two spots in colorectal HT-29 cell line (spot Hn14 and spot Hn15) were identified as 
PPIA. In A2780 cell line, all the selected treatments except one caused significant 
downregulation of PPIA compared to the level found in untreated A2780 cell line. In 
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fact, the level of expression of the protein was below the threshold of detection in 
most cases. Synergistic combination of NH3 with Cur using 0/4 sequence caused 3.62 
folds downregulation of PPIA in A2780 cell line as applied to spot number 224. But 
PPIA was not detectable in the cell line after treatment with combination of NH3 and 
Cur as applied to the spot number 235. Similarly in HT-29 cell line, PPIA was 
downregulated following selected drug treatments administered alone or in 
combinations. NH1 alone caused 4.83 folds downregulation of PPIA as applied to 
spot number Hn14 while the fold factor was 2.85 as applied to spot number Hn15.  
The results of  the study as applied to A2780 cell line suggest that PPIA might be 
antiapoptotic in action in ovarian cancer in agreement with the findings that knock 
down of PPIA induced apoptosis by blocking cell cycle at G1 phase (Mikuriya, 
Kuramitsu et al. 2007). 
However when we consider  the expression of the protein in cisplatin resistant 
A2780cisR cell line, it was found that PPIA did not express at all. Treatments with 
synergistic combinations and that with NH3 alone caused restoration of the protein 
back to the level found in ovarian A2780 cell line, indicating that PPIA might be 
proapoptotic action in the cell line. Disappearance of PPIA spot in A2780cisR cell line 
was also demonstrated in earlier studies (Al-Eisawi 2013, Alamro 2015). Conflicting 
results of proapoptotic and antiapoptotic behaviour of PPIA was also reported 
(Alamro 2015). The author hypothesized that crosstalk between pro-apoptotic and 
anti-apoptotic signals and involvement of a protein earlier than committed 
proapoptotic or anti-apoptotic steps, determine the ultimate cell survival or cell death.   
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PDIA3 (Protein disulfide-isomerase A3) 
Protein disulfide isomerase (PDI) family of proteins containing non-thiol-reactive 
thioredoxin-like domains have chaperone-like activities for endoplasmic reticulum 
folding and secretion of proteins. PDI is the first protein folding catalyst discovered in 
1960s and also the founding member of a family of twenty related mammalian 
proteins that are primarily located and function in the endoplasmic reticulum 
(Goldberger, Epstein et al. 1964). PDIA3 which is also called ERP57 or ERP60 is the 
first protein whose crystal structure has been solved among all PDI family proteins 
available in human (Dong, Wearsch et al. 2009). In addition to isomerisation of 
disulfide bonds during folding of proteins, ERP57 also serves other chaperone like 
activities e.g. inhibition of the aggregation of unfolded substrates and/or assisting in 
the refolding of polypeptides (Ramos, Serino et al. 2015). Upregulation of PDIA3 has 
been evidenced in more than seventy percent of cancers and its expression has been 
connected with cell invasiveness, metastasis, DNA repair and low survival rate 
(Giamogante, Marrocco et al. 2016). However, proapoptotic role of PDIA3 has also 
been recently reported (Zhao, Lu et al. 2015).  
In the present study, PDIA3 was significantly upregulated in HT-29 cell line 
following treatment with combination of Ox and Pat administered as a bolus and with 
NH1 alone. Other synergistic treatments also caused upregulation of PDAI3 but the 
change was not significant. It is proposed that PDIA3 acts as proapoptotic protein in 
colorectal HT-29 cell line which is in agreement with previous findings in A2780cisR 
cell line (Alamro 2015). Elevated expression of PDIA3 was reported to increase 
caspase-3/7 activation and induce cell death via Bak-MOMP pathway (Zhao, Lu et al. 
2015). 
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SERPH (Serpin H1)    
SERPH, also known as HSP47, belongs to serpin family proteins which was initially 
identified as cell membrane collagen binding protein and named as ‘colligin’. 
However, it was later discovered that the protein actually resides in endoplasmic 
reticulum and primarily functions in glycosylation, secretion and crosslinking in 3-D 
assembly of type-IV collagen (Sauk, Nikitakis et al. 2005). SERPH has few special 
distinctive characteristics which differentiate it from other molecular chaperones 
found in endoplasmic reticulum such as substrate specificity towards collagen only, 
does not induce by endoplasmic reticulum stress (Ito and Nagata 2016). Elevated 
expression of SERPH was observed in multiple diseases including: rheumatoid 
arthritis, atherosclerosis, glomerular sclerosis (Razzaque and Taguchi 1997), lung 
fibrosis and hepatic cirrhosis (Razzaque, Hossain et al. 1998, Hattori, Kubota et al. 
2001). Moreover, positive correlation with the overexpression of HSP47 and 
pancreatic, head and neck, breast and gastric cancers has also been reported (Xu, 
Mikami et al. 2013, Zhu, Xiong et al. 2015). 
In the present study, SERPH was extremely downregulated following the selected 
treatments administered alone and in combinations as applied to A2780cisR cell line. 
Since the protein was highly downregulated after treatments, it went below to the 
threshold level of detection for all treatments except the combination of Cis and Pat 
using 4/0 sequence where the change in expression was insignificant. Thus it can be 
assumed that HSP47 is antiapoptotic in action and responsible for cisplatin resistance 
in ovarian A2780cisR cell line. 
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4.7.3 Protein biosynthesis and RNA processing 
proteins 
 
The proteins of this class share similar structural domains, display key responsibility 
in DNA repair; biogenesis of telomerase; cellular signalling mechanism and 
regulation of gene transcription and translation. In the present study four proteins 
belong to this group were found to exhibit significant changes in expression as 
discussed below.  
EFTU (Elongation factor Tu, mitochondrial) 
EFTU or Tu translational elongation factor is a member of the GTPase superfamily of 
proteins which display a vital role in the elongation process of mitochondrial protein 
biosynthesis. It acts by forming a ternary complex with aminoacyl-tRNA and GTP 
which facilitates the binding of the aminoacyl-tRNA to the A-site of the ribosome 
(Zheng, Peng et al. 2010). Moreover, EFTU contributes in cytoskeleton construction, 
in organization of the mitotic spindle, cellular growth and signal transduction 
(Hamrita, Nasr et al. 2011). Overexpression of EFTU was associated in developing 
pancreatic cancer, gastric cancer and melanoma (Forgber, Trefzer et al. 2009) but 
absence of the expression of the protein had been reported in hepatocellular 
carcinoma (Xu, Wang et al. 2011). 
In the present study, the protein was downregulated in A2780cisR cell line by a fold 
factor of 7.96 following the treatment with NH3 alone. Combined treatment of NH3 
and EGCG using 0/4 sequence of administration also caused significant 
downregulation of the protein in the same cell line. Complete disappearance of the 
protein due to extreme downregulation of EFTU was observed after combined 
treatment of Cis and Eme using 4/0 sequence of administration. 
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Compared to the level of expression in untreated A2780 cell line, EFTU was 
upregulated in untreated A2780cisR cell line. The protein was either over restored or 
partially restored back to the level observed in in parent A2780 cell line after 
treatments (NH3 alone and selected combinations). It is obvious from this study that 
EFTU is antiapoptotic in action and responsible for cisplatin resistance in A2780cisR 
cell line. In an earlier study, overexpression of EFTU has been linked with 5-
fluorouracil resistance in MCF-7 breast cancer cell line (Zheng, Peng et al. 2010). 
Anticancer mechanism of NH3 could also be correlated with the downregulation of 
EFTU. 
RSSA (40S ribosomal protein SA) 
 RSSA is a 67 kDa protein which is abundantly located in cytoplasm, but is also found 
in nucleus as a component of nuclear structures. The protein is named as 37 kDa 
laminin receptor precursor (37LRP) and also identified as p40 ribosome-associated 
protein. RSSA is primarily involved in translational machinery; it facilitates cell 
adhesion to the ECM through binding with integrins and also as membrane receptor 
for prion proteins to control endocytosis (Rea, Rossi et al. 2012). Overexpression of 
RSSA has been considered as prognostic factor in variety of cancers including breast 
carcinoma, small cell lung carcinoma, pancreatic adenocarcinoma, ovarian carcinoma 
and gastric carcinoma (Ménard, Tagliabue et al. 1998, Liu, Ning et al. 2007). 
Moreover, the protein has been reported to mediate resistance towards chemotherapy 
e.g. vincristine in gastric cancer (Sun, Liu et al. 2014). 
In the present study, RSSA was downregulated in A2780cisR cell line following 
treatment with NH3 alone. After treatment with combination of Cis with Eme using 
4/0 sequence of administration, the protein was upregulated in the same cell line. All 
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other combined treatments did not produce significant change in the level of 
expression of RSSA in A2780cisR cell line.  
RSSA was upregulated in untreated A2780cisR cell line compared to the level observed 
in parent A2780 cell line. After treatment with NH3 alone, the protein was partially 
restored back the level found in A2780 cell line. The same result was attained 
following combined treatments of NH3 and Cur, NH3 and EGCG using 0/4 sequence 
of administration. Combination of Cis with Pat using 4/0 sequence of administration 
also caused partial restoration of RSSA back to the level of A2780 cell line. However, 
combination of Cis with Eme using 4/0 sequence of administration caused further 
upregulation of the protein. In summary, it can be said that RSSA is an antiapoptotic 
protein and could be targeted to develop new anticancer drugs in future. 
ROA2 (Heterogeneous nuclear ribonucleoproteins A2/B1) 
Heterogeneous ribonucleoproteins (hnRNP) are the family of proteins that display an 
important role in splicing and transport of mRNA in normal cells. ROA2 is the most 
abundant among all different types of hnRNP present in mammals (Yan-Sanders, 
Hammons et al. 2002). Elevated expression of ROA2 was associated in lung cancer, 
breast cancer (Zhou, Allred et al. 2001), pancreatic cancer (Casadonte, Kriegsmann et 
al. 2014) and gastric cancers (Jing, Xu et al. 2011). However, downregulation of 
ROA2 has been reported in metastasized ovarian cancer model study (Zhang, Li et al. 
2014). 
In the present study, the protein was significantly downregulated in CACO-2 
colorectal cancer cell line after treatment with combination of NH3 and EGCG using 
0/4 sequence of administration. But bolus administration of Ox with Pat did not cause 
significant change in the expression of ROA. On balance, the protein is likely to be 
antiapoptotic in action.   
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4.7.4 Redox regulation proteins 
 
These are the group of proteins which are primarily involved in metabolism of the 
drugs and cause acquired resistance of tumour cells towards chemotherapy by 
increasing detoxification. In present study PRDX6, GSTP1 and CISY were listed in 
this class which were found to express differentially following treatment with drugs 
alone or in combination.     
PRDX6 (Peroxiredoxin-6) 
Peroxiredoxins are thiol specific antioxidants which do not require any cofactor for 
reducing cellular peroxide substrates but rather utilize internal cysteine containing 
active sites for target reduction. There are six isozymes of peroxiredoxins have been 
identified in mammals, named as PRDX1, PRDX2, PRDX3, PRDX4, PRDX5 and 
PRDX6 (Park, Jo et al. 2016). The last discovered family member of these non-seleno 
peroxidases is PRDX6 which differ from other members by containing one cysteine 
residue in its active site whereas others contain two. Moreover, catalytic activity of 
PRDX6 is independent of thioredoxin (Fisher 2011). In addition to reduction of 
peroxides, PRDX6 are involved in cell growth, apoptotic cell death, foetal 
development, fat metabolism and immune responses. Overexpression of PRDX6 has 
been associated with various cancers such as: lung cancer , bladder cancer (Quan, Cha 
et al. 2006), breast carcinoma (Chang, Li et al. 2007), mesothelioma and oral cancer 
(Kinnula, Lehtonen et al. 2002, Shukla, Pranay et al. 2009). Increased proliferation 
has been linked with the glutathione peroxidase activity of PRDX6 whereas 
metastasis was correlated with its phospholipase A2 activities. 
In the present study, the protein was extremely downregulated (spot was not visible) 
in A2780cisR cell line after the treatment with NH3 alone, combination of NH3 and 
EGCG using 0/4 sequence of administration and that with combination of Cis and 
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Eme using 4/0 sequence of administration. Combined treatment of NH3 and Cur using 
0/4 sequence of administration also caused significant downregulation of PRDX6 in 
A2780cisR cell line. Compared to parent A2780 cell line the protein was upregulated 
by 10.22 folds in cisplatin resistant A2780cisR cell line. Following treatments PRDX6 
was partially restored back to the level observed in parent A2780 cell line. 
In CACO-2 colorectal cell line, the protein was also downregulated following 
combined treatments of NH3 and EGCG using 4/0 sequence of administration, Ox 
and Pat using bolus addition (spot disappeared). It is evident from this study that 
PRDX6 is antiapoptotic in action and could be targeted as developing new anticancer 
agents.    
 GSTP1 (Glutathione S-transferase P) 
Gutathione S-transferases (GSTs) are phase-II metabolic enzymes which constitute 
the major driving forces behind the cellular detoxification mechanism of eukaryotes. 
Among the three major families of GSTs (cytosolic, mitochondrial and microsomal), 
cytosolic family constitutes the largest share in mammals which are further 
categorized into seven classes such as: PS)θ (T)ω 
(O)and (Singh 2015). GSTP1 is the most studied protein among all GSTs 
which encompasses GSH binding site (G-site, N-terminal domain 1) and hydrophobic 
substrate binding site (H-site, C-terminal domain 2). G-site of GSTP1 adopts a 
topology similar to that of the thioredoxin fold, consists of 3 alpha helices and four 
beta sheets. In contrast, H-site is composed of 5 alpha helices and forms the substrate-
binding site together with the loops of N-terminal domain (Tew, Manevich et al. 
2011). Identical to other GSTs, GSTP1 is well known for its role in conjugation of 
glutathione with exogenous or internal metabolites prone to cause cellular damage or 
genotoxicity. In addition, the protein can modulate cellular signalling pathways (e.g. 
 298 
JNK, p38-MAPK signalling cascade), and thus regulate cell cycle, proliferation and 
cell death. Most of human cancer cell lines including multiple drug resistant cell lines 
displayed over expression of GSTP1 (Singh 2015).  
In the present study, the protein was significantly downregulated in CACO-2 cell line 
following combined treatments of NH3 and EGCG using 0/4 sequence of 
administration (spot was disappeared) and Ox with Pat using bolus addition. The 
result of the study is in agreement with the idea that GSTP1 is antiapoptotic in action 
and inhibitors of the protein could be lead to design newer anticancer agents. Few 
small molecules i.e. Telintra, NBDHEX, Nitazoxanide and Haloenol lactone which 
can inhibit GSTP1 were investigated as anticancer agents and Telintra has already 
entered into clinical trials (Laborde 2010). 
CISY (Citrate synthase, mitochondrial) 
Citrate synthase or CISY plays a key role in the central metabolic pathway of 
Tricarboxylic acid cycle in all eukaryotes by catalysing the condensation reaction 
between acetyl-CoA and oxaloacetate to form citrate. CISY is synthesized in cytosol, 
but primary located in mitochondria. The protein is a dimer consisting of two identical 
subunits, each of which encompasses 437 amino acids (Wiegand and Remington 
1986). CISY has been reported to regulate cell proliferation via STAT-3 pathway 
(MacPherson, Horkoff et al.). Overexpression of the protein was observed in 
pancreatic and ovarian cancers (Chen, Liu et al. 2014). 
In the present study, CISY was downregulated in A2780cisR cell line after treatment 
with NH3 alone, combined treatments of NH3 with Cur and NH3 with EGCG using 
0/4 sequence of administration. However, combination treatment of Cis with Eme 
using 4/0 sequence of administration did not change the level of expression of the 
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protein in the same cell line. Upregulation of CISY was observed after combined 
treatment of Cis with Pat using 4/0 sequence of administration.  
Compared to parent A2780 cell line, the expression of CISY was elevated by a factor 
of 22 in A2780cisR cell line. After treatment of NH3 alone and combined treatment of 
NH3 with EGCG using 0/4 sequence of administration the protein was partially 
restored back to the level observed in A2780 cell line. In contrast, combined 
treatments of Cis with phytochemicals (Eme and Pat) using 4/0 sequence of 
administration caused further upregulation of CISY. On balance, it can be said that 
antitumour action of NH3 either alone or in combinations is mediated through 
downregulation of CISY which might be an antiapoptotic protein. 
4.7.5 Enzyme and catalytic proteins 
 
ALDOA, TERA and NDKB were classified into this group which were found to be 
significantly expressed following treatments with selected drugs alone or in 
combinations. 
ALDOA (Fructose-biphosphate aldolase A) 
Aldolase is the glycolytic enzyme composed of four subunits that are 40 kDa each. In 
mammals, three distinct types of aldolase have been discovered namely muscle form 
(ALDOA), liver form (ALDOB) and brain form (ALDOC) (Kukita, Yoshida et al. 
1987). Primary function of ALDOA is to control cellular shape and motility, 
contraction of striated muscles, synthesis of ATP and maintain homeostasis of actin 
filament (Du, Guan et al. 2014). Moreover, upregulation of ALDOA has been 
implicated in various neoplastic conditions i.e. pancreatic cancer, lung cancer, oral 
cancer, renal cancer, colorectal cancer, liver cancer and osteosarcoma (Peng, Li et al. 
2012, Ji, Zhang et al. 2016).  
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In the present study, ALDOA was significantly downregulated in CACO-2 colorectal 
cell line following combined treatments of NH3 with EGCG using 0/4 sequence of 
administration and Ox with Pat using bolus administration. Of note, the protein 
disappeared due to extreme downregulation after combined treatment of NH3 and 
EGCG while combined treatment of Ox and Pat caused 8.31 folds downregulation of 
ALDOA. It is evident from this study that ALDOA is antiapoptotic in action in 
colorectal cancer and could be targeted further to design anticancer drugs. Our 
findings are in agreement with the previous reports where ALDOA showed oncogenic 
activities and induced metastasis through modulating HIF1-α (Chang 2014).  
TERA (Transitional endoplasmic reticulum ATPase) 
TERA is also known as p97 or vasolin containing protein (VCP) in mammals consists 
of 806 amino acids, belongs to the large ATPase family named AAA (ATPases 
associated with various cellular activities). Due to the presence of two ATPase 
domains in TERA, it has been categorized into type –II AAA.  The protein is 
hexameric in structure which can be divided into N terminal end, ATPase domain 
1(D1), ATPase domain 2 (D2), C terminal end, N–D1 linker and D1–D2 linker (Xia, 
Tang et al. 2016). The function of N-domain is to bind with substrate and cofactor; 
D1 domain is to form stable hexamer; D2 domain is to display ATPase activity; C-
domain is to regulate membrane fusion and nuclear translocation via tyrosine 
phosphorylation (Wang, Song et al. 2004). As a whole, TERA is linked with diverse 
cellular functions including regeneration of nuclear envelope; cell cycle regulation; 
reassembly of Golgi apparatus after mitosis; inhibition of apoptosis; recognition of 
DNA damage and endoplasmic reticulum associated degradation (Vij 2008). In an 
earlier study, transfection of VCP in cancer cells displayed suppression of apoptosis 
via TNF-α (tumour necrosis factor-α) stimulation and increased invasiveness (Asai, 
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Tomita et al. 2002). Overexpression of TERA has been reported for various cancers 
and postulated as biomarker in prostate and pancreatic cancer (Tsujimoto, Tomita et 
al. 2004, Magnaghi, D'alessio et al. 2013, Kaistha, Schimanski et al. 2017). 
In the present study, TERA was not detected in A2780 cell line but was highly 
expressed in cisplatin resistant A2780cisR cell line. After treatment of A2780cisR cell 
line with NH3 alone, the protein was downregulated by 3.87 folds whereas combined 
treatment of NH3 and EGCG using 0/4 sequence of administration caused 
downregulation by a factor of 4.75. However, no significant change in the expression 
of TERA was shown following combined treatments of NH3 with Cur using 0/4 
sequence of administration, Cis with Eme and Cis with Pat using 4/0 sequence of 
administration. It can be proposed from this study that TERA is an antiapoptotic 
protein and could be potentially targeted to design anticancer drugs. In fact, inhibitors 
of VCP has already been investigated as cancer therapy (Xia, Tang et al. 2016). 
NDKB (Nucleoside diphosphate kinase B) 
NDKB also known as NME2 or NM23B, is one of the tenth members of nucleoside 
diphosphate kinases family of proteins which are the first identified metastatic 
inhibitors. Structurally, NDKB is a hexameric protein where two antiparallel helices 
fused by a turn form one edge of the nucleotide binding cleft (Webb, Perisic et al. 
1995). The protein catalyses phosphoryl transfer and acts as transcription regulator. 
Inverse relationship between the expression level of NDKB and metastasis in breast 
cancer, melanoma, lung cancer and gastric cancer has been demonstrated in many 
studies (Hartsough and Steeg 2000, Liu, Yang et al. 2015). However, increased 
expression of the protein was reported in prostate cancer cells compared to 
noncancerous cells (Igawa, Rukstalis et al. 1994, Shiina, Igawa et al. 1997).  
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In the present study, NDKB was downregulated in HT-29 colorectal cancer cell line 
after treatment with NH1 alone, NH3 alone and combined treatment of NH3 and Cur 
using 4/0 sequence of administration. Combined treatment of Ox and Pat using bolus 
administration displayed extreme downregulation of the protein (spot disappeared) in 
HT-29 cell line. This study reveals that NDKB might be antiapoptotic in action which 
is supported from previous study where increased proliferation of cancer cells was 
linked with upregulation of NME2(Igawa, Rukstalis et al. 1994).  
4.7.6 Calcium binding proteins 
 
Intracellular calcium ions are very important in maintaining different biological 
processes occurring in our body continuously, for example cell-cycle progression; 
differentiation; muscle contraction and enzyme activities. Calcium binding proteins 
thus serve important roles in normal physiological and pathological conditions e.g. 
neoplasia, ischemia and Alzheimer’s disease (Schäfer and Heizmann 1996). More 
than seventy different proteins have been listed as calcium binding proteins. In this 
study, ANXA1 and CALR belonged to this group displayed significant changes in 
expression after treatment with drugs. 
 ANXA1 (Annexin A1) 
Among 13 members of calcium binding proteins identified in annexin family, 
ANXA1 is the first characterized protein in 1970s. Annexin 1 also known as 
lipocortin-1, is a 37 kDa protein, acts as inhibitor of phospholipase A2 and 
glucocorticoids. Structurally, ANXA1 is a monomeric amphipathic protein 
comprising 346 amino acids in which N-terminal end encompassing 49 residues act as 
regulatory region, responsible for phosphorylation and proteolysis (D'acquisto, 
Perretti et al. 2008). Other than the modulation of inflammatory pathways, ANXA1 
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contributes in cell growth, regulation of apoptotic and necrotic cell death, and 
phagocytic clearance of dying cells. Although, Annexin 1 is obviously involved in 
carcinogenesis but its role remains unclear due to variation of expression in different 
cancer models. Downregulation of Annexin 1 has been reported in lymphoma as well 
as in oral, stomach, head and neck, prostate, and breast cancers (Shen, Nooraie et al. 
2006, Moraes, Kar et al. 2017). In contrast, several reports were also found where 
upregulation of Annexin 1 has been described e.g. gastric cancer, prostate cancer, 
pancreatic cancer, colorectal cancer, liver cancer and breast cancer (Lim and Pervaiz 
2007, Su, Xu et al. 2010, Cheng, Wu et al. 2012). 
In the present study, ANXA1 was extremely downregulated in A2780 ovarian cancer 
cell line following treatment with NH3 alone, combined treatments with NH1 and 6-
SG and with Cis and Eme using 0/4 sequence of administration. The protein was not 
detectable after the above mentioned treatments. Following combined treatments of 
NH3 with Cur using 0/4 sequence of administration and NH3 with EGCG also caused 
significant downregulation of the protein by 2.32 folds and 5.32 folds respectively in 
A2780 cell line. The finding indicates that ANXA1 serves as antiapoptotic protein in 
ovarian A2780 cell line. 
ANXA1 was absent in A2780cisR cell line and partially restored back to the level 
found in A2780 cell line after combined treatment of NH3 with Cur using 0/4 
sequence of administration. Following combined treatment of NH3 and EGCG caused 
over restoration of the level of ANXA1 in A2780 cell line. The finding is in 
agreement with the earlier report where it was hypothesised that decreased ANXA1 
mediates resistance in A2780cisR cell line (Nessa 2013). 
In HT-29 colorectal cell line, ANXA1 was also significantly downregulated following 
treatment with NH1 alone and NH3 alone; combined treatments of NH3 with Cur 
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using 4/0 sequence of administration and Ox with Pat using bolus administration. The 
finding also supports the idea that ANXA1 serves antiapoptotic action (Su, Xu et al. 
2010).   
CALR (Calreticulin) 
CALR or calreticulin is a 46 kDa protein primarily located in endoplasmic reticulum 
shows critical functions inside and outside of endoplasmic reticulum. The protein is 
composed of three domains namely N-terminal domain, P-domain and C-terminal 
domain. N-terminal domain contains the binding site for α-integrins and steroid 
receptors. P-domain helps to control the chaperone like activities, whereas C-domain 
is responsible for Calcium buffering actions (Lu, Weng et al. 2015). In addition to 
maintaining calcium homeostasis, CALR serves in regulation of protein folding, cell 
adhesion, immune response, gene transcription and RNA stability. Recent studies also 
show that CALR is involved in tumour initiation and development. Upregulation of 
CALR has been observed in ovarian, colon, oral, breast, bladder and prostate cancers 
(Zamanian, Hamadneh et al. 2016). 
In the present study, the protein was extremely downregulated in A2780 cell line 
(disappeared) following combined treatment of NH3 with Cur using 0/4 sequence of 
administration. After combined treatment of NH3 with EGCG using bolus 
administration the protein was downregulated by a factor of 4.14 in A2780 cell line. 
Synergistic combination treatments of NH1 with 6-SG and Cis with Eme using 0/4 
sequence of addition also caused significant downregulation of CALR after treatment 
in the same cell line. The protein did not express at all in untreated A2780cisR cell line 
but fully restored back to the level found in A2780 cell line following combined 
treatment of NH3 with EGCG using 0/4 sequence of administration. CALR was found 
 305 
to be over restored to the level observed in A2780 cell line after treatment with NH3 
alone and combined treatment of NH3 and Cur using 0/4 sequence of addition. 
The nature of the CALR remained undefined in this study because it seemed to be 
antiapoptotic from the study in A2780 cell line but proapoptotic from the study in 
A2780cisR cell line.  
4.7.7 Chromatin assembly proteins 
 
Histone chaperones act as central element in chromatin assembly which is inevitable 
during the duplication of eukaryotic chromosomes. In the present study, two histone 
proteins Histone H3.3 and Histone H4 exhibited significant altered expression after 
treatment with different drugs alone or in combinations.  
H3.3 (Histone H3.3) 
Nucleosome is the basic unit of chromatin which consists of 147 bp DNA wrapped a 
histone octamer. Histone octamers are composed of two copies of each histone core 
proteins (H2A, H2B, H3 and H4) with a firm tetrameric core of H3 and H4, flanked 
by labile dimers of H2A and H2B. To date, four types of H3 histones have been 
identified namely canonical histones (H3.1 and H3.2) and replacement histones (H3.3 
and CENPA). H3.3 differs from other H3 variants by 5 amino acids in N-terminal 
chain. Moreover H3.3 is expressed through the cell cycle but the canonical H3 
proteins only found in S phase (Ahmad and Henikoff 2002). Histone H3.3 acts in the 
development of stem cells, during fertilization and restart of transcription following 
DNA damage (Reddy and Gupta 2017). Moreover, H3.3 confers genetic stability and 
the mutation in the protein has been reported to be associated with neoplastic 
disorders i.e. glioblastoma, chondroblastoma and giant cell tumours of the bone 
(Kallappagoudar, Yadav et al. 2015). 
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In the present study, the protein was downregulated in A2780 cell line after treatment 
with NH3 alone by 6.63 folds. Following combined treatment of NH3 with Cur using 
0/4 sequence of administration also caused significant downregulation in A2780 cell 
line. The protein disappeared after treatment with synergistic combined combinations 
of NH3 with EGCG using bolus administration, NH1 with 6-SG and Cis with Eme 
using 0/4 sequence of administration in the same cell line. The findings suggest that 
H3.3 might be antiapoptotic in action.  
H4 (Histone H4) 
As mentioned in the previous section Histone H4 forms the core protein of 
nucleosome structure, alteration in H4 protein leads to affect in transcription factors 
and, consequently in gene expression. Post translational modifications like 
acetylation, methylation and phosphorylation in H4 protein can lead towards cancer. 
Hyperacetylation of H4 proteins has been linked with cancer and histone deacetylases 
were found to be overexpressed in many cancers (West and Johnstone 2014). 
Inhibitors of histone deacetylases have been recently considered a new era of cancer 
treatment and few of them investigated in phase-I clinical trials (Dung, Oanh et al. 
2015). 
In the present study, the protein was extremely downregulated in HT-29 cell line 
following treatment with NH1 alone, combined treatments of NH3 with Cur using 4/0 
sequence of administration and Ox with Pat using bolus administration. In fact, H4 
was not detectable following above mentioned treatments. The protein was also 
significantly downregulated after NH3 alone treatment. All of these findings suggest 
that the protein might play antiapoptotic role in HT-29 colorectal cancer cells. 
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4.7.8 Other proteins 
 
NACA (Nascent polypeptide associated complex subunit alpha) 
Nascent polypeptide associated complex (NAC) is predominantly located in 
cytoplasm, which is involved in trafficking growing nascent polypeptides to suitable 
co-factors via its communication with the nascent chains on the ribosome. NAC is a 
heterodimer consisting of two subunits, alpha and beta. Alpha subunit of NAC is 
known as NACA which has transcriptional activating activity and bind to DNA, 
ribosomal RNA and transfer RNA. On the other hand, NACB binds with RNA 
polymerase II and does not show any transcriptional activity (Karan and Subudhi 
2012). NACA displays transcriptional activity by co-activating c-Jun. NACA has 
been found to be overexpressed in different tumour cells including hepatic carcinoma 
through activation of ERK pathway (Lee, Yu et al.).  
In the present study, the protein was highly downregulated in A2780 cell line 
following the treatment of NH3 alone, combined treatments of NH3 with Cur using 
0/4 sequence of administration, NH3 with EGCG using bolus administration, NH1 
with 6-SG using 0/4 sequence of administration. Indeed, NACA was not detectable 
after the above mentioned treatments. Synergistic combination of Cis with Eme using 
0/4 sequence of administration also caused significant downregulation of the protein 
after treatment in A2780 cell line. In A2780cisR cell line NACA was upregulated by 
8.14 folds compared to untreated parent A2780 cell line. Following treatment with 
NH3 alone the expression of the protein was partially restored back to the level 
observed in A2780 cell line. Following other treatments, NACA was disappeared in 
A2780cisR cell line. The finding of this study strongly suggests that NACA is 
antiapoptotic protein and its upregulation is responsible for cisplatin resistance in 
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A2780cisR cell line. Antitumour action of NH3 alone and in combination with 
phytochemicals could be correlated with the downregulation of NACA. This might be 
the first report showing that downregulation of NACA can be the strategy to treat 
ovarian cancer and overcoming cisplatin resistance. 
ALDH2 (ALDH class 2) 
Aldehyde dehydrogenase (ALDH) superfamily consists of the group of proteins 
which maintain cellular homeostasis through detoxification of endogenous and 
exogenous molecules. Many of the members of this superfamily are involved in 
cellular response to oxidative stress as well as proliferation differentiation and 
survival (Muzio, Maggiora et al. 2012). To date, 18 isoforms of ALDH have been 
identified in humans among whom ALDH2 has substrate specificity for acetaldehyde 
and plays an important role in its metabolism. ALDH2 is a tetrameric protein located 
in mitochondria, having three domains in structure. The protein contains two 
dinucleotide-binding domains and a three-stranded β-sheet domain which is 
responsible for subunit interactions (Steinmetz, Xie et al. 1997). Genetic 
polymorphism of ALDH2*2 results in a diminution in ALDH2 activity which has 
been identified as prognostic factor in alcohol induced oesophageal cancer. 
In the present study, ALDH2 was downregulated in HT-29 cell line below the 
threshold of detection following treatments with NH1 and NH3 alone and 
combination of Ox with Pat using bolus administration. Synergistic combination of 
NH3 with Cur using 4/0 sequence of administration also resulted in significant 
downregulation of the protein in the same cell line. This is the first report linking 
downregulation of ALDH2 in HT-29 cell line to possible anticancer effects of drugs 
administered either alone or in combination with phytochemicals. However, diadzin 
which is a potent inhibitor of ALDH2 has historical evidence of using in Chinese 
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medicines against cancer (Koppaka, Thompson et al. 2012). Inhibitors of ALDH1A1 
and ALDH3A1 have come into focus for development as oxazaphosphorine 
anticancer drugs (Parajuli, Kimble-Hill et al. 2011). 
Putting proteomics results into context 
Overcoming cisplatin resistance: From this study several proteins have been found 
to be upregulated in A2780cisR cell line compared to the level found in the parent 
A2780 cell line. Some other proteins have also been identified which were expressed 
in A2780 cell line but absent in A2780cisR cell line and vice-versa. All of these 
proteins could potentially involve in mediating cisplatin resistance in A2780cisR cell 
line. The proteins which were not detected in parent cell line but significantly 
expressed in A2780cisR cell line included: COF1, CH10 and TERA. The proteins 
which displayed higher expression in A2780cisR cell line were ACTB, VIME, ENPL, 
CH60, HSP7C, EFTU, RSSA, PRDX6, CISY and NACA. Search can be made to find 
out the existing chemicals (natural or synthetic) which can interact with the above 
proteins towards overcoming cisplatin resistance in ovarian cancer. Novel drugs can 
also be designed which can interact with the targeted proteins. The proteins which did 
not express at all in A2780cisR cell line but significantly expressed in parent A2780 
cell line were PPIA, ANXA1 and CALR. To overcome cisplatin resistance analogues 
of these proteins could be designed or combination therapies could be designed to 
upregulate the proteins. 
Antiapoptotic and proapoptotic proteins: We have proposed few proteins as being 
antiapoptotic or proapoptotic in action based on their differential expressions 
(upregulation, downregulation, partial restoration, over restoration and further 
upregulation) in different cell lines following drug treatments alone and in 
combinations. The proteins which are considered antiapoptotic are: ACTB, VIME, 
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PROF1, COF1, ACTG, ENPL, GRP78, CH10, HSP7C, SERPH, EFTU, RSSA, 
PRDX6, GSTP1, CISY, ALDOA, TERA, NDKB, ANXA1, H3.3, H4 and NACA. On 
the other hand two proteins namely TBB5 and PDIA3 are suggested to be 
proapoptotic in action. However, the nature of some other proteins could not be 
ascertained due to variation in response following drug treatments. These include 
CH60, PPIA, ROA2 and CALR. In this study three proteins have been reported for 
the first time, namely TBA1C, NACA and ALDH2 which underwent significant 
changes in expression in cancer cells.   
Anticancer mechanism of action of NH3 alone: Following treatment with palladium 
based potential anticancer agent administered NH3 alone in ovarian cancer cell lines, 
a number of proteins were identified to be significantly downregulated. The proteins 
which have been proposed to be associated with the anticancer action of NH3 in 
ovarian cancer (A2780 and A2780cisR cell lines) were ACTB, VIME, ENPL, CH60, 
GRP78, PPIA, ANXA1, H3.3, NACA, COF1, CH10, HSP7C, SERPH, EFTU, RSSA, 
PRDX6, CISY and TERA. Among these proteins, seven of them were considered to 
be highly significant (more than 3 folds downregulation) in relation to the antitumour 
action of NH3 in ovarian cancer A2780 cell line (Figure 4.10). Similarly, six proteins 
including CH10, HSP7C, SERPH, EFTU, PRDX6 and TERA were suggested to be 
highly significant in regards to the anticancer action of NH3 in cisplatin resistant 
A2780cisR cell line. In case of HT-29 colorectal cancer cell line, antitumour activity of 
NH3 was proposed to be associated with the downregulation of ACTG, NDKB, 
ANXA1, H4 and ALDH2.  
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Figure 4.10: Mechanism for anticancer action of NH3 in A2780 cell line 
Anticancer mechanism of action of NH1 alone: Downregulation of PROF1, PPIA, 
ACTG, NDKB, ANXA1, H4 and ALDH2 as well as upregulation of PDIA3 were 
found to be responsible for anticancer action of NH1 in HT-29 colorectal cancer cell 
line. Figure 4.11 depicts the suggested molecular mechanism of action of NH1. 
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Figure 4.11: Mechanism for anticancer action of NH1 in HT-29 cell line 
Mechanism of synergistic action for combination of NH3 with Cur: Following 
combined treatment of NH3 with Cur using 0/4 sequence of administration in either of 
the ovarian cancer cell lines A2780 and A2780cisR the following proteins were found 
to be significantly downregulated: ACTB, VIME, COF1, GRP78, CH10, PPIA, 
SERPH, PRDX6, CISY, ANXA1, CALR, H3.3 and NACA. Among these proteins, 
eight of them were highly significant (3 folds or more change) in ovarian cancer 
model including: ACTB, COF1, CH10, PPIA, SERPH, CISY, CALR and NACA.  
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In HT-29 cell line, following combined treatment of NH3 with Cur using 4/0 
sequence of administration seven proteins including PROF1, ACTG, PPIA, NDKB, 
ANXA1, H4 and ALDH2 were significantly downregulated.  
Mechanism of synergistic action for combination of NH3 with EGCG: After 
combined treatment of NH3 with EGCG using bolus administration the following 
proteins displayed highly significant downregulation (greater than 3 folds change) in 
ovarian cancer A2780 cell line: ENPL, GRP78, CH60, PPIA, ANXA1, CALR, H3.3 
and NACA. After combined treatment of NH3 and EGCG using 0/4 sequence of 
administration in A2780cisR cell line seven proteins including ACTB, COF1, CH10, 
HSP7C, SERPH, PRDX6 and TERA were found to undergo highly significant 
downregulation.  
In case of CACO-2 colorectal cell line, following combined treatment of NH3 with 
EGCG using 0/4 sequence of administration the proteins PROF1, COF1, TBA1C, 
ROA2, PRDX6, GSTP1 and ALDOA exhibited significant downregulation.  
Mechanism of synergistic action for combination of NH1 with 6-SG: Following 
combined treatment of NH1 with 6-SG using 0/4 sequence of administration in A2780 
ovarian cancer cell line, seven proteins identified to undergo significant 
downregulation were: GRP78, CH60, PPIA, ANXA1, CALR, H3.3 and NACA. 
Mechanism of synergistic action for combination of Cis with Eme: After 
combined treatment of Cis and Eme using 0/4 sequence of administration the 
following proteins displayed significant downregulation in ovarian cancer A2780 cell 
line: VIME, ENPL, GRP78, CH60, ANXA1, CALR, and NACA. After combined 
treatment of Cis and Eme using 4/0 sequence of administration in A2780cisR cell line, 
seven proteins including ACTB, VIME, CH10, HSP7C, SERPH, EFTU and PRDX6 
underwent significant downregulation. 
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Mechanism of synergistic action for combination of Cis with Pat: Following 
combined treatment of Cis with Pat using 4/0 sequence of administration in A2780cisR 
ovarian cancer cell line, three proteins identified to undergo significant 
downregulation were: ACTB, VIME and CH10. Significant upregulation of CISY 
was also evident after the same treatment in same cell line. 
Mechanism of synergistic action for combination of Ox with Pat: Following 
combined treatment of Ox with Pat using bolus administration in colorectal cancer 
models (HT-29 and CACO-2 cell lines) ten proteins identified to undergo significant 
downregulation were: COF1, ACTG, TBA1C, PRDX6, ANXA1, GSTP1, ALDOA, 
NDKB, H4 and ALDH2. Significant upregulation of TBB5 and PDIA3 were also 
observed following the same combined treatments in same models. 
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CHAPTER FIVE 
5  CONCLUSION 
 
Although platinum based anticancer drugs is still being considered as frontline 
chemotherapy, problems of adverse effects and drug resistance limit their 
applications. Researchers have now focused on other metals including palladium to 
design anew anticancer agents with the aim of achieving better candidates than the 
existing drugs in terms of efficacy and overcoming drug resistance with minimum 
side effects. In this study, six palladium compounds namely NH1, NH2, NH3, NH4, 
NH5 and NH6 containing planaramine bulky ligands (quinoline, benzimidazole, 8-
hydroxyquinoline and imdazo(1,2- α pyridine) have been synthesized. All of the 
complexes have been characterized based on elemental microanalysis, IR spectral 
analysis, mass spectrometry and proton-NMR spectroscopy. Additionally, structures 
of NH3, NH4 and NH6 were confirmed by single crystal x-ray diffraction study. 
The antitumour activity of the designed palladiums was investigated against a panel of 
ovarian (A2780, A2780cisR and A2780ZDO473R), colorectal (HT-29 and CACO-2), 
breast (MCF-7) and cervical (Hela) cancer cell lines. Three of the designed palladium 
complexes NH1, NH3 and NH5 were found to be highly tumour active against the 
tested cell lines during MTT reduction assay. NH3 displayed highest anticancer 
activity with 10 to 96 folds lower IC50 values than cisplatin against the selected cancer 
cell lines. NH1 also exhibited greater activity than cisplatin against resistant ovarian 
cancer and breast cancer cell lines. NH5 also showed better capability to overcome 
drug resistance in ovarian cancer models. Higher activity of the palladium complexes 
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was assumed to be due to differential binding and non-covalent interactions with the 
nucleobases in the DNA. 
Another specific objective of this study was to exploit the anticancer potential of 
phytochemicals in combination with existing platinums and designed palladiums to 
conquer drug resistance. Selected phytochemicals (emetine, patulin, curcumin, EGCG 
and 6-shogaol) were combined with platinums (cisplatin and oxaliplatin) and 
palladiums (NH1 and NH3) at three different concentrations and sequences of 
administration (bolus, 0/4 h and 4/0 h) in ovarian and colorectal cancer models. 
Combined action was determined based on combination indices and dose response 
curves generated by Calcusyn software using Chou-Talalay method. Most significant 
synergism was observed from combined treatments of NH1 with 6-SG (0/4), NH3 
with Cur (0/4), NH3 with EGCG (0/0) and Cis with Eme (0/4) in A2780 cell line. 
Combined treatments of NH3 with Cur (0/4), NH3 with EGCG (0/4), Cis with Eme 
(4/0) and Cis with Pat (4/0) displayed greater synergistic action in cisplatin resistant 
A2780cisR cell line. In colorectal cancer models, combined treatments of NH3 with 
Cur (4/0) and Ox with Pat (bolus) displayed greatest synergism in HT-29 cell line. 
Whereas in CACO-2 colorectal cancer cell line, combined treatments of NH3 with 
EGCG (0/4) as well as Ox with Pat (bolus) exhibited the greatest synergistic outcome. 
In general, combined action was more synergistic when the drugs were added at lower 
concentrations (ED50 level) than higher added concentrations (ED75 and ED90 levels). 
DNA damage study was conducted to obtain the preliminary idea regarding 
mechanism of action of designed palladiums. It is obvious from DNA mobility and 
DNA fluorescence data that all of the investigated palladium complexes displayed 
antitumour activity via interaction with DNA. Palladium complex NH4 having four 
bulky ligands (imdazo 1,2- α pyridine) bonded to the central palladium, caused 
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highest damage towards DNA but showed very low antitumour activity. The study 
revealed that interaction with DNA is necessary for antitumour action but the extent 
of damage is not the key determinant, rather pattern of binding and downstream 
protein recognition is indispensable for activity of a complex. 
Increased cellular accumulation of anticancer drugs might provide better outcome and 
decreased cellular accumulation is one of the prominent causes of drug resistance. 
Cellular accumulations of palladiums from designed palladiums administered alone 
and in synergistic combinations were determined to obtain the mechanistic 
information. It has been observed that accumulation of palladium from combined 
treatments was greater than single drug treatments which indicated the positive 
correlation between synergism and cellular accumulation of palladium. 
PalladiumDNA binding study also showed positive association between synergistic 
drug effect and increased PdDNA binding; however controversy existed.  
Finally proteomic study was conducted to identify downstream proteins involved in 
cellular signalling pathways leading towards cancer cell death or inhibition of 
carcinogenesis following treatments with drugs administered alone and in 
combination. From this study ACTB, VIME, PROF1, COF1, ACTG, ENPL, GRP78, 
CH10, HSP7C, SERPH, EFTU, RSSA, PRDX6, GSTP1, CISY, ALDOA, TERA, 
NDKB, ANXA1, H3.3, H4 and NACA were identified as antiapoptotic proteins. On 
the contrary two proteins namely TBB5 and PDIA3 were assumed to be proapoptotic 
in action.  
Antitumour activity of NH3 alone has been found to be associated with 
downregulation of ACTB, VIME, ENPL, CH60, GRP78, PPIA,  ANXA1, H3.3, 
NACA, COF1, CH10, HSP7C, SERPH, EFTU, RSSA, PRDX6, CISY, ACTG, 
NDKB, H4, ALDH2 and TERA. Modulation of the expression of PROF1, PPIA, 
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ACTG, NDKB, ANXA1, H4, ALDH2 and PDIA3 was considered to be responsible 
for antitumour activity of NH1 alone. 
The observed synergism from combination of NH3 with Cur was mainly due to 
downregulation of ACTB, COF1, CH10, PPIA, SERPH, CISY, CALR, NACA and 
H4. On the other hand, NH3 in combination with EGCG displayed synergism by 
down regulating ENPL, GRP78, CH60, PPIA, ANXA1, CALR, H3.3 and NACA. 
Highly synergistic combination Ox with Pat was found to downregulate COF1, 
ACTG, TBA1C, PRDX6, ANXA1, GSTP1, ALDOA, NDKB, H4 and ALDH2 as 
well as upregulate TBB5 and PDIA3 protein. 
Potential directions 
Since two new palladium compounds (NH1 and NH3) have shown optimistic 
anticancer activity against a variety of cancer cell lines including drug resistant cells, 
the activity and toxicity profile of the compounds could be carried out using suitable 
in vivo animal model study. Synergistic combinations could also be further evaluated 
in human xenograft model study in rodents. During proteomic study, only 47 spots 
were chosen from around 100 significantly expressed proteins following drug 
treatments. The rest of the proteins need to be identified to get the complete picture of 
their involvement in drug action. The proteins which have been found to be 
significantly expressed following drug treatments and associated with the antitumour 
activity of the compounds could be confirmed by western blot assay. Moreover, 
combination of protein expression profiling data with a network of protein-protein 
interactions and signalling pathways can be conducted to get a system level outlook of 
proteome changes associated with drug actions alone or in combinations. 
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7.2 APPENDIX II: Proteomic study  
 
The protocol is based on the published article (Al-Eisawi, Z., Beale, P., Chan, C. et al. 
BMC Cancer, 2016, 16: 688) from our group. 
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